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FSP Section 11,000
Checklists and Illustrative Financial 
Statements for Health Care Organizations
Description
.01 Health care organizations may be classified by sponsorship or legal structure within the following 
broad categories:
Not-for-profit business-oriented: These are essentially self-sustaining from fees charged for goods and 
services. The fees charged by such organizations generally are intended to help the organization 
maintain its self-sustaining status rather than to maximize profits for the owner's benefit. Such 
organizations often are exempt from federal income taxes and may receive contributions of relatively 
small amounts from resource providers that do not expect commensurate or proportionate pecuniary 
returns.
Not-for-profit non-business-oriented: These are voluntary health and welfare organizations as defined 
in FASB Statement of Financial Accounting Standards (SFAS) No. 117, Financial Statements of Not-for- 
Profit Organizations. Such organizations are within the scope of the AICPA Audit and Accounting 
Guide Not-for-Profit Organizations rather than that of the Health Care Organizations Guide.
Governmental: Often called public health care entities, the entities are owned and operated by federal, 
state, city, or county governments or other political subdivisions.
Investor- (or operator-) owned: These organizations operate as stock corporations, partnerships, or sole 
proprietorships.
.02 Health care organizations include, but are not limited to, the following:
• Clinics, medical group practices, individual practitioners and practice associations, and other ambu­
latory care organizations
• Continuing care retirement communities (CCRCs)
• Health maintenance organizations and similar prepaid health care plans
• Home health agencies
• Hospitals
• Nursing homes that provide skilled, intermediate, and less intensive levels of health care
• Parent companies, holding companies, and other organizations that primarily plan, organize, and 
oversee health care services
Applicability of This Checklist
.03 This checklist, and the illustrative financial statements included herein, follow the guidance con­
tained in the AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes as of 
May 1, 1998), referred to as "the Guide." The checklist and illustrative financial statements should be used 
for not-for-profit business-oriented and investor-owned health care organizations. Not-for-profit health care pro­
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viders that receive federal financial assistance may be required to have an audit conducted in accordance 
with Office of Management and Budget (OMB) Circular A-133, Audits of States, Local Governments, and 
Non-Profit Organizations. Section 11,300 includes guidance for auditors' reports for audits performed under 
OMB Circular A-133.
.04 Although the Guide also applies to state and local government-owned health care providers, this 
checklist does not include disclosures or sample financial statements of government-owned providers. Chapter 
1 of the Guide discusses the application of generally accepted accounting principles (GAAP) to governmental 
health care providers.
.05 In addition, this checklist does not apply to not-for-profit non-business-oriented health care organiza­
tions. For these types of organizations, follow the guidance in the AICPA Audit and Accounting Guide 
Not-for-Profit Organizations, and the AICPA's disclosure checklist entitled Not-for-Profit Organizations.
Legislation and Regulation
.06 Significant aspects of health care organization operations are affected by government legislation and 
regulation with many states adopting laws governing the granting of licenses, as well as scope of services to 
be rendered. In addition, many independent organizations and governmental agencies, including Medicare 
and Medicaid, evaluate programs and services of health care organizations to determine compliance with 
set standards.
Basic Financial Statements
.07 The financial reporting for not-for-profit business-oriented organizations and investor-owned health 
care enterprises generally is consistent except for transactions that clearly are not applicable. For example, 
not-for-profit business-oriented organizations, by their nature, do not have shareholders' equity. On the 
other hand, investor-owned health care enterprises typically do not receive contributions. Throughout this 
checklist, disclosure/presentation questions are preceded by certain symbols. Not-for-profit business- 
oriented organizations should complete all disclosure items denoted with a star (★). Investor-owned health 
care enterprises should complete all disclosure items denoted with a diamond (♦).
.08 The basic financial statements of health care providers generally consist of a statement of financial 
position or balance sheet, a statement of activities or income statement or statement of operations, a statement 
of changes in net assets (equity), a statement of cash flows, and notes to the financial statements. The titles 
of the financial statements will depend upon the business form of the provider (i.e., not-for-profit, investor- 
owned, etc.). See the chart below.
Basic Financial Statements
* May be combined with the Statement of Operations.
Not-for-Profit 
Business-Oriented Organization Investor-Owned Organization
Balance Sheet/Statement of Financial Position Balance Sheet
Statement of Operations/Statement of Activities Statement of Operations/Income Statement
Statement of Changes in Net Assets (Fund Balance)* Statement of Changes in Equity*
Statement of Cash Flows Statement of Cash Flows
Note: This publication was extracted from sections 11,000 through 11,500 of the AICPA Financial Statement 
Preparation Manual (FSP).
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FSP Section 11,100 
Instructions
Purpose
.01 The checklists and illustrative financial statements included in this section have been developed by 
the staff of the Accounting and Auditing Publications Team of the AICPA as nonauthoritative technical 
practice aids to be used as a memory jogger to aid in the audit of financial statements of health care 
organizations.
The checklists have been updated to include guidance relevant to health care organizations 
contained in official pronouncements through:
• FASB Statement of Financial Accounting Standards No. 135, Rescission of FASB 
Statement No. 75 and Technical Corrections
• FASB Interpretation No. 42, Accounting for Transfers of Assets in Which a Not-for-Profit 
Organization Is Granted Variance Power
• FASB Technical Bulletin No. 97-1, Accounting under Statement 123 for Certain Employee 
Stock Purchase Plans with a Look-back Option
• AICPA Statement on Auditing Standards No. 87, Restricting the Use of an Auditor's 
Report
• AICPA Statement of Position No. 98-9, Modification of SOP 97-2, Software 
Revenue Recognition, With Respect to Certain Transactions
• AICPA Statement on Standards for Accounting and Review Services No. 7, Omnibus 
Statement on Standards for Accounting and Review Services—1992
• AICPA Audit and Accounting Guide Health Care Organizations (with conforming 
changes as of May 1, 1999)
• AICPA Practice Bulletin No. 15, Accounting by the Issuer of Surplus Notes
• FASB EITF consensuses adopted up to and including the January 1999 Emerging 
Issues Task Force meeting
The checklists and illustrative financial statements should be modified, as appropriate, for 
subsequent pronouncements. In determining the applicability of a pronouncement, its effective 
date should also be considered.
Instructions
.02 The checklists consist of a number of questions or statements that are accompanied by references to 
the applicable authoritative pronouncements. The checklists provide for checking off or initialing each 
question or point to show that it has been considered. Users should check: "yes" if the disclosure has been 
appropriately made, "no" if the disclosure has not been made, or "n/a" if the disclosure is not applicable to 
the organization. The auditor should consider the effect of a "no" answer on his/her report. A "no" answer 
that is material to the financial statements may warrant a departure from an unqualified opinion. (See paragraphs 
3
20-63 of SAS No. 58, Reports on Audited Financial Statements, as amended [AICPA, Professional Standards, vol. 
1, AU sec. 508.20-.63].) If a "no" answer is checked, the authors recommend that a note be made in the right 
margin to explain why the disclosure was not made (for example, if the disclosure was not made because it 
was not material to the financial statements, write "not material" in the right margin). The right margin may 
be used for other remarks or comments as appropriate, including cross-referencing to applicable workpapers 
where the support to a disclosure may be found. Use of the checklists requires the exercise of individual 
professional judgment and may likely require some modification based on the circumstances of individual 
engagements.
.03 This checklist is applicable to not-for-profit business-oriented and investor-owned health care organiza­
tions. While financial reporting for these types of organizations is generally consistent, there are requirements 
that apply to only not-for-profit business-oriented organizations and those that apply to only investor-owned 
enterprises. Symbols have been used to indicate the applicability of presentation and disclosure requirements 
to these types of organizations. Not-for-profit business-oriented organizations should complete all disclosure 
items denoted with a star (★). Investor-owned organizations should complete all disclosure items denoted 
with a diamond (♦).
.04 The checklist is not a substitute for the authoritative pronouncements. Users of the checklists and 
illustrative financial statements are urged to refer directly to applicable authoritative pronouncements 
when appropriate. The checklists and illustrative financial statements do not include all disclosures and 
presentation items promulgated nor do they represent minimum requirements. Disclosures prescribed 
by pronouncements deemed remote for health care organizations are not included in this document. The 
checklists and illustrative financial statements are "tools" and in no way represent official positions or 
pronouncements of the AICPA.
.05 If you have further questions, call the AICPA Technical Hotline at 1-888-777-7077.
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FSP Section 11,200
Financial Statements and 
Notes Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of 
the AICPA as a nonauthoritative practice aid. The checklists and illustrative financial statements do not 
include all disclosures and presentation items required by GAAP; as a result, pronouncements deemed 
unlikely to be encountered in financial statements of health care providers are not included.
.02 Explanation of References:
★ = Disclosure applicable for not-for-profit organizations
♦ = Disclosure applicable for investor-owned organizations
AAG = AICPA Audit and Accounting Guide Health Care Organizations (with conform­
ing changes as of May 1, 1998)
AC = Reference to section number in FASB Accounting Standards—Current Text
APB = Accounting Principles Board Opinion
ARB = Accounting Research Bulletin
AU = Reference to section number in AICPA Professional Standards (vol. 1)
EITF = FASB Emerging Issues Task Force consensus
FASBI = FASB Interpretation
FASCON = FASB Statement of Financial Accounting Concepts
SAS = AICPA Statement on Auditing Standards
SFAS = FASB Statement of Financial Accounting Standards
SOP = AICPA Statement of Position
TB = FASB Technical Bulletin
.03 Checklist Questionnaire:
This checklist is organized into the sections listed below. Carefully review the topics listed and consider 
whether they represent potential disclosure items for the health care provider. Place a check mark by the 
topics or sections considered not applicable; these sections need not be completed. For example, if the entity 
does not have any extraordinary items, place a check by "Extraordinary Items" and skip this section when 
completing the checklist.
Place  by 
Sections Not Applicable
• General
A. Titles and References
B. Comparative Financial Statements
• Statement of Financial Position/Balance Sheet
A. General
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Place  by
Sections Not Applicable
B. Cash and Cash Equivalents
C. Investments
D. Receivables
E. Property and Equipment, Supplies, and Other Assets
F. Current Liabilities, Notes Payable, and Other Debt
G. Other Liabilities and Deferred Credits
H. Lessor Leases
I. Lessee Leases
J. Net Assets
K. Restricted Resources
• Statement of Activities / Income Statement/Statement of 
Operations/Statement of Changes in Net Assets
A. General
B. Revenue
C. Income Taxes
D. Discontinued Operations
E. Extraordinary Items
F. Unusual or Infrequent Items
G. Advertising Costs
H. Donated or Contributed Services
I. Fund Raising
J. Contributions/Pledges
K. Expenses
L. Wills
M. Endowments
N. Earnings Per Share
O. Comprehensive Income
• Statement of Cash Flows
• Other Financial Statement Disclosures
A. Accounting Changes
B. Accounting Policies
C. Business Combinations
D. Commitments and Contingencies
E. Costs to Exit an Activity
F. Derivatives
G./G 1. Financial Instruments
H. Nonmonetary Transactions
I. Pension and Other Postretirement Benefit Plans
J. Related Organizations and Economic Dependency
K. Risks and Uncertainties
L. Segment Information
M. Subsequent Events
• Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees
B. Fees Refundable to Residents Only From Reoccupancy 
Proceeds of a Contract Holder's Unit
C. Nonrefundable Advance Fees
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Place  by
Sections Not Applicable
D. Obligation to Provide Future Services and Use of Facilities 
to Current Residents
E. Costs of Acquiring Initial Continuing-Care Contracts
F. Other
• OMB Circular A-133 Presentation Requirements
• Exhibit A—Stock-Based Compensation
• Auditors' Reports
• Auditors' Reports on Audits Performed Under Government Auditing 
Standards and Under OMB Circular A-133
Yes No
General
A. Titles and References
1. Are the financial statements suitably titled? ____ ___
[SFAS 62, par. 7 (AU 623.07)]
2. Does each statement include a general reference that the notes are an
integral part of the financial statement presentation? ____ ___
[Generally Accepted]
★ 3. Do the basic financial statements of the health care organization 
include:
a. Statement of financial position (balance sheet)? ____ ___
b. Statement of activities (statement of operations/income statement)? ____ ___
c. Statement of cash flows? ____ ___
d. Statement of changes in net assets (equity)? [Note that this state­
ment may be combined with the statement of activities.] ____ ___
[SFAS 117, pars. 1 and 6 (AC No5.104); AAG, par. 1.05]
B. Comparative Financial Statements
★♦1. Has presentation of comparative statements been considered? ____ ___
[SFAS 117, par. 69; ARB 43, Ch. 2A, pars. 1 and 2 (AC F43.101 and
■ 102)]
2. Are the disclosures included in the prior year's financial statements 
repeated, or at least referred to, to the extent that they continue to be 
of significance? ____ ___
[ARB 43, Ch. 2A, par. 2 (AC F43.102)]
★♦3. If changes have occurred in the manner of or basis for presenting 
corresponding items for two or more periods, are appropriate expla­
nations of the changes disclosed? ____ ___
[ARB 43, Ch. 2A, par. 3 (AC F43.103)]
N/A
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Yes No N/A
★ 4. If comparative annual financial statements are presented for earlier
periods, are those financial statements reclassified (or restated) to 
reflect retroactive application of the provisions of SFAS 116 and SFAS 
117? ____
[SFAS 116, par. 30; SFAS 117, par. 31]
Statement of Financial Position/Balance Sheet
A. General
★♦1. For classified statements of financial position/balance sheets, are 
assets and liabilities segregated into current and noncurrent classifi­
cations, with totals presented for current assets and current liabilities? ____
[ARB 43, Ch. 3A, par. 3; SFAS 78, pars. 5 and 13 (AC B05.102-.109B); 
SFAS 6, par. 15 (AC B05.118); FASBI 8, par. 3 (AC B05.117); TB 79-3, 
par. 2 (AC B05.501-.503); SFAS 117, par. 12 (AC No5.110)]
2. Are assets not expected to be realized during the current operating 
cycle classified as noncurrent? ____
[ARB 43, Ch. 3A, pars. 5 and 6 (AC B05.106 and .107)]
★ 3. Does the statement of financial position/balance sheet report total
assets, liabilities, and net assets as well as separate amounts for each 
of three classes of net assets with captions used to describe their 
meaning as explained in SFAS 117? ____
[SFAS 117, pars. 10,13, and 100 (AC No5.108, .111, and .131, fn. a)]
★4. Does the entity provide information about liquidity by one or more 
of the following presentations:
a. Sequencing assets according to their nearness of conversion to
cash and sequencing liabilities according to the nearness of their 
maturity and resulting use of cash? ____
b. Classifying assets and liabilities as current and noncurrent? ____
c. Disclosing in notes to financial statements relevant information
about the liquidity or maturity of assets and liabilities, including 
restrictions on the use of particular assets? ____
[SFAS 117, par. 12 (AC No5.110)]
★♦5. Are valuation allowances for assets shown as deductions from their 
related assets with appropriate disclosure? ____
[APB 12, par. 3 (AC V18.102)]
★♦6. Is the need for disclosure of the impact of a new FASB Statement, 
issued but not yet effective where restatement of prior periods is 
required, considered? ____
[SAS 1, secs. 9410.13-18 (AU 9410.13-.18)]
B. Cash and Cash Equivalents
★♦1. Is restricted cash appropriately segregated from cash available for 
current operations? ____
[ARB 43, Ch. 3A, par. 6 (AC B05.107); AAG, par. 3.01]
2. Are restrictions on cash (such as for plant acquisition, debt reduction 
or working capital maintenance) appropriately disclosed? ____
[SFAS 5, pars. 18 and 19 (AC C59.120)]
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Yes No NIA
3. Are personal funds of patients, residents and others under an agency 
arrangement reported as unrestricted assets and corresponding li­
abilities in the balance sheet/statement of financial position? 
[AAG, par. 3.02]
★♦4. If a concentration of credit risk arises from deposits in excess of 
federally insured limits, is it disclosed?
[SFAS 105, par. 20 (AC F25.115)]
Note: SFAS 133, Accounting for Derivative Instruments and Hedging Activi­
ties, which is effective for all fiscal quarters of fiscal years beginning after 
June 15, 1999, supersedes SFAS 105. If SFAS 133 has been adopted, refer 
to the disclosure requirements listed in the Other Financial Statement 
Disclosures section G1 of this checklist.
The FASB has issued an exposure draft dated May 20, 1999 of a proposed 
Statement titled "Accounting for Derivative Instruments and Hedging 
Activities—Deferral of the Effective Date of FASB Statement No. 133, an 
amendment of FASB Statement No. 133," which would amend SFAS 133 
to defer its effective date to all fiscal quarters of all fiscal years beginning 
after June 15, 2000. The comment deadline was June 19, 1999. Users of this 
checklist should be alert to the issuance of a final pronouncement.
5. If the organization has material bank overdrafts or material balance 
of undelivered checks as of the statement-of-financial-position/bal­
ance-sheet date, are:
a. Bank overdrafts presented as a separate caption within current 
liabilities?
b. Undelivered checks classified as accounts payable? 
[Generally Accepted]
6. Are internally designated funds reported separately from externally 
designated funds?
[AAG, par. 3.01]
7. Is the policy for determining cash equivalents disclosed? 
[SFAS 95, par. 10 (AC C25.108)]
C. Investments
1. Are investments reported as current or noncurrent assets in conform­
ity with GAAP?
[AAG, par. 4.14]
★♦2. Are the appropriate disclosures made for investments in common 
stock accounted for by the equity method?
[APB 18, par. 20 (AC I82.110)]
3. Are other investments (such as real estate) reported at amortized cost, 
or at lower of cost or market if an impairment in value is deemed to 
be other than temporary?
[AAG, par. 4.02]
♦ 4. Are debt and equity securities classified as (a) held-to-maturity, (b) 
available-for-sale, or (c) trading?
[SFAS 115, par. 6 (AC I80.103)]
9
Yes No N/A
Note: SFAS 133, Accounting for Derivative Instruments and Hedging Activi­
ties, which is effective for all fiscal quarters of fiscal years beginning after 
June 15, 1999, modifies the disclosure requirements of SFAS 115, para­
graphs 19, 20, 21, and 22. If SFAS 133 has been adopted, replace Questions 
5, 6, 7, 9, and 10 below with those shown in the Other Financial Statement 
Disclosures section G1 of this checklist.
The FASB has issued an exposure draft dated May 20, 1999 of a proposed 
Statement titled "Accounting for Derivative Instruments and Hedging 
Activities—Deferral of the Effective Date of FASB Statement No. 133, an 
amendment of FASB Statement No. 133," which would amend SFAS 133 
to defer its effective date to all fiscal quarters of all fiscal years beginning 
after June 15, 2000. The comment deadline was June 19, 1999. Users of this 
checklist should be alert to the issuance of a final pronouncement.
♦ 5. For debt and marketable equity securities classified as available-for-
sale or held-to-maturity, are the following disclosures made, by ma­
jor-security type, for each balance sheet presented:
a. Aggregate fair value?
b. Gross unrealized holding gains or losses?
c. Amortized cost basis?
♦ 6. For investments in debt securities classified as available-for-sale or
held-to-maturity is:
a. Disclosure made about their contractual maturities, as of the date 
of the latest balance-sheet date presented (maturity information 
may be combined in appropriate groupings)?
[SFAS 115, par. 20 (AC I80.119)]
♦ 7. Is consideration given to separate disclosure for securities not due
at a single date and the basis for allocation if such securities are 
allocated?
[SFAS 115, par. 20 (AC I80.119)]
♦ 8. If an option (to purchase securities that will be accounted for under SFAS
115) is classified as held-to-maturity or available-for-sale, is the account­
ing policy for the premium paid to acquire the option disclosed? 
[EITF 96-11]
♦ 9. For each period for which an earnings statement is presented, are the
following disclosures made:
a. The proceeds from sales of available-for-sale securities and gross 
realized gains and losses on those sales?
b. The basis on which cost was determined in computing realized 
gain or loss (i.e., specific identification, average cost, or other 
method used)?
c. The gross gains and losses included in earnings from transfers 
of securities from the available-for-sale category to the trading 
category?
d. The change in net unrealized holding gain or loss on available-for- 
sale securities that is included in other comprehensive income 
during the period?
10
Yes No N/A
e. The change in net unrealized holding gain or loss on trading 
securities that is included in earnings during the period? 
[SFAS 115, par. 21 (AC I80.120)]
♦ 10. For any sales of or transfers from securities classified as held-to-ma- 
turity, are the following disclosed for each period for which an earn­
ings statement is presented:
a. Amortized cost amount of the sold or transferred security?
b. Related realized or unrealized gain or loss?
c. The circumstances leading to the decision to sell or transfer the 
security?
[SFAS 115, par. 22 (AC I80.121)]
★♦11. Are significant concentrations of credit risk arising from concentra­
tions of securities of a particular issuer disclosed?
[SFAS 105, par. 20 (AC F25.115)]
Note: SFAS 133, Accounting for Derivative Instruments and Hedging Activi­
ties, which is effective for all fiscal quarters of fiscal years beginning after 
June 15, 1999, supersedes SFAS 105. If SFAS 133 has been adopted, refer 
to the disclosure requirements listed in the Other Financial Statement 
Disclosures section G1 of this checklist.
The FASB has issued an exposure draft dated May 20, 1999 of a 
proposed Statement titled "Accounting for Derivative Instruments and 
Hedging Activities—Deferral of the Effective Date of FASB Statement 
No. 133, an amendment of FASB Statement No. 133," which would 
amend SFAS 133 to defer its effective date to all fiscal quarters of all 
fiscal years beginning after June 15, 2000. The comment deadline was 
June 19, 1999. Users of this checklist should be alert to the issuance of 
a final pronouncement.
★ 12. Are realized gains and losses; unrealized gains and losses; dividend,
interest, and other similar investment income; and other than tempo­
rary impairment losses reported in the statement of activities as 
increases or decreases in unrestricted net assets or in temporarily 
restricted net assets or in permanently restricted net assets, depending 
on the existence of or lack of donor restrictions or law?
[SFAS 124, pars. 8 and 9 (AC No5.154 and .155); AAG, pars. 4.07 and 
4.08]
★ 13. Are realized gains and losses; dividend, interest and other similar invest­
ment income; and other than temporary impairment losses included in 
the performance indicator within the statement of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 14. Are unrealized gains and losses on trading securities (as defined in
SFAS 115) included in the performance indicator within the statement 
of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
★ 15. Are unrealized gains and losses on available-for-sale and held-to-ma­
turity securities excluded from the performance indicator within the 
statement of activities?
[SFAS 124, par. 49; AAG, par. 4.07]
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Yes No N/A
★ 16. If a provider reports gains and investment income that are limited to
specific uses by donor-imposed restrictions as increases in unre­
stricted net assets because the restrictions are met in the same report­
ing period as the gains and income are recognized, does the provider:
a. Have a similar policy for reporting contributions received?
b. Report consistently from period to period?
c. Disclose its accounting policy?
[SFAS 124, par. 10 (AC No5.156); AAG, par. 4.09]
★ 17. For each period that a statement of activities is presented, are the
following disclosures made on the face of the financial statements or 
in the notes thereto:
a. The composition of investment return including, at a minimum, 
investment income, net realized gains or losses on investments 
reported at other than fair value, and net gains or losses on 
investments reported at fair value?
b. A reconciliation of investment return to amounts reported in the 
statement of activities, if investment return is separated into oper­
ating and nonoperating amounts?
c. A description of the policy used to determine the amount of invest­
ment return included in the measure of operations, if investment 
return is separated into operating and nonoperating amounts?
d. A discussion of circumstances leading to a change, if any, in the 
policy referred to in Step 17c above?
[SFAS 124, par. 14 (AC No5.161); AAG, par. 4.11]
★ 18. For each period for which a statement of financial position is pre­
sented, are the following disclosures made on the face of the financial 
statements or in the notes thereto:
a. The aggregate carrying amount of investments by major types 
(e.g., equity securities, corporate debt securities, etc.)?
b. The basis for determining the carrying amount for investments 
other than equity securities with readily determinable fair values 
and all debt securities?
c. The methods and assumptions used to estimate the fair values of 
investments other than financial instruments, if those other invest­
ments are reported at fair value?
d. The aggregate amount of the deficiencies for all donor-restricted 
endowment funds, for which the fair value of the assets at the 
reporting date is less than the level required by donor stipulations 
or law?
[SFAS 124, par. 15 (AC No5.162); AAG, par. 4.11]
★ 19. For the most recent period for which a statement of financial position
is presented, does the provider disclose the nature of and carrying 
amount for every individual investment or group of investments that 
represents a significant concentration of market risk (market risk may 
result from the nature of the investments, a lack of diversity of 
industry, currency, or geographic location)?
[SFAS 124, pars. 16 and 86 (AC No5.163); AAG, par. 4.11]
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Yes No N/A
★ 20. In the period that SFAS 124 is first applied, does the provider disclose
the nature of any restatements and its effect on the change in net assets 
and on each class of net assets for each period presented? 
[SFAS 124, par. 19]
★ 21. If SFAS 124 is not applied retroactively, is the cumulative effect of the
change in accounting on each class of net assets reported in the 
statement of activities between the captions "extraordinary items," if 
any, and "change in unrestricted net assets," "change in temporarily 
restricted net assets," and "change in permanently restricted net 
assets"?
[SFAS 124, par. 18]
22. Are significant net realized and net unrealized gains and losses that 
arose after the latest statement of financial position date, but before 
issuance of the financial statements, disclosed?
[SAS 1, sec. 560, pars. 5 and 7 (AU 560.05 and .07)]
D. Receivables
1. Are charity care revenue and receivables excluded from the financial 
statements?
[AAG, par. 5.03]
2. Are differences between the estimates originally reported and sub­
sequent revisions, including final settlements:
a. Included in the statement of activities/income statement in the 
period the revisions are made and disclosed, if material?
b. Reported in the current period unless they meet the criteria for 
prior-period adjustments?
[AAG, par. 5.07; SFAS 16 (AC A35)]
3. Are advances from third-party payors reported as a liability (unless 
the right of setoff against a related receivable applies)?
[AAG, par. 7.01]
★♦4. Are deposits received from individuals reported as a liability (to the 
extent that a right of setoff does not exist)?
[AAG, par. 7.01]
5. Are receivables (less an allowance for uncollectibles, discounts, and 
contractual adjustments) reported as current assets?
a. If the terms of payment are extended beyond one year from the 
balance-sheet date, is that portion classified as noncurrent?
b. Are amounts due from third-party payors for retroactive adjust­
ments of items (such as final settlements or appeals) reported 
separately in the financial statements?
[AAG, pars. 5.17 and 5.18]
★ 6. When displaying total assets and total liabilities, are interfund assets
and liabilities eliminated?1
1 The display of interfund items in a statement of financial position is not prohibited by SFAS 117. However, since interfund items are 
not organizational assets or liabilities, those interfund items must be clearly labeled and arranged in the statement of financial position 
to eliminate their amounts when total assets and liabilities are displayed.
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Yes No N/A
★ 7. Do entities that receive unconditional promises to give disclose the
following:
a. The amounts of promises receivable in less than one year, in one
to five years, and in more than five years? ____
b. The amount of any allowance for uncollectible promises receivable? ____
[SFAS 116, par. 24 (AC C67.121)]
★ 8. Do entities that receive conditional promises to give disclose the
following:
a. The total of the amounts promised? ____
b. A description and amount for each group of promises having 
similar characteristics (such as amount of promises conditioned 
on establishing new programs, completing a new building, and
raising matching gifts by a specified date)? ____
[SFAS 116, par. 25 (AC C67.122)]
9. Are all receivables reported net of any related allowance for uncol­
lectible amounts, with appropriate disclosure? ____
[AAG, par. 5.17; APB 12, par. 3 (AC V18.102)]
10. Are accounts and notes receivable from officers, employees, and affili­
ated organizations shown separately with appropriate disclosures? ____
[ARB 43, Ch. 1A, par. 5 (AC R36.105)]
★♦11. Are significant concentrations of credit risk arising from receivables 
disclosed? ____
[SFAS 105, par. 20 (AC F25.115)]
Note: SFAS 133, Accounting for Derivative Instruments and Hedging Activi­
ties, which is effective for all fiscal quarters of fiscal years beginning after 
June 15, 1999, supersedes SFAS 105. If SFAS 133 has been adopted, refer 
to the disclosure requirements listed in the Other Financial Statement 
Disclosures section G1 of this checklist.
The FASB has issued an exposure draft dated May 20, 1999 of a proposed 
Statement titled "Accounting for Derivative Instruments and Hedging 
Activities—Deferral of the Effective Date of FASB Statement No. 133, an 
amendment of FASB Statement No. 133," which would amend SFAS 133 
to defer its effective date to all fiscal quarters of all fiscal years beginning 
after June 15, 2000. The comment deadline was June 19, 1999. Users of this 
checklist should be alert to the issuance of a final pronouncement.
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E. Property and Equipment, Supplies, and Other Assets
★ 1. Is property and equipment that is donor-restricted reported as tem­
porarily or permanently restricted assets?
[SFAS 116, par. 14]
★♦ 2. Are donor or legal restrictions on the proceeds from the disposition 
of property and equipment disclosed?
[AAG, par. 6.07]
★♦ 3. For depreciable assets, do the financial statements or notes disclose:
a. Depreciation expense for each period?
Yes No N/A
b. Balances of major classes of depreciable assets by nature or function? ____
c. Accumulated depreciation, either by major classes of assets or in
total? ____
d. The method or methods used in computing depreciation with
respect to major classes of depreciable assets? ____
[APB 12, par. 5 (AC D40.105)]
★♦4. Do disclosures include the method and period of amortization of 
intangible assets? ____
[APB 22, par. 13 (AC A10.106)]
♦ 5. In a classified balance sheet:
a. Are deferred tax assets and deferred tax liabilities classified as 
current or noncurrent based on the classification of the related
asset or liability for financial reporting? ____
[SFAS 109, par. 41 (AC I27.140)]
b. Are deferred tax assets or liabilities not related to an asset or
liability for financial reporting (including those related to carry­
forwards) classified according to the expected reversal date of the 
temporary difference? ____
[SFAS 109, pars. 41 and 288p (AC I27.140)]
c. Is the valuation allowance for a particular tax jurisdiction allocated
between current and noncurrent deferred tax assets for that tax 
jurisdiction on a pro rata basis? ____
[SFAS 109, par. 41 (AC I27.140)]
d. Are the following items offset and presented as a single amount 
for a particular taxpaying component and within a particular 
taxpaying jurisdiction:
(1) All current deferred tax liabilities and assets? ____
(2) All noncurrent deferred tax liabilities and assets? ____
[SFAS 109, par. 42 (AC I27.141)]
♦ 6. Are the totals of (a) all deferred tax liabilities, (b) all deferred tax assets,
and (c) the related valuation allowance recognized in the balance sheet 
disclosed? ____
[SFAS 109, par. 43 (AC I27.142)]
♦ 7. Is the net change during the year in the total valuation allowance
disclosed? ____
[SFAS 109, par. 43 (AC I27.142)]
8. Is the amount of interest cost incurred and charged to expense during 
the period disclosed for an accounting period in which no interest cost 
is capitalized? ____
[SFAS 34, par. 21a (AC I67.118)]
★♦9. Is the amount of interest cost incurred during the period and the 
amount that has been capitalized disclosed for an accounting period 
in which some interest cost is capitalized? ____
[SFAS 34, par. 21b (AC I67.118)]
10. Are material commitments for property expenditures disclosed? ____
[SFAS 5, pars. 18 and 19 (AC C59.120)]
15
Yes No N/A
★♦11. For an existing property with an asbestos problem, are the costs 
incurred to treat the problem, if charged to expense, not classified as 
an extraordinary item?
[EITF 89-13]
★♦ 12. If an impairment loss is recognized for assets to be held and used, are 
the following disclosures made in financial statements that include 
the period of the impairment write-down:
a. A description of the impaired assets and the facts and circum­
stances leading to the impairment?
b. The amount of the impairment loss and how fair value was 
determined?
c. The caption in the income statement or statement of activities in 
which the impairment loss is aggregated if that loss has not been 
presented as a separate caption or reported parenthetically on the 
face of the statement?
[SFAS 121, par. 14 (AC I08.133)]
★♦13. If assets to be disposed of are accounted for in accordance with 
paragraphs 15-17 of SFAS 121, are all of the following disclosed in 
financial statements that include a period during which those assets 
are held:
a. A description of assets to be disposed of, the facts and circum­
stances leading to the expected disposal, the expected disposal 
date, and the carrying amount of those assets?
b. The loss resulting from the application of paragraph 15 of SFAS 
121?
c. The gain or loss, resulting from changes in the carrying amounts 
of assets to be disposed of that arises from application of para­
graph 17 of SFAS 121?
d. The caption in the statement of activities/income statement in 
which the gains or losses in b. and c. are aggregated if those gains 
or losses have not been presented as a separate caption or reported 
parenthetically on the face of the statement?
e. The results of operations for assets to be disposed of to the extent 
that those results are included in the entity's results of operations 
for the period and can be identified?
[SFAS 121, par. 19 (AC I08.138)]
★♦ 14. If an impairment loss is recognized, is it reported as a component of 
income from continuing operations before income taxes, or similar 
caption, in the statement of activities or income statement?
[SFAS 121, pars. 13 and 18]
F. Current Liabilities, Notes Payable, and Other Debt
1. Current liabilities:
★♦ a. For classified balance sheets and classified statements of financial 
position, do current liabilities include:
(1) Obligations for items that entered the operating cycle?
(2) Collections received in advance of the performance of services?
(3) Debts that arise from operations directly related to the oper­
ating cycle?
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Yes No NLA
(4) Other liabilities whose regular and ordinary liquidation is
likely to occur within a relatively short time period? ____
(5) Obligations that, by their terms, are due on demand or will
be due within one year (or operating cycle, if longer) from the 
balance-sheet date, even though liquidation may not be ex­
pected within that period? ____
[ARB 43, Ch. 3A, pars. 7 and 8 (AC B05.108 and .109); SFAS
78, par. 5 (AC B05.109A)]
b. Do current liabilities exclude short-term obligations that the
provider intends to refinance on a long-term basis, provided the 
provider has demonstrated the ability to consummate the long­
term financing? ____
[SFAS 6, pars. 8-14 (AC B05.113-.116); FASBI 8, pars. 2-4 (AC 
B05.117, .138, and .139)]
c. In classified statements of financial position and in classified bal­
ance sheets, are current portions of debt obligations presented as
current liabilities? ____
[ARB 43, Ch. 3A, pars. 7 and 8 (AC B05.108 and .109)]
2. Notes payable and other debt:
a. Is there adequate disclosure of interest rates, maturities, and other 
terms and conditions provided in loan agreements and bond 
indentures (such as assets pledged as collateral, and covenants to
reduce debt, and maintain working capital)? ____
[FASCON 5, par. 11; SFAS 5, par. 18 (AC C59.120)]
b. Are the combined aggregate amounts of maturities and sinking
fund requirements for all long-term borrowings disclosed for each 
of the five years following the date of the latest balance sheet 
presented? ____
[SFAS 47, par. 10b (AC C32.105b)]
c. For unconditional purchase obligations that have been recorded
in accordance with SFAS 47, paragraph 6, is the amount of pay­
ments due in the aggregate and for every year during the five years 
following the date of the latest statement of financial position/bal­
ance sheet presented disclosed? ____
[SFAS 47, par. 10a (AC C32.105a)]
d. If a note is non-interest-bearing or has an inappropriate stated 
interest rate:
(1) Is the discount or premium presented as a deduction from or
addition to the face amount of the note? ____
(2) Does the disclosure include the effective interest rate and face
amount of the note? ____
(3) Is amortization of the discount or premium reported as interest? ____
(4) Are issue costs reported in the balance sheet/statement of
financial position as deferred charges? ____
[APB 21, par. 16 (AC I69.109)]
e. Are debt conversion features (such as rates and pertinent dates)
disclosed? ____
[FASCON 5, par. 11; APB 14 (AC D10)]
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Yes No N/A
If a short-term obligation is to be excluded from current liabilities 
in a classified balance sheet/statement of financial position, do 
disclosures include:
(1) General description of the financing agreement?
(2) Terms of any new obligation incurred or expected to be 
incurred, or equity securities issued or expected to be issued 
as a result of the refinancing?
[SFAS 6, par. 15 (AC B05.118)]
g. For troubled debt restructuring occurring during the current pe­
riod, do disclosures include:
(1) Description of the principal changes in terms and/or the 
major features of settlement?
(2) Aggregate gain on restructuring of payables and the related 
income tax effect?
(3) Aggregate net gain or loss on transfers of assets recognized 
during the period?
(4) Per-share amount, if applicable, of the aggregate gain on 
restructuring of payables, net of related income tax effect? 
[SFAS 15, par. 25 (AC D22.121)]
h. For periods after a troubled debt restructuring, do disclosures include:
(1) Extent to which amounts contingently payable are included 
in the carrying amount of restructured payables?
(2) Total amounts contingently payable, if applicable, and con­
ditions under which those amounts would become payable 
or forgiven?
[SFAS 15, par. 26 (AC D22.122)]
i. Are the gains and losses from extinguishment(s) of debt aggre­
gated and, if material, shown as an extraordinary item, net of 
related income tax effect? (Note: Does not apply to gains and 
losses from extinguishments of debt made to satisfy sinking fund 
requirements that the reporting entity must meet within one year 
of the date of the extinguishment.)
[SFAS 4, par. 8, as amended by SFAS 64, par. 4 (AC L35.107)]
j. Are gains or losses from extinguishment(s) made to satisfy sinking 
fund requirements that the reporting entity must meet within one 
year of the date of the extinguishment aggregated and identified 
as a separate item?
[SFAS 4, par. 8, as amended by SFAS 64, par. 4 (AC L35.107)]
k. Do disclosures related to gains and losses classified as extraordi­
nary include the following:
(1) A description of the extinguishment transactions, including 
the sources of any funds used to extinguish debt if it is 
practicable to identify the sources?
(2) The income tax effect in the period of extinguishment?
(3) The per-share amount of the aggregate gain or loss net of 
related income tax effect?
[SFAS 4, par. 9 (AC L35.109)]
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Yes No N/A
l. If debt was considered to be extinguished under the provisions of 
SFAS 76 prior to the effective date of SFAS 125, do disclosures 
include:
(1) A general description of the transaction?
(2) The amount of debt that is considered extinguished at the end 
of the period as long as the debt remains outstanding? 
[SFAS 125, par. 17b (AC L35.109)]
m. If assets are set aside after the effective date of SFAS 125 solely for 
satisfying scheduled payments of a specific obligation, is disclo­
sure made describing the nature of restrictions placed on those 
assets?
[SFAS 125, par. 17c (AC L35.109)]
n. Are long-term obligations that are or will be callable by the credi­
tor, either because the debtor's violation of the debt agreement at 
the balance-sheet/statement-of-financial-position date makes the 
obligation callable, or because the violation (if not cured within a 
specified grace period) will make the obligation callable, classified 
as current unless one of the following conditions is met:
(1) The creditor waives or subsequently loses the right to de­
mand repayment for more than one year (or operating cycle, 
if longer) from the balance-sheet date?
(2) The obligation contains a grace period within which the 
debtor may cure the violation and it is probable that the 
violation will be cured within that period, thus preventing 
the violation from becoming callable?
[SFAS 78, par. 5 (AC B05.109A)]
o. If an obligation under Question n(2) above is included in long­
term liabilities (or in the case of an unclassified balance sheet is 
included as a long-term liability in the disclosure of debt maturi­
ties), are the circumstances disclosed?
[SFAS 78, par. 5 (AC B05.118); see also EITF 86-30]
★ p. Does the not-for-profit provider report tax-exempt obligations 
that were issued for its benefit as liabilities if the provider is 
responsible for repayment?
[AAG, par. 7.15]
q. Is consideration given to the effects, if any, of current and prior tax 
examinations on the financial statements and disclosures related 
to the existence of contingent liabilities for unrelated business 
income tax, additional payroll tax liabilities, or penalties and 
interest on delinquent taxes?
[AAG, par. 7.11]
r. Is disclosure considered for any changes in the provider's activi­
ties that could affect its tax-exempt status?
[AAG, par. 7.11]
s. Are disclosures appropriate regarding the provider's tax-exempt 
status and any other significant tax matters?
[AAG, par. 7.11]
t. Is appropriate disclosure made if unrelated business income tax 
has not been accrued on income from:
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Yes No N/A
(1) Debt-financed investments that are not functionally related
to the exempt purpose? ____
(2) Certain related entities not engaged in an exempt activity? ____
(3) Pharmacy operations in a medical building for the conven­
ience of physicians' private patients? ____
(4) A gift shop, cafeteria or food shop that the provider encour­
ages the general public (except patients, visitors and employ­
ees) to use? ____
(5) A parking lot available to the general public (except patients,
visitors, and employees)? ____
[AAG, pars. 7.10 and 7.11]
G. Other Liabilities and Deferred Credits
1. If the reporting entity has not accrued compensated absences (SFAS
43) because the amount cannot be reasonably estimated, is that fact 
disclosed? ____
[SFAS 43, par. 6 (AC C44.104)]
2. If an obligation for postemployment benefits is not accrued in accord­
ance with SFAS 5 or SFAS 43 only because the amount cannot be 
reasonably estimated, is the fact that the benefits have not been 
accrued disclosed in the financial statements? ____
[SFAS 112, par. 7 (AC P32.105)]
H. Lessor Leases
1. For sales-type and direct financing leases, do disclosures include:
a. Appropriate components of the net investment in the leases as of
the date of each balance sheet/statement of financial position 
presented? ____
[SFAS 91, par. 25d (AC L10.119a)]
b. Future minimum lease payments to be received for each of the five
succeeding fiscal years as of the latest balance-sheet/statement-of- 
financial-position date presented? ____
[SFAS 13, par. 23a (AC L10.119a)]
c. Total contingent rentals included in income for each period for
which an income statement/statement of activities is presented? ____
[SFAS 13, par. 23a (AC L10.119a)]
d. For direct financing leases, the amount of initial direct costs as part
of the investment? ____
[SFAS 91, par. 25d (AC L10.119a(1))]
2. For operating leases, do disclosures include:
a. Cost and carrying amount of property on lease or held for leasing
by major classes and the amount of accumulated depreciation as 
of the date of the latest balance sheet/statement of financial posi­
tion presented? ____
b. Minimum future rentals on noncancelable leases as of the date of 
the latest balance sheet presented in the aggregate and for each of
the five succeeding fiscal years? ____
20
Yes No N/A
c. Total contingent rentals included in income for each period for 
which an income statement/statement of operations is presented? 
[SFAS 13, par. 23b (AC L10.119b)]
★♦3. Do disclosures include a general description of the lessor's leasing 
arrangements?
[SFAS 13, par. 23 (AC L10.119c)]
4. For investments in leveraged leases, do disclosures include:
a. In the balance sheet, the amount of deferred taxes presented 
separately from the remainder of the net investment?
b. In the income statement or the notes thereto, separate presentation 
(from each other) of pretax income from the leveraged lease, the 
tax effect of pretax income, and the amount of investment tax 
credit recognized as income during the period?
c. When leveraged leasing is a significant part of the lessor's business 
activities in terms of revenue, net income, or assets, the compo­
nents of the net investment balance in leveraged leases in the notes 
to the financial statements?
[SFAS 13, par. 47 (AC L10.149)]
5. For leasing transactions with related parties, are the nature and extent 
of the transaction disclosed?
[SFAS 13, par. 29 (AC L10.125)]
I. Lessee Leases
1. For capital leases do disclosures include:
a. Gross amounts of assets recorded by major classes, as of the date 
of each balance sheet/statement of financial position presented? 
[SFAS 13, par. 16a.i. (AC L10.112a(1))]
b. Future minimum lease payments, as of the date of the latest 
balance sheet/statement of financial position presented, in total 
and for each of the next five years, with separate deductions for 
executory costs and imputed interest to reduce net minimum lease 
payments to present value?
[SFAS 13, pars. 10 and 16a.ii. (AC L10.106 and .112a(2))]
c. Total future minimum sublease rentals under noncancelable sub­
leases as of the date of the latest balance sheet/statement of 
financial position presented?
[SFAS 13, par. 16a.iii (AC L10.112a(3))]
d. Total contingent rentals actually incurred for each period presented? 
[SFAS 13, par. 16a.iv (AC L10.112a(4))]
e. Assets recorded under capital leases and the related accumulated 
amortization, and obligations under those leases identified sepa­
rately in the balance sheet/statement of financial position or a 
note?
[SFAS 13, pars. 13 and 16 (AC L10.112a)]
2. For operating leases that have initial or remaining noncancelable lease 
terms in excess of one year, do disclosures include:
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Yes No N/A
a. Future minimum rental payments required as of the latest balance 
sheet/statement of financial position presented in total and for
each of the next five years? ____
b. Total future minimum rentals under noncancelable subleases as
of the date of the latest balance sheet/statement of financial posi­
tion presented? ____
[SFAS 13, par. 16b (AC L10.112b)]
3. For all operating leases, do disclosures include rental expense for each 
period presented, with separate amounts for minimum rentals, con­
tingent rentals, and sublease rentals? ____
[SFAS 13, par. 16c (AC L10.112c)]
★♦4. Do disclosures include a general description of the lessee's leasing 
arrangements including, but not limited to:
a. Bases for determination of contingent rentals? ____
b. Terms of any renewal or purchase options or escalation clauses? ____
c. Restrictive covenants? ____
[SFAS 13, par. 16d (AC L10.112d)]
5. Is the nature and extent of leasing transactions with related parties 
disclosed? ____
[SFAS 13, par. 29 (AC L10.125)]
★♦6. If material, is the accounting policy used in recognizing amounts 
related to a modification of an operating lease (that does not change 
the lease classification) disclosed? ____
[EITF 95-17]
J. Net Assets
♦ 1. Are the equity accounts of investor-owned providers presented in a
similar fashion as other investor-owned businesses? ____
[AAG, par. 9.01]
2. Is the nature of restrictions on donor-restricted resources disclosed? ____
[AAG, par. 9.07]
♦ 3. Are limits on the use of unrestricted net assets (such as loan covenants
and board-designated endowments) and information about the na­
ture and amounts of different types of permanent and temporary 
restrictions disclosed? ____
[SFAS 117, par. 16 (AC No5.114); AAG, pars. 9.03 and 9.04]
★4. Are net assets released from restriction, such as those related to the 
fufillment of time or purpose restrictions, reported separately in the 
financial statements or disclosed in the notes? ____
[AAG, par. 10.07]
♦ 5. Shareholders' equity (corporations):
a. For each class of stock, do disclosures include the number of shares 
authorized, issued and outstanding, and par or stated value per 
share and changes therein? ____
[Generally Accepted]
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Yes No N/A
b. Do the financial statements include a description, in summary 
form, sufficient to explain the pertinent rights and privileges of the 
various securities outstanding, (e.g., dividend and liquidation 
preferences, participation rights, call prices and dates, conversion 
or exercise prices or rates and pertinent dates, sinking fund re­
quirements, unusual voting rights, significant terms of contracts 
to issue additional shares)?
[SFAS 129, par. 4 (AC C24.102)]
c. Do disclosures include the number of shares issued upon conver­
sion, exercise, or satisfaction of required conditions during at least 
the most recent annual fiscal period and any subsequent interim 
period presented?
[SFAS 129, par. 5 (AC C24.103)]
d. Are the following disclosed on the face of the statement of financial 
position or in the notes:
(1) The aggregate or per-share amounts at which preferred stock 
may be called or is subject to redemption through sinking- 
fund operations or otherwise?
(2) The aggregate and per-share amounts of arrearages in cumu­
lative preferred dividends?
[SFAS 129, par. 7 (AC C24.105)]
e. For preferred stock that has a preference in involuntary liquida­
tion considerably in excess of par or stated value of the shares, is 
the liquidation preference disclosed? [Note: Disclosure shall be 
made in the equity section of the statement of financial position 
in the aggregate, either parenthetically or "in short," rather than 
on a per-share basis or through disclosure in the notes.]
[SFAS 129, par. 6 (AC C24.104)]
f. For redeemable stock, do disclosures include the amount of re­
demption requirements, separately by issue or combined, for all 
issues of capital stock that are redeemable at fixed or determinable 
prices on fixed or determinable dates in each of the five years 
following the date of the latest statement of financial position 
presented?
[SFAS 129, par. 8 (AC C24.106)]
g. Are any appropriations of retained earnings for loss contingencies 
clearly identified and included in stockholders' equity?
[SFAS 5, par. 15 (AC R70.103)]
h. Are restrictions on payment of dividends disclosed? 
[SFAS 5, pars. 18 and 19 (AC C59.120)]
i. Are receivables for stock issued or subscribed appropriately iden­
tified and presented as a deduction from capital or, if presented as 
an asset, stated separately, clearly labeled, and their status clearly 
described to distinguish them from any other type of assets?
♦ j. Are the carrying basis, the cost and the number of shares disclosed 
for treasury stock?
[Generally Accepted]
k. Are preferred stock dividends in arrears and dividend restrictions 
disclosed?
[SFAS 5, par. 18 (AC C59.120)]
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Yes No N/A
♦ I. After completion of a quasi-reorganization, is a new retained
earnings account established and dated with the date being dis­
closed in subsequent financial statements until it is no longer 
deemed significant?
[ARB 43, Ch. 7A, par. 10; ARB 46, par. 2 (AC Q15.111)]
♦ m. Are the nature and extent to which retained earnings is restricted
indicated?
[APB 6, par. 13 (AC C23.104)]
6. Changes in net assets:
a. When both financial position and results of operations are 
presented:
(1) Are changes in the separate component accounts of equity 
disclosed?
[APB 12, par. 10 (AC C08.102)]
(2) Are changes in the number of shares of capital stock disclosed 
for at least the latest year and any subsequent interim periods 
presented (for-profit only)?
[APB 12, par. 10 (AC C08.102)]
b. Are prior-period adjustments and their resulting effects (both 
gross and net of applicable income taxes) appropriately presented 
and disclosed?
[APB 9, par. 26 (AC A35.107)]
c. For a correction of an error, is the nature of the error disclosed in 
the period in which the error was discovered and corrected?
(1) Nature of the error in previously issued financial statements?
(2) Effect of its correction on income before extraordinary items, 
net income, and related per-share amounts, if applicable? 
[APB 20, par. 37 (AC C35.105)]
K. Restricted Resources
★ 1. Are cash or other assets received with a donor-imposed restriction
that limits their use to long-term purposes reported separately from 
assets that are unrestricted and available for current use?
[SFAS 117, par. 11 (AC No5.109)]
★ 2. Does the entity provide information about the nature and amounts of
different types of permanent restrictions and temporary restrictions by 
reporting their amounts on the face of the statement of financial position 
or by including relevant details in notes to financial statements? 
[SFAS 117, par. 14 (AC No5.112)]
Statement of Activities/Income Statement/Statement of 
Operations/Statement of Changes in Net Assets
A. General
★ 1. Does the statement of activities/operations or statement of changes
in net assets report the amount of change in net assets for the period 
for the provider as a whole (using a descriptive term such as "change 
in net assets" or "change in equity"), and does that amount articulate 
to the net assets reported in the statement of financial position? 
[SFAS 117, par. 18 (AC No5.116)]
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★ 2. Does the statement of activities/operations or the statement of
changes in net assets report the amount of change in permanently 
restricted net assets, temporarily restricted net assets, and unre­
stricted net assets for the period? ____
[SFAS 117, par. 19 (AC No5.117)]
★ 3. Does the statement of activities/operations report the following:
a. Revenues as increases in unrestricted net assets unless the use of
the assets received is limited by donor-imposed restrictions? ____
b. Expenses as decreases in unrestricted net assets? ____
c. Events that simultaneously increase one class of net assets and 
decrease another (reclassifications), including expiration of donor- 
imposed restrictions, separately from revenues, expenses, gains,
and losses? ____
[SFAS 117, pars. 19 and 20 (AC No5.117 and .118); SFAS 116, par.
17 (AC No5.147)]
★ 4. Are revenues and expenses (arising from ongoing activities associated
with health care services) classified as operating and displayed as 
gross amounts? ____
[SFAS 117, par. 24 (AC No5.121)]
★ 5. If the provider elects to report investment revenues net of related
expenses, does the provider disclose the amount of expenses, either 
on the face of the statement of activities or in the notes to the financial 
statements? ____
[SFAS 117, par. 24 (AC No5.121)]
★ 6. If the entity reports an intermediate measure of operations (for exam­
ple, excess or deficit of operating revenues over expenses), is this 
intermediate measure reported only in a financial statement that, at a 
minimum, reports the change in unrestricted net assets for the period? ____
[SFAS 117, par. 23 (AC No5.120)]
★ 7. If the entity's use of the term operations is not apparent from the details
provided on the face of the statement of activities, does a note to 
financial statements describe the nature of the reported measure of 
operations or the items excluded from operations? ____
[SFAS 117, par. 23 (AC No5.120)]
★ 8. If the entity reports net gains and losses or revenue and expense on
its statement of activities/operations, do these net amounts result 
from peripheral or incidental transactions or from events largely 
beyond the control of the entity and its management? ____
[SFAS 117, pars. 25 and 138 (AC No5.122)]
★ 9. Does the not-for-profit provider report total income or loss in a
statement that, at a minimum, also presents the total changes in 
unrestricted net assets? ____
[AAG, par. 10.17]
10. Is management's policy for providing charity care, as well as the level 
of charity care provided, disclosed? ____
[AAG, par. 10.21]
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★ 11. Does the statement of activities/operations include a performance
indicator that reports results of operations and that is clearly labeled 
with a descriptive term such as revenues over expenses, revenues and 
gains over expenses and losses, earned income, or performance earnings? 
[AAG, par. 10.17]
★ 12. Do the notes to the financial statements include a description of the
nature and composition of the performance indicator? 
[AAG, par. 10.17]
★♦ 13. Does the organization report the following items separately from the 
performance indicator:
a. Transactions with owners acting in that capacity?
b. Equity transfers involving other entities that control the reporting 
entity, are controlled by the reporting entity, or are under common 
control with the reporting entity?
c. Receipt of restricted contributions, including temporary restric­
tions (such as time or purpose) or permanent restrictions?
d. Contributions of (and assets released from donor restrictions re­
lated to) long-lived assets?
e. Unrealized gains and losses on investments not restricted by 
donors or by law, except for those investments classified as trading 
securities?
f. Investment returns restricted by donors or by law?
g. Other items that are required by GAAP to be reported separately 
(such as extraordinary items, the effect of discontinued operations, 
or the cumulative effect of accounting changes)?
[AAG, par. 10.18]
★♦14. For investments in common stock accounted for by the equity 
method, is the investor's share of earnings shown as a single amount 
except for investee extraordinary items and prior-period adjustments 
that are material to the investor?
[APB 18, pars. 19c and d (AC 182.109c and d)]
★♦ 15. Are total research and development costs charged to expenses dis­
closed for each period for which a statement of activities/income 
statement is presented?
[SFAS 2, pars. 12 and 13 (AC R50.108 and .109); FASBI 4, par. 5 (AC 
B50.152); FASBI 6, par. 8 (AC R50.117); SFAS 86, par. 3 (AC Co2.102)]
★♦ 16. If the provider accounts for its obligation under a research and devel­
opment arrangement as a contract to perform research and develop­
ment for others, is there disclosure of:
a. The terms of significant agreements under the research and develop­
ment arrangement as of the date of each balance sheet presented?
b. The amount of compensation earned or costs incurred under such 
contracts for each period for which a statement of revenues and 
expenses (statement of operations) is presented?
[SFAS 68, par. 14 (AC R55.112)]
26
Yes No N/A
♦ 17. Are the following excluded from the determination of net income or 
results of operations under all circumstances:
a. Adjustments or charges or credits resulting from transactions in 
the provider's own capital stock?
b. Transfers to and from accounts properly designated as appropri­
ated retained earnings?
c. Adjustments made pursuant to a quasi-reorganization? 
[APB 9, par. 28 (AC C08.101)]
★ 18. Are net assets released from restriction, such as those related to the 
fulfillment of time or purpose restrictions, reported separately in the 
financial statements or disclosed in the notes?
[AAG, par. 10.07]
B. Revenue
★♦ 1. Is revenue classified based on the type of service (such as patient or 
resident) rendered or contracted to be rendered? ____
[AAG, par. 10.04]
★♦ 2. Are gains, losses, and interest earned properly classified and reported? ____
[AAG, par. 10.07]
★♦ 3. Is patient service revenue reported net of provisions for contractual 
charity care and other adjustments? ____
[AAG, par. 10.20]
★♦4.
★♦5.
Do disclosures include methods of revenue recognition? 
[AAG, par. 10.20]
With regard to contractual adjustments and third-party settlements, 
does the provider identify and explain the estimated amounts payable 
or receivable?
[AAG, par. 10.20]
★ 6. Is significant revenue earned under capitation arrangements reported 
separately?
[AAG, par. 10.20]
C. Income Taxes
♦ 1. Are the types of significant temporary differences and carryforwards
disclosed?
[SFAS 109, par. 43 (AC I27.142)]
♦ 2. Are the following significant components of income tax expense
attributable to continuing operations for each year presented dis­
closed in the financial statements or notes thereto:
a. Current tax expense or benefit?
b. Deferred tax expense or benefit (exclusive of the effects of other 
components listed below)?
c. Investment tax credits?
27
Yes No N/A
d. Government grants (to the extent recognized as a reduction of 
income tax expense)?
e. The benefits of operating loss carryforwards?
f. Tax expense that results from allocating certain benefits, either 
directly to contributed capital or to reduce goodwill or other 
noncurrent intangible assets of an acquired entity?
g. Adjustments of a deferred tax liability or asset for enacted changes 
in tax laws or rates or a change in the tax status of the provider?
h. Adjustments of the beginning-of-the-year balance of a valuation 
allowance because of a change in circumstances that causes a 
change in judgment about the realizability of the related deferred 
tax asset in future years?
i. Any portion of the valuation allowance for deferred tax assets for 
which subsequently recognized tax benefits will be allocated to 
reduce goodwill or other noncurrent intangible assets of an ac­
quired entity or directly to contributed capital?
[SFAS 109, pars. 45 and 48 (AC I27.144 and .147)]
♦ 3. Is the amount of income tax expense or benefit allocated to continuing
operations and the amounts separately allocated to other items dis­
closed for each year for which those items are presented? 
[SFAS 109, pars. 35-39 and 46 (AC I27.134-.138 and .145)]
♦ 4. a. Is a reconciliation for public enterprises disclosed by the use of
percentages or dollars of (i) the reported amount of income tax 
expense attributable to continuing operations for the year to date 
to (ii) the amount of income tax expense that would result from 
applying domestic federal statutory rates to pretax income from 
operations?
b. Is the nature of significant reconciling items (omission of numerical 
reconciliation is permitted) for a non-public enterprise disclosed?
c. If not otherwise evident, are the nature and effect of any other 
significant matters affecting comparability of information for all 
periods present?
[SFAS 109, par. 47 (AC 127.145)]
♦ 5. Are the amounts and expiration dates of operating loss and tax credit
carryforwards for tax purposes disclosed?
[SFAS 109, par. 48 (AC I27.147)]
♦ 6. If the provider is a member of a group that files a consolidated tax
return, are the following items disclosed in its separately-issued finan­
cial statements:
a. The aggregate amount of current and deferred tax expense for 
each period presented, and the amount of any tax-related balances 
due to or from affiliates as of the date of each balance sheet 
presented?
b. The method by which the consolidated amount of current and de­
ferred tax expense is allocated to members of the group and the 
nature and effect of any changes in that method (and in determining 
related balances to or from affiliates) for each period presented? 
[SFAS 109, par. 49 (AC I27.148)]
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♦ 7. Are the amounts of income taxes applicable to the results of discon­
tinued operations disclosed on the income statement or in related 
notes?
[APB 30, par. 8 (AC I13.105)]
♦ 8. Are the income taxes applicable to extraordinary events disclosed on
the face of the income statement or in related notes?
[APB 30, par. 11 (AC I17.102)]
D. Discontinued Operations
1. Are operations of a segment that are discontinued or are the subject 
of a formal plan for disposition:
a. Reported separately from continuing operations and as a compo­
nent (including applicable income taxes) of income before extraor­
dinary items and the cumulative effect of accounting changes (if 
any)?
b. Accompanied by disclosure in the notes of revenue applicable to 
the discontinued operations?
[APB 30, par. 8 (AC I13.105)]
★♦2. Is gain or loss from disposal of a discontinued segment reported 
separately (including applicable income taxes) in conjunction with 
results of discontinued operations as a component of income before 
extraordinary items and the cumulative effect of accounting changes 
(if any)?
[APB 30, pars. 8, 13, and 15-18 (AC I13.101-.103, .105, .106, .108, and 
.109)]
3. If a provider has accounted for the discontinuance of a segment in 
accordance with APB 30 and subsequently decides to retain the seg­
ment, is any impairment write-down of the individual assets classi­
fied in continuing operations?
[EITF 90-16]
4. If the entity plans to dispose of two segments of a business, and a net 
gain is expected (one has a net gain and the other a net loss), is that 
gain shown net?
[EITF 85-36]
5. Are the revenues applicable to the discontinued operations disclosed 
in the notes to the financial statements?
[APB 30, par. 8 (AC I13.105)]
★♦6. For the period encompassing the measurement date, do notes to 
financial statement disclose:
a. Identity of the segment discontinued?
b. Expected disposal date, if known?
c. Expected manner of disposal?
d. Description of the remaining assets and liabilities of the discontin­
ued segment at the balance-sheet date?
e. Results of operations and any proceeds from disposal of the 
discontinued segment during the period from the measurement 
date to the balance-sheet date?
[APB 30, par. 18 (AC I13.108)]
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 7. If the loss on disposal cannot be estimated within reasonable limits, 
is that fact disclosed?
[APB 30, par. 18, fn. 7 (AC I13.109)]
8. For periods subsequent to the measurement date and including the 
period of disposal, do notes to the financial statements disclose the 
information listed in Questions 6a, b, c, and d above as well as the 
information in 6e compared with prior estimates?
[APB 30, par. 18 (AC I13.108)]
★♦9. If the entity decides to dispose of a segment of a business and the 
measurement date occurs after the balance-sheet/statement-of-finan- 
cial-position date but before the financial statements for the prior 
period have been issued:
a. Are the segment's operating results presented as discontinued 
operations in the income statement/statement of operations of the 
not-yet-released financial statements?
b. Is the estimated loss on disposal recognized in the period that 
includes the measurement date, if the decision to dispose of the 
segment results from a discrete and identifiable event that occurs 
unexpectedly after the balance-sheet date?
c. Is the estimated loss on disposal recognized in the period prior to 
the measurement date, if the decision to dispose of the segment 
does not result from a discrete and identifiable event that occurs 
unexpectedly after the balance-sheet date?
[EITF 95-18]
E. Extraordinary Items
1. Are extraordinary items segregated and shown (including applicable 
income taxes) after income before extraordinary items and before net 
income?
[APB 30, pars. 10-12 (AC I17.102 and .103)]
2. Are descriptive captions and amounts (including applicable income 
taxes) presented for individual extraordinary events or transactions, 
preferably on the face of the statement of operations/income state­
ment, if practicable?
[APB 30, par. 11 (AC I17.102)]
★♦3. Do disclosures include descriptions of extraordinary events or trans­
actions and the principal items entering into determination of extraor­
dinary gains or losses?
[APB 30, par. 11 (AC I17.102)]
4. For an adjustment of an extraordinary item reported in a prior period 
(except for correction of an error):
a. Is the adjustment classified separately as an extraordinary item in 
the current period?
b. Are the nature, origin, and amount of the item disclosed? 
[SFAS 16, par. 16(c) (AC I17.119)]
F. Unusual or Infrequent Items
1. Are material events or transactions that are either unusual in nature 
or of infrequent occurrence, but not both (and therefore not meeting 
criteria for extraordinary items):
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a. Reported as a separate component of income from continuing
operations? ____ ___
b. Accompanied by disclosure of the nature and financial effects of
each event? ____ ___
[APB 30, par. 26 (AC I22.101)]
G. Advertising Costs
1. Do disclosures for advertising costs include:
a. The accounting policy selected from the two alternatives in the 
beginning of paragraph 26 of SOP 93-7 for reporting advertising, 
indicating whether such costs are expensed as incurred or the first
time the advertising takes place? ____ ___
b. A description of the direct-response advertising reported as assets
(if any), the accounting policy for it, and the amortization period? ____ ___
c. The total amount charged to advertising expense for each state­
ment of activities/income statement presented, with separate dis­
closure of amounts, if any, representing a write-down to net
realizable value? ____ ___
d. The total amount of advertising reported as assets in each balance
sheet/statement of financial position presented? ____ ___
[SOP 93-7, par. 49]
H. Donated or Contributed Services
★ 1. If the provider receives contributed services, does it disclose the 
following:
a. A description of the programs or activities for which those services 
were used, including the nature and extent of contributed services 
received for the period and the amount recognized as revenues for
the period? ____ ___
b. The fair value of contributed services received but not recognized,
if practicable (optional)? ____  ___
c. Nonmonetary information such as the number and trends of 
donated hours received or service outputs provided by volunteer
efforts (optional)? ____ ___
d. Dollar amount of contributions raised by volunteers (optional)? ____ ___
[SFAS 116, pars. 10 and 123 (AC C67.110)]
I. Fund Raising
Note: SOP 98-2, Accounting for Costs of Activities of Not-for-Profit Organiza­
tions and State and Local Governmental Entities That Include Fund Raising, is 
effective for financial statements for years beginning on or after December 
15, 1998. Earlier application is encouraged in fiscal years for which finan­
cial statements have not been issued. If comparative financial statements 
are presented, retroactive application is permitted but not required.
★ 1. Do financial statement disclosures include:
a. The types of activities for which joint costs have been incurred?
b. A statement that such costs have been allocated?
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c. The total amount allocated during the period and the portion 
allocated to each functional expense category?
[SOP 98-2, par. 18]
Note: SOP 98-2 encourages, but does not require, that the amount of joint 
costs for each kind of joint activity be disclosed, if practical.
J. Contributions/Pledges
★ 1. Does the provider distinguish between contributions received with per­
manent restrictions, those received with temporary restrictions, and 
those received without donor-imposed restrictions, so that they are 
reported as support increasing permanently restricted net assets, tempo­
rarily restricted net assets, or unrestricted net assets, respectively? 
[SFAS 116, par. 14 (AC No5.143)]
★ 2. If donor-restricted contributions whose restrictions are met in the
same reporting period are reported as unrestricted support, is such 
treatment consistent from period to period and is the policy disclosed? 
[SFAS 117, par. 21; SFAS 116, par. 14 (AC No5.143)]
★ 3. Does the provider report receipt of unconditional promises to give 
with payments due in future periods as restricted support, unless 
explicit donor stipulations or circumstances surrounding the receipt 
of the promise make clear that the donor intended the contribution to 
be used to support activities of the current period?
[SFAS 116, par. 15 (AC No5.144)]
★4. Does an entity that receives gifts of long-lived assets without donor 
stipulation about how long the donated asset must be used:
a. Disclose its accounting policy of implying or not implying a time 
restriction that expires over the useful life of the asset?
b. Report such support as restricted if it is the provider's policy to 
imply a time restriction that expires over the useful life of the 
donated asset?
c. Report such support as unrestricted in the absence of such a 
policy?
[SFAS 116, par. 16 (AC No5.145)]
★ 5. Does a provider that receives unconditional promises to give, in
which cash promised will be received in future periods, measure the 
fair value of the contribution as the present value of estimated future 
cash flows, using a discount rate commensurate with the risks in­
volved, and report subsequent accruals of the interest element as 
contribution income increasing either the temporarily or permanently 
restricted class of net assets if the underlying promise to give is donor 
restricted?
[SFAS 116, par. 20 (AC C67.116)]
★ 6. In discounting unconditional promises to give (as described in Step
5), are the provisions of APB 21 applied?
[SOP 94-2, par. 20]
7. Are unrestricted pledges/contributions reported in the statement of 
operations?
[AAG, par. 10.08]
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K. Expenses
★ 1. Does the provider provide information about expenses reported by
their functional classification (such as major classes of program serv­
ices and supporting services) either in the statement of activities or in 
notes to financial statements?
[SFAS 117, par. 26 (AC No5.123)]
★ 2. For deferred compensation agreements, are estimated amounts to be
paid properly accrued?
[APB 12, pars. 6 and 7 (AC C38.101 and .102)]
L. Wills
★♦1. If the entity receives a promise to give conditioned on a future 
uncertain event that is contained in a will and the will has been 
declared valid by the probate court, has the provider disclosed the 
conditional promise to give?
[SFAS 116, par. 208 (AC C67.160)]
M. Endowments
★ 1. Does the provider report gains and losses on endowments in the
following manner:
a. As an increase or decrease in permanently restricted net assets if the 
governing board has determined that the relevant law requires the 
entity to retain permanently some portion of gains on investments? 
[SFAS 117, pars. 22 and 129 (AC No5.119)]
b. As an increase or decrease in unrestricted or temporarily restricted 
net assets, whichever is consistent with the reporting of the en­
dowment's income in the absence of such a law noted in Step a.? 
[SFAS 117, par. 129 (AC No5.119, fn. 8)]
N. Earnings Per Share
Note: SFAS 128, Earnings per Share, applies only to entities with publicly 
held common stock or potential common stock.
♦ 1. Are earnings per share (EPS) data presented for all periods for which
an income statement or summary of earnings is presented? 
[SFAS 128, par. 38 (AC E11.133)]
♦ 2. If diluted EPS data are reported for at least one period, are they reported
for all periods presented, even if they are the same amounts as basic EPS? 
[SFAS 128, par. 38 (AC E11.133)]
♦ 3. For entities with only common stock outstanding, are basic EPS
amounts for income from continuing operations and for net income 
presented on the face of the income statement?
[SFAS 128, par. 36 (AC E11.131)]
♦ 4. For entities with potential common stock, are basic and diluted EPS
amounts for income from continuing operations and for net income 
presented on the face of the income statement with equal prominence? 
[SFAS 128, par. 36 (AC E11.131)]
♦ 5. If discontinued operations, extraordinary items, or the cumulative 
effect of accounting changes are reported in a period, are the basic and
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diluted per share amounts for those line items presented on the face 
of the income statement or in the notes? ____
[SFAS 128, par. 37 (AC E11.132)]
♦ 6. If per share amounts not required to be presented by SFAS 128 are
disclosed, are they disclosed only in the notes and do the disclosures 
indicate whether the per share amounts are pretax or net of tax? ____
[SFAS 128, par. 37 (AC E11.132)]
♦ 7. Are the following disclosed for each period for which an income
statement is presented:
a. A reconciliation of the numerators and denominators of the basic
and diluted per share computations for income from continuing 
operations? ____
b. The effect that has been given to preferred dividends in arriving at
income available to common stockholders in computing basic EPS? ____
c. Securities (including those issuable pursuant to contingent stock 
agreements) that could potentially dilute basic EPS in the future 
that were not included in the computation of diluted EPS because
to do so would have been antidilutive for the period(s) presented? ____
[SFAS 128, par. 40 (AC E11.135)]
♦ 8. For the latest period for which an income statement is presented, do
disclosures include a description of any transaction that occurs after 
the end of the most recent period but before issuance of the financial 
statements that would have changed materially the number of com­
mon shares or potential common shares outstanding at the end of the 
period if the transaction had occurred before the end of the period? ____
[SFAS 128, par. 41 (AC E11.136)]
O. Comprehensive Income
♦ 1. If there are components of other comprehensive income (SFAS 130,
paragraphs 5 and 10) for the period presented, is comprehensive 
income reported? ____
[SFAS 130, par. 15 (AC C49.109)]
♦ 2. Is total comprehensive income displayed in the financial statement in
which the components of other comprehensive income are reported? ____
[SFAS 130, par. 14 (AC C49.108)]
♦ 3. Is other comprehensive income classified separately into foreign cur­
rency items, minimum pension liability adjustments, and unrealized 
gains and losses on certain investments in debt and equity securities? ____
[SFAS 130, par. 17 (AC C49.111)]
♦ 4. Are reclassification adjustments presented on the face of the financial
statement in which comprehensive income is reported or disclosed in 
the notes? ____
[SFAS 130, par. 20 (AC C49.114)]
♦ 5. Is net income displayed as a component of comprehensive income? ____
[SFAS 130, par. 22 (AC C49.116)]
♦ 6. (Not required, but encouraged) Are the components of other compre­
hensive income and total comprehensive income displayed below the 
total for net income? ____
[SFAS 130, par. 23 (AC C49.117)]
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  7. Are the components of other comprehensive income displayed either 
net of related tax effects, or before related tax effects with one amount 
shown for the aggregate tax effect related to the total of other compre­
hensive income items?
[SFAS 130, par. 24 (AC C49.118)]
♦ 8. Is the amount of income tax expense or benefit allocated to each 
component of other comprehensive income (including reclassifica­
tion adjustments) disclosed in the notes?
[SFAS 130, par. 25 (AC C49.119)]
♦ 9. Is the total of other comprehensive income for a period transferred to a
component of equity that is displayed separately from retained earnings 
and additional paid-in-capital in a statement of financial position with a 
descriptive title such as accumulated other comprehensive income? 
[SFAS 130, par. 26 (AC C49.120)]
♦ 10. Are accumulated balances for each classification within accumulated
other comprehensive income disclosed on the face of the statement of 
financial position, in a statement of changes in equity, or in the notes? 
[SFAS 130, par. 26 (AC C49.120)]
♦ 11. If condensed interim financial statements are issued, is total compre­
hensive income reported?
[SFAS 130, par. 27 (AC C49.121)]
♦ 12. Are unrealized holding gains and losses for available-for-sale securi­
ties, including those classified as current assets, reported in other 
comprehensive income?
[SFAS 115, par. 13, as amended by SFAS 130 (AC I80.110)]
★♦ 13. If an additional pension liability is required to be recognized and 
exceeds unrecognized prior service cost, is the excess (which would 
represent a net loss not yet recognized as net periodic pension cost) 
reported in other comprehensive income net of any tax benefits that 
result from considering such losses as temporary differences? 
[SFAS 87, par. 37, as amended by SFAS 130 (AC P16.131)]
Note: Questions 14 and 15 apply only if SFAS 133, Accounting for Derivative 
Instruments and Hedging Activities, has been adopted. SFAS 133 is effective for 
all fiscal quarters of fiscal years beginning after June 15, 1999.
The FASB has issued an exposure draft dated May 20, 1999 of a 
proposed Statement titled "Accounting for Derivative Instruments and 
Hedging Activities—Deferral of the Effective Date of FASB Statement 
No. 133, an amendment of FASB Statement No. 133," which would 
amend SFAS 133 to defer its effective date to all fiscal quarters of all 
fiscal years beginning after June 15, 2000. The comment deadline was 
June 19, 1999. Users of this checklist should be alert to the issuance of 
a final pronouncement.
♦ 14. Has the entity displayed as a separate classification within other 
comprehensive income the net gain or loss on derivative instruments 
designated and qualifying as cash flow hedging instruments that are 
reported in comprehensive income pursuant to paragraphs 30 and 41 
of SFAS 133?
[SFAS 133, par. 46 (AC D50.143)]
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♦ 15. As part of the disclosures of accumulated other comprehensive in­
come, pursuant to paragraph 26 of SFAS 130, Reporting Comprehensive 
Income, has the entity separately disclosed the beginning and ending 
accumulated derivative gain or loss, the related net change associated 
with current period hedging transactions, and the net amount of any 
reclassification into earnings?
[SFAS 133, par. 47 (AC D50.144)]
Statement of Cash Flows2
2 SFAS 95, Statement of Cash Flows, and GASB Statement 9, Reporting Cash Flows of Proprietary and Nonexpendable Trust Funds and 
Governmental Entities That Use Proprietary Fund Accounting, established standards for cash flow reporting for investor-owned 
organizations and governmental entities, respectively. SFAS 95 excludes not-for-profit organizations from its scope; however, not-for- 
profit health care entities should apply the provisions of SFAS 95 to ensure that their financial statements are comparable with those of 
investor-owned entities. The statement of cash flows may be prepared using the direct or indirect method of reporting cash flows. 
(SFAS 117 amends SFAS 95 to extend its provisions to not-for-profit organizations and to extend its description of cash flows from 
financing activities to include certain donor-restricted cash that must be used for long-term purposes.)
1. Is a statement of cash flows presented as a basic financial statement for 
each period for which both a statement of financial position/balance 
sheet and a statement of activities/income statement is presented? 
[SFAS 95, par. 3, as amended by SFAS 117, par. 30a (AC C25.101); 
AAG, par. 1.07]
2. Does the statement of cash flows show the change in cash and cash 
equivalents?
[SFAS 95, par. 7 (AC C25.105)]
3. Is the policy for defining cash equivalents disclosed? 
[SFAS 95, par. 10 (AC C25.108)]
Note: Any change in policy for determining which items are treated as 
cash equivalents is a change in accounting principle.
★♦4. If the direct method is used, is a separate schedule provided to 
reconcile net income of an investor-owned provider or change in net 
assets (or excess of revenue and support over expenses) of a not-for- 
profit provider to net cash flow from operating activities?
[SFAS 95, par. 30, as amended by SFAS 117, par. 30f (AC C25.128)]
5. If the indirect method is used:
a. Is the same amount for net cash flow from operating activities 
reported indirectly by adjusting net income of an investor-owned 
provider or change in net assets (or excess of revenue and support 
over expenses) of a not-for-profit provider to reconcile it to net 
cash flow from operating activities?
[SFAS 95, par. 28, as amended by SFAS 117, par. 30f (AC C25.126)]
b. Is the reconciliation of net income of an investor-owned provider or 
change in net assets (or excess of revenue and support over expenses) 
of a not-for-profit provider to net cash flows from operating activities 
reported, either within the statement of cash flows or provided in a 
separate schedule, with the statement of cash flows reporting only 
the net cash flow from operating activities?
[SFAS 95, par. 30, as amended by SFAS 117, par. 30f (AC C25.128)] 
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★♦ 6. Are cash receipts and cash payments from operating activities shown 
separately on the statement of cash flows?
[SFAS 95, par. 27 (AC C25.125)]
7. Are cash receipts and cash payments for the following transactions 
classified as cash flows from operating activities:
a. Interest received on loans?
b. Insurance proceeds except those directly related to investing or 
financing activities?
c. Interest paid to creditors?
d. Payments to suppliers and employees?
e. Payments to governments for taxes, duties, fines, and other fees 
or penalties?
f. Payments to settle lawsuits?
g. Contributions to charities?
[SFAS 95, pars. 22 and 23 (AC C25.120 and .121)]
h. Cash flows from purchases, sales, and maturities of trading secu­
rities?
[SFAS 115, par. 18 (AC I80.117); AAG, par. 4.15]
8. Are cash receipts and cash payments from investing activities shown 
separately on statement of cash flows?
[SFAS 95, par. 31 (AC C25.129)]
9. Are cash receipts and cash payments for the following transactions 
classified as cash flows from investing activities:
a. Receipts from collections or sales of loans?
b. Receipts from sales of property?
c. Loans to others?
d. Payments to acquire property?
e. Purchases of and proceeds from sales of available-for-sale securi­
ties?
f. Proceeds from maturities of available for sale and held-to-matur­
ity securities?
g. Purchases of held-to-maturity securities?
[SFAS 95, pars. 16 and 17 (AC C25.114 and .115); SFAS 115, par. 18 
(AC I80.117)]
★♦ 10. Are cash receipts and cash payments from financing activities shown 
separately on the statement of cash flows?
[SFAS 95, par. 31 (AC C25.129)]
★♦11. Are cash receipts and cash payments for the following transactions 
classified as cash flows from financing activities:
a. Proceeds from issuing debt?
b. Repayments for amounts borrowed?
[SFAS 95, pars. 19 and 20 (AC C25.117 and .118)]
c. Cash payments for debt issue costs? 
[EITF 95-13]
37
Yes No N/A
 12. Are investing and financing activities that affect recognized assets or 
liabilities but that do not result in cash receipts or cash payments 
disclosed?
[SFAS 95, par. 32, as amended by SFAS 117, par. 30g (AC C25.134)]
13. In its statement of cash flows, does the organization include in cash 
flows from financing activities any amounts received with donor-im­
posed stipulations that they must be used for long-term purposes? 
[SFAS 117, par. 30c (AC C25.116)]
14. Are the following classes of operating cash receipts and payments for 
providers using the direct method, at a minimum, separately disclosed:
a. Cash received from service recipients?
b. Cash received from contributors?
c. Interest and dividends received?
d. Cash collected on contributions receivables?
e. Other operating cash receipts, if any?
f. Cash paid to employees and suppliers?
g. Interest paid?
h. Income taxes paid?
i. Grants paid?
j. Other operating cash payments, if any?
[SFAS 95, par. 27, as amended by SFAS 117, par. 30e (AC C25.125)]
Note: SFAS 95 encourages enterprises to provide further breakdowns of 
operating cash receipts and payments that they consider meaningful and 
feasible.
15. Is the reconciliation of net income to net cash flow from operating 
activities, including separate reporting of all major classes of reconcil­
ing items, presented?
[SFAS 95, par. 29 (AC C25.127)]
★♦16. If the indirect method of reporting net cash flow from operating 
activities is used, are amounts of interest paid (net of amounts capi­
talized) and income taxes paid during the period provided in related 
disclosures?
[SFAS 95, par. 29 (AC C25.127)]
Other Financial Statement Disclosures
A. Accounting Changes
★ 1. In the initial year of application of SFAS 117, is the nature of any
restatement and its effect on the change in net assets for each period 
presented disclosed?
[SFAS 117, par. 31]
★ 2. For a not-for-profit health care organization, in the initial year of
application of SFAS 116, is the nature of any restatement and its effect 
on the change in net assets for each period presented disclosed? 
[SFAS 116, par. 30]
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♦ 3. For an investor-owned health care organization, in the initial year of
application of SFAS 116, is the restatement accounted for as a change 
in accounting principle applied retroactively in accordance with APB 
20, paragraphs 27 and 28?
[SFAS 116, par. 30]
♦ 4. For a not-for-profit health care organization, if SFAS 116 is not applied
retroactively, is the cumulative effect of the change in accounting on 
each class of net assets reported in the statement of activities between 
the captions "extraordinary items," if any, and "change in unre­
stricted net assets," "change in temporarily restricted net assets," and 
"change in permanently restricted net assets"?
[SFAS 116, par. 29]
♦ 5. For an investor-owned health care organization, if SFAS 116 is not
applied retroactively, is the cumulative effect of the change in ac­
counting reported in the income statement between the captions 
"extraordinary items," if any, and "net income"?
[SFAS 116, par. 29]
♦ 6. For a not-for-profit health care organization, in the initial year of appli­
cation of the June 1996 Guide, is the nature of any restatement and its 
effect on the change in net assets for each period presented disclosed? 
[AAG, Preface]
♦ 7. For an investor-owned health care organization, in the initial year of
application of the June 1996 Guide, is the restatement accounted for 
as a change in accounting principle applied retroactively in accord­
ance with APB 20, paragraphs 27 and 28?
[AAG, Preface]
♦ 8. For a not-for-profit health care organization, if the June 1996 Guide is
not applied retroactively, is the cumulative effect of the change in 
accounting on each class of net assets reported in the statement of 
activities between the captions "extraordinary items," if any, and 
"change in unrestricted net assets," "change in temporarily restricted 
net assets," and "change in permanently restricted net assets"? 
[AAG, Preface]
♦ 9. For an investor-owned health care organization, if the June 1996
Guide is not applied retroactively, is the cumulative effect of the 
change in accounting reported in the income statement between the 
captions "extraordinary items," if any, and "net income"? 
[AAG, Preface]
10. For an accounting change, does disclosure in the period of the change 
include:
a. Nature of the change?
b. Justification for the change, including a clear explanation of why 
the newly adopted principle is preferable?
c. Effect on income?
[APB 20, par. 17 (AC A06.113)]
★♦11. For other changes in accounting principle (excluding specific excep­
tions related to an initial public offering, change in the reporting entity, 
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or adoption of certain authoritative pronouncements), is the presen­
tation and disclosure guidance in APB 20 properly applied?
[APB 20, pars. 17-22 and 24-26 (AC A06.113-.118, .121, and .122); 
FASBI 20, par. 5, as amended by SFAS 111 (A06.127)]
12. Is the correction of an error shown as a prior-period adjustment 
with disclosure of the following in the period of its discovery and 
correction:
a. Nature of the error in previously issued financial statements?
b. Effect of its correction on revenue and gains in excess of expenses 
and losses (income) before extraordinary items and net revenue 
and gains in excess of expenses and losses (net income) (and 
related per share amounts if applicable)?
[APB 20, par. 37 (AC A35.105); SFAS 109, par. 288n (AC A35.103)]
B. Accounting Policies
★♦1. Is a description of all pertinent accounting policies of the provider 
presented as an integral part of the financial statements?
[APB 22, pars. 8 and 9 (AC A10.102 and .103)]
2. Does disclosure of significant accounting policies encompass impor­
tant judgments as to the appropriateness of principles concerning 
recognition of revenue and allocation of asset costs to current and 
future periods?
[APB 22, par. 12 (AC A10.105)]
3. Does disclosure of significant accounting policies include appropriate 
reference to details presented elsewhere (in the statements and notes 
thereto) so duplication of details is avoided?
[APB 22, par. 14 (AC A10.107)]
C. Business Combinations
Note: EITF 97-2, Application of FASB Statement No. 94 and APB Opinion No. 
16 to Physician Practice Management Entities and Certain Other Entities with 
Contractual Management Arrangements, provides guidance to assist physi­
cian practice management companies (PPMs) in applying APB 16 when 
PPMs acquire a physician practice.
★♦1. If a business combination occurred during the period and met the 
specified conditions for a pooling-of-interests, do the statements and 
notes include the required disclosures?
[APB 16, pars. 63-65 (AC B50.122-.124)]
Note: Not-for-profit organizations are, under certain circumstances, per­
mitted to use the pooling-of-interests method, even though they generally 
do not issue common stock. [AAG, pars. 1.33 and 1.34]
2. If a business combination occurred during the period and is to be 
accounted for under the purchase method, do the statements and 
notes include the required disclosures?
[APB 16, pars. 95 and 96 (AC B50.164 and .165); SFAS 79, par. 6 (AC 
B50.165); SFAS 38, par. 10 (AC B50.166)]
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D. Commitments and Contingencies
1. Uninsured medical malpractice claims:
a. If a minimum amount of a probable loss (usually associated with 
litigating or settling malpractice claims) is accrued, is there disclo­
sure as to a reasonable possibility of an additional potential loss 
in excess of the amount accrued?
[AAG, par. 8.07; SFAS 5 (AC C59)]
b. If a range of loss cannot be reasonably estimated, is a contingency 
disclosed?
[AAG, par. 8.11; SFAS 5 (AC C59)]
c. Is the program of medical malpractice coverage and basis for loss 
accruals disclosed?
[AAG, par. 8.11]
d. If the provider discounts accrued malpractice claims, are the fol­
lowing disclosed:
(1) The carrying amount of the claims?
(2) The interest rates or other rates used to discount the claims? 
[AAG, par. 8.12]
2. Retrospectively rated premiums:
a. If the provider cannot estimate losses from asserted or unasserted 
malpractice claims, is the existing contingency disclosed? 
[AAG, par. 8.14; SFAS 5 (AC C59)]
b. Does the provider disclose that it is insured under a retrospec­
tively rated policy?
[AAG, par. 8.15]
c. Does the provider disclose that premiums are accrued based on 
the ultimate cost of the experience to date of a group of entities? 
[AAG, par. 8.15]
3. Medical malpractice claims insured with captive insurance compa­
nies (controlled by a parent entity for the main purpose of providing 
insurance for the parent):
a. Does the provider disclose that it is insured under a retrospec­
tively rated policy of a multiprovider captive?
[AAG, par. 8.18]
b. Does the provider disclose that premiums are accrued based on 
the captive's experience to date?
[AAG, par. 8.18]
c. Is the provider's ownership percentage in the captive disclosed? 
[AAG, par. 8.19]
d. Is the method of accounting for its investment in and the opera­
tions of the captive disclosed?
[AAG, par. 8.19]
e. If the provider cannot make the necessary estimates of losses 
from asserted or unasserted claims, does it disclose the existing 
contingency?
[AAG, par. 8.19; SFAS 5 (AC C59)]
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4. Trust funds:
a. If trust funds (revocable or irrevocable) are included in the 
provider's financial statements:
(1) Is a portion of the funds (the amount of assets expected to be 
liquidated to pay malpractice claims classified as current 
liabilities) classified as a current asset in a classified balance 
sheet/statement of financial position?
[AAG, par. 8.20]
(2) Is the balance of the funds, if any, classified as a noncurrent 
asset in a classified balance sheet/statement of financial po­
sition?
[AAG, par. 8.20]
(3) Are trust fund revenue and administrative expenses included 
in the statement of activities (statement of operations)? 
[AAG, par. 8.20]
(4) Are estimated losses from asserted and unasserted claims 
reported?
[AAG, par. 8.21]
(5) Is the existence of trust funds and whether they are irrevoca­
ble disclosed?
[AAG, par. 8.22]
5. Prepaid health care services:
a. Health care costs:
(1) Is the basis for accruing health care costs disclosed?
(2) Are significant business and contractual arrangements with 
hospitals, physicians, and other associated entities disclosed? 
[AAG, par. 13.04]
b. Stop-loss insurance:
(1) Are receivables representing amounts recoverable from in­
surers reported as assets net of any valuation allowance?
(2) Are the nature, amounts, and effects of significant stop-loss 
insurance contracts disclosed?
[AAG, par. 13.08]
c. Loss contracts:
(1) Are losses recognized, in accordance with SFAS 5, when it is 
probable that expected future health care costs and mainte­
nance costs under a group of existing contracts will exceed 
anticipated future premiums and stop-loss insurance on 
those contracts?
[AAG, par. 13.06]
d. Contract acquisition costs:
(1) Are acquisition costs of providers of prepaid health care serv­
ices, other than costs of advertising, expensed as incurred? 
[AAG, par. 13.10]
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6. Other disclosures:
a. Are the nature and, if applicable, amount (or a statement that no 
loss estimate can be made) disclosed for loss contingencies (includ­
ing guarantees)?
[SFAS 5, pars. 9-12 and FASBI 34, pars. 2 and 3 (AC C59.108-.114)]
b. If exposure to loss exists in excess of the amount accrued for a loss 
contingency, do disclosures include the excess amount or state that 
no estimate is possible?
[SFAS 5, par. 10 (AC C59.109)]
c. Are gain contingencies adequately disclosed with care to avoid 
misleading implications as to the likelihood of realization? 
[SFAS 5, par. 17 (AC C59.118)]
d. Are the nature, term, amount and other required information 
disclosed for long-term unconditional purchase obligations? 
[SFAS 47, pars. 7 and 10a (AC C32.102 and .105a)]
e. Are the nature and amount of guarantees disclosed (for example, 
of indebtedness of others)?
[SFAS 5, par. 12 (AC C59.113); FASBI 34, pars. 2 and 3 (AC 
C59.114)]
Is there adequate disclosure of commitments such as those for 
plant acquisition or an obligation to reduce debts, maintain work­
ing capital, or restrict dividends?
[SFAS 5, pars. 18 and 19 (AC C59.120)]
g. If an obligation for postemployment benefits (other than pensions) 
is not accrued in accordance with SFAS 5 (AC C59) or SFAS 43 (AC 
C44) only because the amount cannot reasonably be estimated, is 
the fact of nonaccrual disclosed in the financial statements? 
[SFAS 112, par. 7 (AC P32.105)]
h. Are environmental remediation obligations reported and dis­
closed in accordance with SOP 96-1?
[SOP 96-1]
E. Costs to Exit an Activity
1. If a material liability is recognized for certain employee termination 
benefits in accordance with Section A of EITF 94-3, Liability Recognition 
for Certain Employee Termination Benefits and Other Costs to Exit an 
Activity (including Certain Costs Incurred in a Restructuring), are the 
following disclosures made in all periods until the plan of termination 
is completed:
a. The amount of termination benefits accrued and charged to ex­
pense and the classification of those costs in the income state­
ment/ statement of activities?
b. The number of employees to be terminated?
c. A description of the employee group(s) to be terminated?
d. The amount of actual termination benefits paid and charged 
against the liability and the number of employees actually termi­
nated as a result of the plan to terminate employees?
e. The amount of any adjustment(s) to the liability?
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★♦2. If management commits to an exit plan that meets the criteria in 
Section B of EITF 94-3, are the following reporting requirements 
followed:
a. Reporting the income statement effect of recognizing a liability at 
the commitment date in income from continuing operations and 
not on the face of the income statement net of taxes?
b. No disclosure made on the face of the income statement for 
earnings per share effect?
c. Revenue and related costs and expenses of activities that will not 
be continued should not be combined and reported as a separate 
component of income?
[EITF 94-3, Section B]
3. If the activities that will not be continued are significant to the enter­
prise's revenue or operating results, or if the exit costs recognized at 
the commitment date are material, are the following disclosures made 
in all periods until the exit plan is completed:
a. A description of the major actions comprising the exit plan, activi­
ties that will not be continued, including the method of disposi­
tion, and the anticipated date of completion?
b. A description of the type and amount of exit costs recognized as 
liabilities and the classification of those costs in the income state­
ment/statement of activities?
c. A description of the type and amount of exit costs paid and 
charged against the liability?
d. The amount of any adjustment(s) to the liability?
e. For all periods presented, the revenue and net operating income 
or losses from activities that will not be continued if those activities 
have separately identifiable operations?
[EITF 94-3, Section B]
F. Derivatives
Note: If SFAS 133, Accounting for Derivative Instruments and Hedging Ac­
tivities, has been adopted, the following Questions do not apply. See 
Section G1 for the required disclosures. SFAS 133 is effective for all fiscal 
quarters of fiscal years beginning after June 15, 1999.
The FASB has issued an exposure draft dated May 20, 1999 of a proposed 
Statement titled "Accounting for Derivative Instruments and Hedging 
Activities—Deferral of the Effective Date of FASB Statement No. 133, an 
amendment of FASB Statement No. 133," which would amend SFAS 133 
to defer its effective date to all fiscal quarters of all fiscal years beginning 
after June 15, 2000. The comment deadline was June 19, 1999. Users of this 
checklist should be alert to the issuance of a final pronouncement.
1. For options held and other derivative financial instruments not within 
the scope of SFAS 105 that do not have off-balance-sheet risk, are the 
following disclosures made by category of financial instrument:
a. The face or contract amount (or notional principal amount if there 
is no face or contract amount)?
b. The nature and terms, including a discussion of:
(1) Credit and market risk?
(2) Cash requirements?
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(3) Related accounting policy as required by APB 22?
c. Do disclosures in Steps a. and b. above distinguish between finan­
cial instruments held or issued for:
(1) Trading purposes, including dealing and other trading activi­
ties measured at fair value with gains and losses recognized 
in earnings?
(2) Purposes other than trading?
[SFAS 119, pars. 8 and 9 (AC Appendix E, F25.115L-.115M)]
★♦2. Does the provider that holds or issues derivative financial instru­
ments for trading purposes disclose:
a. The average fair value during the reporting period and the related 
end-of-period fair value, distinguishing between assets and li­
abilities?
b. The net gains or losses (net trading revenue) arising from trading 
activities during the reporting period disaggregated by class, busi­
ness activity, risk or other category consistent with management 
of those activities and where those net trading gains or losses are 
reported in the income statement?
(1) If the disaggregation is other than by class, did the provider 
also disclose for each category the classes of derivative finan­
cial instruments, other financial instruments, and nonfinan­
cial assets and liabilities from which the net trading gains and 
losses arose?
c. The average fair value for assets and liabilities from the trading of 
other types of financial instruments or non financial assets? (This 
disclosure is encouraged but not required.)
[SFAS 119, par. 10 (AC Appendix E, F25.115N)]
3. Does a provider that holds or issues derivative financial instruments 
for purposes other than trading disclose:
a. A description of:
(1) The objectives for holding or issuing?
(2) The context needed to understand those objectives?
(3) The strategies for achieving those objectives?
(4) The classes of derivative financial instruments used?
b. A description of how each class of derivative financial instrument 
is reported in the financial statements, including:
(1) The policies for recognition and measurement or nonrecog­
nition of the derivative financial instruments?
(2) When recognized, where the instruments and related gains 
and losses are reported?
c. For derivative financial instruments that are held or issued and 
accounted for as hedges of anticipated transactions, both firm and 
forecasted transactions for which there is no firm commitment, 
including:
(1) A description of the anticipated transactions whose risks are 
hedged, including the expected time period of occurrence?
(2) A description of the classes of derivative financial instru­
ments used to hedge?
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(3) The amount of explicitly deferred hedging gains and losses?
(4) A description of the transaction or events that result in recog­
nition in earnings of the deferred gains or losses?
[SFAS 119, par. 11 (AC Appendix E, F25.115O)]
4. Are the following encouraged, but not required, quantitative disclo­
sures made:
a. Interest rate?
b. Foreign exchange?
c. Commodity price?
d. Other market risks consistent with management's strategies?
e. Information of the risk of other financial instruments or nonfinan­
cial assets and liabilities related by risk management strategy 
pertaining to the objectives for holding or issuing derivative finan­
cial instruments?
[SFAS 119, pars. 12 and 13 (AC Appendix E, F25.115P-.115Q)]
G. Financial Instruments
Note: If SFAS 133, Accounting for Derivative Instruments and Hedging Ac­
tivities, has been adopted, the following Questions do not apply. See 
Section G1 for the required disclosures. SFAS 133 is effective for all fiscal 
quarters of fiscal years beginning after June 15, 1999.
The FASB has issued an exposure draft dated May 20, 1999 of a proposed 
Statement titled "Accounting for Derivative Instruments and Hedging 
Activities—Deferral of the Effective Date of FASB Statement No. 133, an 
amendment of FASB Statement No. 133," which would amend SFAS 133 
to defer its effective date to all fiscal quarters of all fiscal years beginning 
after June 15, 2000. The comment deadline was June 19, 1999. Users of this 
checklist should be alert to the issuance of a final pronouncement.
★♦1. Except for certain excluded items (SFAS 105, pars. 14 and 15 (AC 
F25.104 and .105)), are the following disclosed in the financial state­
ments or notes for each category of financial instruments with 
off-balance-sheet risk (health care organizations that enter into certain 
types of receivable financing arrangements should disclose their off- 
balance-sheet risk):
a. The face or contract amount, or notional principal amount if there 
is no face or contract amount?
b. The nature and terms, including, at a minimum, a discussion of:
(1) Credit and market risk of those instruments?
(2) Cash requirements of those instruments?
(3) Related accounting policy, as required by APB 22, Disclosure 
of Accounting Policies (AC A10)?
[SFAS 105, par. 17, as amended by SFAS 119, par. 14 (AC 
Appendix E, F25.112-.112A); AAG, par. 5.20]
c. For the disclosures in a. and b. above, distinguish between financial 
instruments with off-balance-sheet risk held or issued for trading 
purposes, and financial instruments with off-balance-sheet risk 
held or issued for purposes other than trading?
2. For financial instruments with off-balance-sheet credit risk (except for 
the items excluded in SFAS 105 (AC Appendix E, F25)), are the following 
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disclosed, either in the financial statements or in the notes, by category 
of financial instrument:
a. The amount of accounting loss the entity would incur if any party 
to the financial instrument failed completely to perform according 
to the terms of the contract and if the collateral or other security, 
if any, for the amount due proved to be of no value to the entity?
b. Regarding collateral or other security to support financial instru­
ments subject to credit risk:
(1) The entity's policy of requiring such collateral or other security?
(2) Information about the entity's access to that collateral or other 
security?
(3) The nature and a brief description of the collateral or other 
security supporting those financial instruments?
[SFAS 105, par. 18, as amended by SFAS 119, par. 14 (AC 
Appendix E, F25.113)]
★♦3. Do disclosures of all significant concentrations of credit risk arising 
from all financial instruments, whether from an individual counter­
party or groups of counterparties (except for certain excluded items 
[SFAS 105, par. 14 (AC Appendix E, F25.104)]), include:
Note: Health care providers that enter into certain types of receivable 
financing arrangements should disclose their off-balance-sheet risk.
a. Information about the (shared) activity, region, or economic char­
acteristic that identifies the concentration?
b. The amount of the accounting loss due to credit risk the entity 
would incur if any party to the financial instruments that make up 
the concentration failed completely to perform according to the 
terms of the contracts and if the collateral or other security, if any, 
for the amount due proved to be of no value to the entity?
c. Regarding collateral or other security to support financial instru­
ments subject to credit risk:
(1) The entity's policy of requiring such collateral or other security?
(2) Information about the entity's access to that collateral or other 
security?
(3) The nature and a brief description of the collateral or other 
security supporting those financial instruments?
[SFAS 105, pars. 14 and 20 (AC Appendix E, F25.104 and .115)]
4. Is disclosure made of the primary geographic sources of patients? 
[AAG, par. 5.19]
Note: SFAS 126, Exemption from Certain Required Disclosures about Financial 
Instruments for Certain Nonpublic Entities, states that disclosures about the 
fair value of financial instruments prescribed in SFAS 107 shall be optional 
for an entity that meets all of the following criteria:
a. The entity is a nonpublic company.
b. The entity's total assets are less than $100 million on the date of the 
financial statements.
c. The entity has not held or issued any derivative financial instru­
ments as defined in SFAS 119 other than loan commitments, during 
the reporting period.
Consider this exemption when reviewing items 5 through 10 below.
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5. Is the fair value of financial instruments for which it is practicable to 
estimate that value (except for those excluded in paragraphs 8 and 13 
of SFAS 107) disclosed, together with the related carrying amount in 
a form that makes it clear whether the fair value and carrying amount 
represent assets or liabilities and how the carrying amounts relate to 
what is reported in the statement of financial position? [Note: If 
disclosed in more than a single note, one of the notes should include 
a summary table containing the fair value and related carrying 
amounts and cross-references to the location(s) of the remaining 
disclosures required by SFAS 107, as amended.]
[SFAS 107, par. 10, as amended by SFAS 119, par. 15 (AC Appendix 
E, F25.115C)]
★♦6. Do the disclosures in Step 5 distinguish between financial instruments 
held or issued for trading purposes, including dealing and other 
trading activities measured at fair value with gains and losses recog­
nized in earnings, and financial instruments held or issued for pur­
poses other than trading?
[SFAS 107, par. 10, as amended by SFAS 119, par. 15 (AC Appendix 
E, F25.115C)]
7. Are the methods and significant assumptions used to estimate the fair 
value of financial instruments disclosed?
[SFAS 107, par. 10 (AC Appendix E, F25.115C)]
8. If it is not practicable to estimate the fair market value of a financial 
instrument, do disclosures include:
a. Information pertinent to estimating the fair value of the financial 
instrument or class of financial instruments, such as the carrying 
amount, effective interest rate, and maturity?
b. The reasons why it is not practicable to estimate fair value? 
[SFAS 107, par. 14 (AC F25.115J)]
9. If the offsetting of derivative financial instruments against nonderi­
vative financial instruments is not permitted under FASBI 39, Offset­
ting of Amounts Related to Certain Contracts, does the organization, in 
disclosing the fair value of a derivative financial instrument, not:
a. Combine, aggregate, or net the fair value with the fair value of a 
nonderivative financial instrument?
b. Net the fair value with the fair value of other derivative financial 
instruments?
[SFAS 107, par. 13, as amended by SFAS 119, par. 15 (AC Appendix 
E, F25.115I)]
10. For all fiscal years subsequent to the year of transition, are SFAS 107 
disclosures included for each year for which a statement of financial 
position is presented for comparative purposes?
[SFAS 107, par. 17]
11. For a written put option involving a reporting entity's own stock that 
gives the reporting entity a choice of settlement methods, is the 
classification within equity based on the settlement method that 
required the written put option to be initially classified as equity 
under the EITF 94-7 framework?
[EITF 96-13]
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  12. Are the classification guidelines under EITF 96-13 followed for writ­
ten put options involving a reporting entity's own stock that give the 
reporting entity a choice of settlement methods?
[EITF 96-13]
Gl. Financial Instruments
Note: The following disclosures apply only if SFAS 133, Accounting for Deriva­
tive Instruments and Hedging Activities, has been adopted. SFAS 133 is effective 
for all fiscal quarters of fiscal years beginning after June 15,1999.
The FASB has issued an exposure draft dated May 20,1999 of a proposed 
Statement titled "Accounting for Derivative Instruments and Hedging 
Activities—Deferral of the Effective Date of FASB Statement No. 133, an 
amendment of FASB Statement No. 133," which would amend SFAS 133 
to defer its effective date to all fiscal quarters of all fiscal years beginning 
after June 15, 2000. The comment deadline was June 19, 1999. Users of this 
checklist should be alert to the issuance of a final pronouncement.
Derivative Instruments and Hedging Activities
1. If an entity holds or issues derivative instruments (or nonderivative instru­
ments that are designated and qualify as hedging instruments pursuant to 
paragraphs 37 and 42 of SFAS 133) has disclosure been made of its objectives 
for holding or issuing those instruments, the context needed to under­
stand those objectives, and its strategies for achieving those objectives? ____
[SFAS 133, par. 44 (AC D50)]
2. Does the description distinguish between derivative instruments (and
nonderivative instruments) designated as fair value hedging instruments, 
derivative instruments designated as cash flow hedging instruments, 
derivative instruments (and nonderivative instruments) designated as 
hedging instruments for hedges of the foreign currency exposure of a net 
investment in a foreign operation, and all other derivatives? ____
[SFAS 133, par. 44 (AC D50)]
3. Does the description also indicate the entity's risk management policy 
for each of those types of hedges, including a description of the items
or transactions for which risks are hedged? ____
[SFAS 133, par. 44 (AC D50)]
4. For derivative instruments not designated as hedging instruments,
does the description indicate the purpose of the derivative activity? ____
[SFAS 133, par. 44 (AC D50)]
5. Qualitative disclosures about an entity's objectives and strategies for 
using derivative instruments may be more meaningful if such objec­
tives and strategies are described in the context of an entity's overall 
risk management profile. If appropriate, an entity is encouraged, but 
not required, to provide such additional qualitative disclosures. Have
such disclosures been made? ____
[SFAS 133, par. 44 (AC D50)]
6. Do the entity's disclosures for every reporting period for which a com­
plete set of financial statements is presented also include the following:
Fair Value Hedges
a. For derivative instruments, as well as nonderivative instruments 
that may give rise to foreign currency transaction gains or losses 
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under SFAS 52, that have been designated and have qualified as 
fair value hedging instruments and for the related hedged items:
(1) The net gain or loss recognized in earnings during the report­
ing period representing(a) the amount of the hedges' ineffec­
tiveness and (b) the component of the derivative instruments' 
gain or loss, if any, excluded from the assessment of hedge 
effectiveness, and a description of where the net gain or loss 
is reported in the statement of income or other statement of 
financial performance? ____
(2) The amount of net gain or loss recognized in earnings when 
a hedged firm commitment no longer qualifies as a fair value
hedge? ____
[SFAS 133, par. 45a (AC D50)]
Cash Flow Hedges
b. For derivative instruments that have been designated and have 
qualified as cash flow hedging instruments and for the related 
hedged transactions:
(1) The net gain or loss recognized in earnings during the report­
ing period representing (a) the amount of the hedges' ineffec­
tiveness and (b) the component of the derivative instruments' 
gain or loss, if any, excluded from the assessment of hedge 
effectiveness, and a description of where the net gain or loss 
is reported in the statement of income or other statement of 
financial performance? ____
(2) A description of the transactions or other events that will 
result in the reclassification into earnings of gains and losses 
that are reported in accumulated other comprehensive in­
come, and the estimated net amount of the existing gains or 
losses at the reporting date that is expected to be reclassified
into earnings within the next 12 months? ____
(3) The maximum length of time over which the entity is hedging
its exposure to the variability in future cash flows for fore­
casted transactions excluding those forecasted transactions 
related to the payment of variable interest on existing finan­
cial instruments? ____
(4) The amount of gains and losses reclassified into earnings as a
result of the discontinuance of cash flow hedges because it is 
probable that the original forecasted transactions will not occur? ____
[SFAS 133, par. 45b (AC D50)]
Note: SFAS 133, paragraph 43, states that an entity that does not report 
earnings as a separate caption in a statement of financial performance (for 
example, a not-for-profit organization) shall recognize the gain or loss on 
a hedging instrument and a nonhedging derivative instrument as a 
change in net assets in the period of change unless the hedging instrument 
is designated as a hedge of the foreign currency exposure of a net invest­
ment in a foreign operation. Entities that do not report earnings shall 
recognize the changes in the carrying amount of the hedged item pursuant 
to paragraph 22 of SFAS 133 in a fair value hedge as a change in net assets 
in the period of change. Those entities are not permitted to use cash flow 
hedge accounting because they do not report earnings separately.
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Hedges of the Net Investment in a Foreign Operation
c. For derivative instruments, as well as nonderivative instruments 
that may give rise to foreign currency transaction gains or losses 
under SFAS 52, that have been designated and have qualified as 
hedging instruments for hedges of the foreign currency exposure 
of a net investment in a foreign operation, the net amount of gains 
or losses included in the cumulative translation adjustment during 
the reporting period?
[SFAS 133, par. 45c (AC D50)]
7. The quantitative disclosures about derivative instruments may be 
more useful, and less likely to be perceived to be out of context or 
otherwise misunderstood, if similar information is disclosed about 
other financial instruments or nonfinancial assets and liabilities to 
which the derivative instruments are related by activity. Accordingly, 
in such situations, has the entity presented a more complete picture 
of its activities by disclosing that information? (Encouraged, but not 
required.)
[SFAS 133, par. 45 (AC D50)]
Disclosures About Fair Value of Financial Instruments
8. Has the entity disclosed, either in the body of the financial statements 
or in the accompanying notes, the fair value of financial instruments 
(except for those excluded in paragraphs 8 and 13 of SFAS 107) for 
which it is practicable to estimate fair value?
[SFAS 107, par. 10 (AC F25)]
Note: If disclosed in more than a single note, one of the notes shall include 
a summary table. The summary table shall contain the fair value and 
related carrying amounts and cross-references to the location(s) of the 
remaining disclosures required by SFAS 107 as amended.
9. Has the fair value disclosed in the notes been presented together with 
the related carrying amount in a form that makes it clear whether the 
fair value and carrying amount represent assets or liabilities and how 
the carrying amounts relate to what is reported in the statement of 
financial position?
[SFAS 107, par. 10 (AC F25)]
10. In disclosing the fair value of a financial instrument, has the entity 
taken care not to net that fair value with the fair value of other financial 
instruments—even if those financial instruments are of the same class 
or are otherwise considered to be related, for example, by a risk 
management strategy—except to the extent that the offsetting of 
carrying amounts in the statement of financial position is permitted 
under the general principle in paragraphs 5 and 6 of FASBI 39, 
Offsetting of Amounts Related to Certain Contracts, or the exceptions for 
master netting arrangements in paragraph 10 of 39 and for amounts 
related to certain repurchase and reverse repurchase agreements in 
paragraphs 3 and 4 of FASBI 41, Offsetting of Amounts Related to Certain 
Repurchase and Reverse Repurchase Agreements?
[SFAS 107, par. 14 (AC F25)]
11. If it is not practicable to estimate the fair value of a financial instru­
ment or a class of financial instruments, are the following disclosed:
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a. Information pertinent to estimating the fair value of that financial 
instrument or class of financial instruments, such as the carrying 
amount, effective interest rate, and maturity?
b. The reasons why it is not practicable to estimate fair value? 
[SFAS 107, par. 14 (AC F25)]
Note: SFAS 126, Exemption from Certain Required Disclosures about Financial 
Instruments for Certain Nonpublic Entities, makes the disclosures about fair 
values of financial instruments prescribed in SFAS 107 optional for report­
ing entities that:
• Are nonpublic entities,
• Have total assets of less than $100 million on the date of the financial 
statements, and
• Have no instrument that, in whole or in part, is accounted for as a 
derivative instrument under SFAS 133, Accounting for Derivative In­
struments and Hedging Activities, during the reporting period.
Disclosure About Concentrations of Credit Risk of All Financial Instruments
12. Except as indicated in paragraph 15B of SFAS 107, has the entity 
disclosed all significant concentrations of credit risk arising from all 
financial instruments, whether from an individual counterparty or 
groups of counterparties (Group concentrations of credit risk exist if a 
number of counterparties are engaged in similar economic charac­
teristics that would cause their ability to meet contractual obligations 
to be similarly affected by changes in economic or other conditions)? ____
[SFAS 107, par. 15A (AC F25)]
Note: SFAS 107, paragraph 15B provides that these disclosure require­
ments do not apply to the following financial instruments, whether writ­
ten or held:
a. Financial instruments of a pension plan, including plan assets, when 
subject to the accounting and reporting requirements of SFAS 87 
(Financial instruments of a pension plan, other than the obligations 
for pension benefits, when subject to the accounting and reporting 
requirements of SFAS 35, Accounting and Reporting by Defined Benefit 
Pension Plans, are subject to the reporting of paragraph 15A).
b. The financial instruments described in paragraphs 8(a), 8(c), 8(e), 
and 8(f) of SFAS 107, as amended by SFAS 112, Employers' Accounting 
for Postemployment Benefits, SFAS 123, Accounting for Stock Based 
Compensation, and SFAS 125, Accounting for Transfers and Servicing 
of Financial Assets and Extinguishments of Liabilities, except for rein­
surance receivables and prepaid reinsurance premiums.
13. Has the entity made the following disclosures about each significant 
concentration:
a. Information about the (shared) activity, region, or economic char­
acteristic that identifies the concentration?
b. The maximum amount of loss due to credit risk that, based on the 
gross fair value of the financial instrument, the entity would incur 
if parties to the financial instruments that make up the concentra­
tion failed completely to perform according to the terms of the 
contracts and the collateral or other security, if any, for the amount 
due proved to be of no value to the entity?
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c. The entity's policy of requiring collateral or other security to 
support financial instruments subject to credit risk, information 
about the entity's access to that collateral or other security, and the 
nature and a brief description of the collateral or other security 
supporting those financial instruments?
d. The entity's policy of entering into master netting arrangements 
to mitigate the credit risk of financial instruments, information 
about the arrangements for which the entity is a party, and a brief 
description of the terms of those arrangements, including the 
extent to which they would reduce the entity's maximum amount 
of loss due to credit risk?
[SFAS 107, par. 15A (AC F25)]
14. Has the entity disclosed quantitative information about the market 
risks of financial instruments that is consistent with the way it man­
ages or adjusts those risks? (Encouraged, but not required.) 
[SFAS 107, par. 15C (AC F25)]
Note: Appropriate ways of reporting the quantitative information en­
couraged will differ for different entities and will likely evolve over time 
as management approaches and measurement techniques evolve. Possi­
bilities include disclosing (a) more details about current positions and 
perhaps activity during the period, (b) the hypothetical effects on compre­
hensive income (or net assets), or annual income, of several possible 
changes in market prices, (c) a gap analysis of interest rate repricing or 
maturity dates, (d) the duration of the financial instruments, or (e) the 
entity's value at risk from derivatives and from other positions at the end 
of the reporting period and the average value at risk during the year. This 
list is not exhaustive, and an entity is encouraged to develop other ways 
of reporting quantitative information.
15. For a written put option involving a reporting entity's own stock that 
gives the reporting entity a choice of settlement methods, is the 
classification within equity based on the settlement method that 
required the written put option to be initially classified as equity 
under the EITF 94-7 framework?
[EITF 96-13]
16. Are the classification guidelines under EITF 96-13 followed for writ­
ten put options involving a reporting entity's own stock that give the 
reporting entity a choice of settlement methods?
[EITF 96-13]
Note: If SFAS 133 has been adopted, replace questions 5, 6, 7, 9, and 10 in 
Section C of the Balance Sheet section with the following Questions:
♦ 5. For securities classified as available-for-sale, has the reporting entity 
made the following disclosures by major-security type as of each date 
for which a statement of financial position is presented:
a. Aggregate fair value?
b. Total gains for securities with net gains in accumulated other 
comprehensive income?
c. Total losses for securities with net losses in accumulated other 
comprehensive income?
[SFAS 115, par. 19 (AC I80.118)]
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♦ 6. For securities classified as held-to-maturity, has the reporting entity 
made the following disclosures by major-security type as of each date 
for which a statement of financial position is presented:
a. Aggregate fair value?
b. Gross unrecognized holding gains or losses?
c. Net carrying amount?
d. Gross gains and losses in accumulated other comprehensive in­
come for any derivatives that hedged the forecasted acquisition of 
the held-to-maturity securities?
[SFAS 115, par. 19 (AC I80.118)]
♦ 7. For investments in debt securities classified as available-for-sale or 
held-to-maturity:
a. Is disclosure made about their contractual maturities as of the date 
of the latest balance sheet presented (maturity information may be 
combined in appropriate groupings)?
b. If securities not due at a single date (such as mortgage-backed 
securities) are allocated over several maturity groupings, is the 
basis for allocation disclosed?
[SFAS 115, par. 20 (AC I80.119)]
♦ 8. For each period for which an income statement is presented, are the 
following disclosed:
a. The proceeds from sales of available-for-sale securities and gross 
realized gains and losses that have been included in earnings as a 
result of those sales?
b. The basis on which the cost of a security sold or the amount 
reclassified out of accumulated other comprehensive income into 
earnings was determined (i.e., specified identification, average 
cost, or other method used)?
c.
d.
The gross gains and losses included in earnings from transfers of 
securities from the available-for-sale category to the trading category? 
The amount of the net unrealized holding gain or loss on avail­
able-for-sale securities for the period that has been included in 
accumulated other comprehensive income and the amount of 
gains and losses reclassified out of accumulated other comprehen­
sive income into earnings for the period?
e. The portion of trading gains and losses for the period that relates 
to trading securities still held at the reporting date?
[SFAS 115, par. 21 (AC I80.120)]
♦ 9. For any sales of or transfers from securities classified as held-to- 
maturity, are the following disclosed for each period for which an 
earnings statement is presented:
a. Net carrying amount of the sold or transferred security?
b. The net gain or loss in accumulated other comprehensive income 
for any derivative that hedged the forecasted acquisition of the 
held-to-maturity security?
c. Related realized or unrealized gain or loss?
d. The circumstances leading to the decision to sell or transfer the 
security?
[SFAS 115, par. 22 (AC I80.121)]
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H. Nonmonetary Transactions
1. Do disclosures include:
a. Nature of the transactions?
b. Basis of accounting for the assets transferred?
c. Gains or losses recognized on the transfers? 
[APB 29, par. 28 (AC C11.102 and N35.120)]
I. Pension and Other Postretirement Benefit Plans
Note: The disclosures required by SFAS 132 may be aggregated for all of 
an employer's defined benefit pension plans and may be aggregated for 
all of an employer's defined benefit postretirement plans or may be 
disaggregated in groups if that is considered to provide the most useful 
information or is otherwise required by paragraph 7 of the Statement. 
Disclosures about pension plans with assets in excess of the accumulated 
benefit obligation generally may be aggregated with disclosures about 
pension plans with accumulated benefit obligations in excess of assets. 
The same aggregation is permitted for postretirement plans. An employer 
may combine disclosures about pension or postretirement benefit plans 
outside the United States with those for U.S. plans unless the benefit 
obligations of the plans outside the United States are significant relative 
to the total benefit obligation and those plans use significantly different 
assumptions. A nonpublic entity, as defined by SFAS 132, may elect the 
reduced disclosure requirements permitted by the Statement.
1. If there is a defined benefit pension plan or a defined benefit postre­
tirement plan, do disclosures include:
a. A reconciliation of beginning and ending balances of the benefit 
obligation showing separately, if applicable, the effects during the 
period attributable to each of the following: service cost, interest 
cost, contributions by plan participants, actuarial gains and losses, 
foreign currency exchange rate changes, benefits paid, plan 
amendments, business combinations, divestitures, curtailments, 
settlements, and special termination benefits?
b. A reconciliation of beginning and ending balances of the fair value 
of plan assets showing separately, if applicable, the effects during 
the period attributable to each of the following: actual return on 
plan assets, foreign currency exchange rate changes, contributions 
by the employer, contributions by plan participants, benefits paid, 
business combinations, divestitures, and settlements?
c. The funded status of the plans, the amounts not recognized in the 
statement of financial position, and the amounts recognized in the 
statement of financial position, including:
(1) The amount of any unamortized prior service cost?
(2) The amount of any unrecognized net gain or loss (including 
asset gains and losses not yet reflected in market-related 
value)?
(3) The amount of any remaining unamortized, unrecognized 
net obligation or net asset existing at the initial date of appli­
cation of SFAS 87 or SFAS 106?
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(4) The net pension or other postretirement benefit prepaid as­
sets or accrued liabilities?
(5) Any intangible asset and the amount of accumulated other 
comprehensive income recognized pursuant to paragraph 37 
of SFAS 87, as amended?
d. The amount of net periodic benefit cost recognized, showing 
separately the service cost component, the interest cost compo­
nent, the expected return on plan assets for the period, the amor­
tization of the unrecognized transition obligation or transition 
asset, the amount of recognized gains and losses, the amount of 
prior service cost recognized, and the amount of gain or loss 
recognized due to a settlement or curtailment?
e. The amount included within other comprehensive income for the 
period arising from a change in the additional minimum pension 
liability recognized pursuant to paragraph 37 of SFAS 87, as 
amended?
f. On a weighted-average basis, the following assumptions used in 
the accounting for the plans: assumed discount rate, rate of com­
pensation increase (for pay-related plans), and expected long-term 
rate of return on plan assets?
g. The assumed health care cost trend rate(s) for the next year used 
to measure the expected cost of benefits covered by the plan (gross 
eligible charges) and a general description of the direction and 
pattern of change in the assumed trend rates thereafter, together 
with the ultimate trend rate(s) and when that rate is expected to 
be achieved?
h. The effect of a one-percentage-point increase and the effect of a 
one-percentage-point decrease in the assumed health care cost trend 
rates on (1) the aggregate of the service and interest cost components 
of net periodic postretirement health care benefit cost and (2) the 
accumulated postretirement benefit obligation for health care bene­
fits (For purposes of this disclosure, all other assumptions shall be 
held constant, and the effects shall be measured based on the sub­
stantive plan that is the basis for the accounting.)?
i. If applicable, the amounts and types of securities of the employer 
and related parties included in plan assets, the approximate 
amount of future annual benefits of plan participants covered by 
insurance contracts issued by the employer or related parties, and 
any significant transactions between the employer or related par­
ties and the plan during the period?
j. If applicable, any alternative amortization method used to amor­
tize prior service amounts or unrecognized net gains and losses 
pursuant to paragraphs 26 and 33 of SFAS 87 or paragraphs 53 and 
60 of SFAS 106?
k. If applicable, any substantive commitment, such as past practice 
or a history of regular benefit increases, used as the basis for 
accounting for the benefit obligation?
l. If applicable, the cost of providing special or contractual termina­
tion benefits recognized during the period and a description of the 
nature of the event?
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m. An explanation of any significant change in the benefit obligation 
or plan assets not otherwise apparent in the other disclosures 
required by SFAS 132?
[SFAS 132, par. 5 (AC P16.150)]
2. For employers that sponsor more than one defined benefit pension 
plan or more than one defined benefit postretirement plan, are the 
disclosures required by Step I.2 above aggregated for all of the em­
ployer's defined benefit pension plans and for all of the employer's 
defined benefit postretirement plans or disaggregated in groups if 
that is considered to provide the most useful information or is other­
wise required by paragraph 7 of SFAS 132?
[SFAS 132, par. 6 (AC P16.153)]
3. For employers that have aggregated disclosures about postretirement 
plans with assets in excess of the accumulated benefit obligations with 
disclosures about postretirement plans with accumulated benefit ob­
ligations in excess of assets, do disclosures include:
a. The aggregate benefit obligation and aggregate fair value of plan 
assets for plans with benefit obligations in excess of plan assets?
b. The aggregate pension accumulated benefit obligation and aggre­
gate fair value of plan assets for pension plans with accumulated 
benefit obligations in excess of plan assets?
c. Amounts recognized separately in the statement of financial posi­
tion as prepaid benefit costs and accrued benefit liabilities? 
[SFAS 132, par. 6 (AC P16.153)]
4. Are disclosures about pension or postretirement benefit plans outside 
the United States separate from those for U.S. plans when the plans 
outside the United States have benefit obligations that are significant 
relevant to the total benefit obligation and use significantly different 
assumptions?
[SFAS 132, par. 7 (AC P16.153A)]
5. For a nonpublic entity that has elected the reduced disclosure require­
ments for its pension and other postretirement benefit plans in lieu of 
the disclosures required by paragraph 5 of SFAS 132 (Step I.2.), do 
disclosures include:
a. The benefit obligation, fair value of plan assets, and funded status 
of the plan?
b. Employer contributions, participant contributions, and benefits 
paid?
c. The amounts recognized in the statement of financial position, 
including the net pension and other postretirement benefit pre­
paid assets or accrued liabilities and any intangible asset and the 
amount of accumulated other comprehensive income recognized 
pursuant to paragraph 37 of SFAS 87, as amended?
d. The amount of net periodic benefit cost recognized and the 
amount included within other comprehensive income arising 
from a change in the minimum pension liability recognized pur­
suant to paragraph 37 of SFAS 87, as amended?
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e. On a weighted-average basis, the following assumptions used in 
the accounting for the plans: assumed discount rate, rate of com­
pensation increase (for pay-related plans), and expected long-term 
rate of return on plan assets?
f. The assumed health care cost trend rate(s) for the next year used 
to measure the expected cost of benefits covered by the plan (gross 
eligible charges) and a general description of the direction and 
pattern of change in the assumed trend rates thereafter, together 
with the ultimate trend rate(s) and when that rate is expected to 
be achieved?
g. If applicable, the amounts and types of securities of the employer 
and related parties included in plan assets, the approximate 
amount of future annual benefits of plan participants covered by 
insurance contracts issued by the employer or related parties, and 
any significant transactions between the employer or related par­
ties and the plan during the period?
h. The nature and effect of significant nonroutine events, such as 
amendments, combinations, divestitures, curtailments, and 
settlements?
[SFAS 132, par. 8 (AC P16.150A)]
6. If there are one or more defined contribution plans:
a. Is the amount of cost recognized for the defined contribution 
pension or other postretirement benefit plans during the period 
disclosed separately from the amount of cost recognized for de­
fined benefit plans?
b. Do disclosures include a description of the nature and effect of any 
significant changes during the period affecting comparability, 
such as a change in the rate of employer contributions, a business 
combination, or a divestiture?
[SFAS 132, par. 9 (AC P16.162)]
7. If there are one or more multiemployer plans:
a. Do disclosures include the amount of contributions to the mul­
tiemployer plan(s) during the period?
b. If the employer discloses total contributions to multiemployer 
plans without disaggregating the amounts attributable to pen­
sions and other postretirement benefits, do the disclosures include 
a description of the nature and effect of any changes affecting 
comparability, such as a change in the rate of employee contribu­
tions, a business combination, or a divestiture?
[SFAS 132, par. 10 (AC P16.166)]
c. If the situation arises where the withdrawal from a multiemployer 
plan may result in the employer having an obligation to the plan for 
a portion of its unfunded benefit obligations that is either probable or 
reasonably possible, are the provisions of SFAS 5 (AC C59) applied? 
[SFAS 87, par. 70 (AC P16.167)]
8. Are the provisions of SFAS 5 (AC C59) applied if the situation arises 
where withdrawal from a multiemployer plan may result in an em­
ployer's having an obligation to the plan for a portion of the plan's 
unfunded accumulated postretirement benefit obligation and it is 
probable or reasonably possible that:
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a. An employer would withdraw from the plan under circumstances 
that would give rise to an obligation?
or
b. An employer's contribution to the fund would be increased during 
the remainder of the shortfall in the funds necessary to maintain 
the negotiated level of benefit coverage?
[SFAS 106, par. 83 (AC P40.179)]
J. Related Organizations and Economic Dependency
1. Consolidation and combination:
a. If the provider and another entity are related and they meet the 
criteria for consolidation or combination ("consolidation"), are 
consolidated or combined ("consolidated") financial statements 
presented?
[AAG, pars. 11.10 and 11.11; ARB 51 (AC C51); SFAS 94 (AC C51)]
b. If consolidated statements are presented:
(1) Is the consolidation policy disclosed?
[ARB 51, par. 5 (AC C51.108); APB 22, par. 13 (AC A10.106)]
(2) When the financial reporting periods of consolidated entities 
differ, is recognition given, by disclosure or otherwise, to the 
effect of intervening events that materially affect financial 
position or results of operations?
[ARB 51, par. 4 (AC C51.107)]
c. Do disclosures about formerly unconsolidated subsidiaries that 
are now consolidated include summarized information about the 
assets, liabilities, and results of operations (or separate statements) 
in the consolidated financial statements or notes?
[SFAS 94, par. 14 (AC C51.120A)]
2. Related parties and economic dependency:
a. If the reporting entity controls a separate not-for-profit entity 
through a form other than majority ownership or voting interest, 
has an economic interest in that other entity, and consolidated 
financial statements are not presented, is identification of the other 
entity and the nature of its relationship with the reporting entity 
disclosed; and is summarized financial data of the related organi­
zation disclosed?
[AAG, par. 11.12]
b. If the reporting entity has control over a related party, or has an 
economic interest in a related party, but the related party is not 
consolidated, are the following disclosures made:
(1) The nature of the relationship between the entity and the 
related party?
(2) If there are material transactions between the entity and the 
related party:
(i) A description of the transactions, including transactions 
to which nominal or no amounts were ascribed?
(ii) The amount of such transactions?
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(iii) Amounts due from or to the related party and, if not
apparent, the terms and manner of settlement? ____
(iv) The information required by paragraph 49 of SFAS 109? ____
[AAG, par. 11.13; SFAS 13, par. 29 (AC L10.125); SFAS
57, pars. 2-4, as amended by SFAS 109, paragraph 288(s) 
(AC R36.102-.104)]
c. If consolidated financial statements are presented and they in­
clude a controlled not-for-profit organization, are the following 
disclosed:
(1) Restrictions made by entities outside of the reporting entity
on distributions from the controlled not-for-profit organiza­
tion to the reporting entity? ____
and
(2) Any resulting unavailability of the net assets of the controlled
not-for-profit organization for use by the reporting entity? ____
[AAG, par. 11.14]
d. Are significant relationships and transactions not in the ordinary
course of business with directors, management, medical staff, etc. 
disclosed in the financial statements? ____
[AAG, par. 11.25]
K. Risks and Uncertainties
1. Are the following disclosed:
a. A description of the principal services performed by the health
care provider and the revenue sources for the entity's services? ____
b. The fact that financial statements prepared in accordance with
GAAP require the use of management's estimates? ____
[SOP 94-6, pars. 10 and 11]
★♦2. If (1) it is at least reasonably possible that the estimate(s) used in 
preparing the financial statements will change in the near term, and 
(2) the effect(s) of the change will be material, are the following 
disclosed:
a. The nature of uncertainties inherent in estimates used to deter­
mine the carrying amounts of assets and liabilities, or used to 
disclose gain or loss contingencies? ____
b. That a material change in the estimate could occur in the near
term? ____
[SOP 94-6, pars. 12-14]
3. If the estimate in Step 2 above involves a loss contingency covered by 
SFAS 5, Accounting for Contingencies, do disclosures include an esti­
mate of the possible loss or range of loss, or state that such an estimate 
cannot be made?3 ____
3 If risk reduction techniques are used to mitigate losses or the uncertainty that may result from certain events, these disclosures are 
encouraged but not required.
[SOP 94-6, par. 14]
★♦4. If (1) concentrations exist at the financial statement date, and (2) the 
concentrations could cause the provider a near-term severe impact, 
are the following disclosed:
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a. Concentrations in the volume of the business transacted with a 
particular customer (patient), supplier, lender, grantor, or con­
tributor?
b. Concentrations in revenue from particular services provided or 
fund-raising events?
c. Concentrations in the available sources of supply of labor, serv­
ices, or of applicable licenses necessary to provide services?
d. Concentrations in the market or geographical area in which an 
entity conducts its operations, including the carrying amounts of 
net assets and their locations?
e. Concentrations of labor subject to collective bargaining agree­
ments, including the percentage of the labor force covered by a 
collective bargaining agreement and the percentage of the labor 
force covered by a collective bargaining agreement that will expire 
within one year?
f. Information adequate to inform users of the general nature of the 
risk associated with the concentration?
[SOP 94-6, pars. 21-24]
L. Segment Information
Note: Public business enterprises are required to provide the disclosures 
described in SFAS 131, Disclosures about Segments of an Enterprise and Related 
Information, and nonpublic business enterprises are encouraged to do so.
1. Are the following items disclosed for each reportable segment for each 
period for which an income statement is presented:
a. General information as described in SFAS 131, paragraph 26?
b. Information about profit or loss (including certain revenues and 
expenses included in profit or loss), segment assets, and the basis 
of measurement, as described in SFAS 131, paragraphs 27-31?
c. Reconciliations of the totals of segment revenues, reported profit 
or loss, assets, and other significant items to corresponding enter­
prise amounts as described in SFAS 131, paragraph 32?
d. Interim period information as described in SFAS 131, paragraph 
33?
[SFAS 131, pars. 25-33, as amended by SFAS 135, par. 4 (AC 
S30.124-.132)]
Note: Reconciliations of balance sheet amounts for reportable segments 
to consolidated balance sheet amounts are required only for each year for 
which a balance sheet is presented.
2. If an enterprise changes the structure of its internal organization in a 
manner that changes the composition of its reportable segments, has 
it disclosed whether it has restated the corresponding items of seg­
ment information for earlier periods?
[SFAS 131, par. 34 (AC S30.133)]
3. If segment information is not restated to reflect a change in the 
composition of reportable segments, is current year segment informa­
tion under both the old basis and the new basis of segmentation 
disclosed, unless it is impracticable to do so?
[SFAS 131, par. 35 (AC S30.134)]
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Yes No N/A
4. For all enterprises subject to SFAS 131, including those that have a 
single reportable segment, are the following enterprise-wide items 
disclosed:
a. Revenues from external customers for each product and service or 
each group of similar products and services unless it is impracti­
cable to do so?
b. Geographic information as described in paragraph 38 unless it is 
impracticable to do so?
c. Information about the extent of the enterprise's reliance on its 
major customers as described in paragraph 39?
[SFAS 131, pars. 36-39 (AC S30.135-.138)]
5. If the information described in items 4.a. and 4.b. above has not been 
disclosed because it is impracticable, is that fact disclosed?
[SFAS 131, pars. 37 and 38 (AC S30.136-.137)]
M. Subsequent Events
1. Are subsequent events that provide evidence about conditions that 
did not exist at the date of the balance sheet, but arose subsequent to 
that date, adequately disclosed to keep the financial statements from 
being misleading?
[SFAS 5, par. 11 (AC C59.112); APB 16 (AC B50.120); SAS 1, secs. 
560.05-.07, .09, and 561.01-.09 (AU 560.05-.07, .09, and 561.01-.09)]
Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees
Is the estimated amount of advance fees expected to be refunded to 
current residents reported as a liability?
[AAG, par. 14.22]
Is the remaining amount of advance fees reported in the balance sheet 
as deferred revenue?
[AAG, par. 14.22]
Are the following disclosed:
a. The gross amount of contractual refund obligations under existing 
contracts?
b. The CCRC's refund policy? 
[AAG, par. 14.22]
Are amounts refunded disclosed in the statement of cash flows as a 
financing transaction?
[AAG, par. 14.22]
Is the method of accounting, including the amortization method, for 
deferred revenue disclosed?
[AAG, par. 14.23]
B. Fees Refundable to Residents Only From Reoccupancy Proceeds of a 
Contract Holder's Unit
1. Are the following reported as deferred revenue:
★♦1.
★♦2.
★♦3.
★♦4.
★♦5.
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Yes No N/A
a. The portion of fees to be paid to current residents or their desig­
nees, only to the extent of a contract holder's unit reoccupancy 
proceeds, if law and management policy and practice support the 
withholding of refunds under this condition?
b. Similar amounts received from new residents in excess of the 
amount to be paid to previous residents or their designees? 
[AAG, par. 14.25]
C. Nonrefundable Advance Fees
1. Are nonrefundable advance fees reported as deferred revenue? 
[AAG, par. 14.26]
★♦2. Is unamortized deferred revenue reported as revenue upon a resi­
dent's death or contract termination?
[AAG, par. 14.23]
D. Obligation to Provide Future Services and Use of Facilities to Current 
Residents
★♦1. If the obligation to provide future services and use of facilities to 
current residents under continuing-care contracts results in a liability, 
are the following disclosed:
a. The carrying amount of the liability that is presented at present 
value in the financial statements (if not separately disclosed in the 
balance sheet/statement of financial position)?
b. The interest rate used to discount that liability? 
[AAG, par. 14.31]
E. Costs of Acquiring Initial Continuing-Care Contracts
1. Are costs of acquiring initial continuing-care contracts capitalized if 
they are expected to be recovered from future contract revenues? 
[AAG, par. 14.33]
2. Are continuing-care contract acquisition costs expensed if incurred 
after (a) the CCRC is substantially occupied or (b) one year following 
completion?
[AAG, par. 14.33]
F. Other
★♦1. Do the notes to the financial statements of the CCRC include a 
description of the CCRC and the nature of the related continuing-care 
contracts entered into by the CCRC?
[AAG, par. 14.35]
★♦2. Do the notes to the financial statements of the CCRC include the 
statutory escrow or similar requirements?
[AAG, par. 14.35]
OMB Circular A-133 Presentation Requirements
1. Does the schedule of expenditures of federal awards disclose the basis 
of accounting and the significant accounting policies used in prepar­
ing the schedule?
[SOP 98-3, par. 5.5]
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Yes No N/A
2. Did the auditee prepare a schedule of expenditures of federal awards 
for the period covered by the auditee's financial statements that, at a 
minimum:
a. Lists individual federal programs by federal agency? ____
b. Include, for federal awards received as a subrecipient, the name 
of the pass-through entity and the identifying number assigned by
the pass-through entity? ____
c. Provide the total federal awards expended for each individual
federal program and the CFDA number or other identifying num­
ber when the CFDA information is not available? ____
d. Include notes that describe the significant accounting policies used
in preparing the schedule? ____
e. Identify, to the extent practical, the total amount provided to
subrecipients by pass-through entities from each federal program? ____
f. Include, in either the schedule or a note to the schedule, the value
of federal awards expended in the form of noncash assistance, the 
amount of insurance in effect during the year, and loans or loan 
guarantees outstanding at year end? ____
[SOP 98-3, par. 5.6]
3. If nonfederal data are presented in the schedule of expenditures of 
federal awards:
a. Are the nonfederal data segregated and clearly designated as
nonfederal? ____
b. Is the title of the schedule modified to indicate that nonfederal
awards are included? ____
[SOP 98-3, par. 5.9]
4. If the auditee is unable to obtain the CFDA number, does the schedule 
include:
a. A statement that the CFDA number is not available? ____
b. The program's name and, if available, other identifying numbers? ____
[SOP 98-3, par. 5.10]
Exhibit A
Stock-Based Compensation
♦1. If an entity continues to apply APB 25 in accounting for its stock-based 
compensation arrangements, is the pro forma net income and, if pre­
sented, earnings per share (determined as if the fair value based 
method had been applied in measuring compensation cost) disclosed? ____
[SFAS 123, pars. 11 and 45 (AC C36.110 and .144)]
♦2. If an entity has one or more stock-based compensation plans, is a 
description of the plan(s), including the general terms of awards 
under the plan(s), disclosed? ____
[SFAS 123, par. 46 (AC C36.145)]
♦3. Is the information in paragraph 47 of SFAS 123 disclosed for each year 
for which an income statement is presented? ____
[SFAS 123, par. 47a-f (AC C36.146)]
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Yes No N/A
♦4. If an entity grants options under multiple stock-based employee 
compensation plans, are the items in paragraph 47 disclosed sepa­
rately for different types of awards to the extent that the differences 
in the characteristics of the awards make separate disclosure important 
to an understanding of the entity's use of stock-based compensation? ____
[SFAS 123, par. 47 (AC C36.146)]
♦5. Are the following disclosed for options outstanding at the date of the 
latest statement of financial position presented:
a. The range of exercise prices? ____
b. The weighted-average exercise price? ____
c. The weighted-average remaining contractual life? ____
[SFAS 123, par. 48 (AC C36.147)]
♦ 6. If the range of exercise prices is wide, are they segregated into ranges? ____
[SFAS 123, par. 48 (AC C36.147)]
♦7. Are the following disclosed for each range identified in Step 6:
a. The number, weighted-average exercise price, and weighted-av­
erage remaining contractual life of options outstanding? ____
b. The number and weighted-average exercise price of options cur­
rently exercisable? ____
[SFAS 123, par. 48 (AC C36.147)]
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FSP Section 11,300
Auditors' Reports Checklist
.01 This checklist has been developed by the staff of the Accounting and Auditing Publications Team of 
the AICPA as a nonauthoritative practice aid.
.02 Explanation of References:
SAS = AICPA Statement on Auditing Standards
AU = Reference to section number in AICPA Professional Standards (vol. 1)
SSARS = AICPA Statements on Standards for Accounting and Review Services
AR = Reference to section number in AICPA Professional Standards (vol. 2)
.03 Checklist Questionnaire:
Yes No N/A
1. Is each financial statement audited specifically identified in the intro­
ductory paragraph of the auditor's report? ____ ____  ____
[SAS 58, par. 6 (AU 508.06)]
2. Does the auditor's report include:
a. Appropriate addressee? ____ ____  ____
[SAS 58, par. 9 (AU 508.09)]
b. Date (or dual dates) of the report? ____ ____  ____
[SAS 1, sec. 530.05 (AU 530.05)]
c. A title that includes the word "independent"? ____ ____  ____
[SAS 58, par. 8a (AU 508.08a)]
d. A statement that the financial statements identified in the report
were audited? ____ ____  ____
[SAS 58, par. 8b (AU 508.08b)]
e. A statement that the financial statements are the responsibility of 
management and that the auditor's responsibility is to express an
opinion on the financial statements based on his or her audit? ____ ____  ____
[SAS 58, par. 8c (AU 508.08c)]
f. A statement that the audit was conducted in accordance with 
generally accepted auditing standards? ____ ____  ____
[SAS 58, par. 8d (AU 508.08d)]
g. A statement that generally accepted auditing standards require
that the auditor plan and perform the audit to obtain reasonable 
assurance about whether the financial statements are free of ma­
terial misstatement? ____ ____  ____
[SAS 58, par. 8e (AU 508.08e)]
h. A statement that an audit includes examining, on a test basis, 
evidence supporting the amounts and disclosures in the financial 
statements; assessing the accounting principles used and signifi­
cant estimates made by management; and evaluating the overall
financial statement presentation? ____ ____  ____
[SAS 58, par. 8f (AU 508.08f)]
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Yes No N/A
i. A statement that the auditor believes that his or her audit provides 
a reasonable basis for his or her opinion?
[SAS 58, par. 8g (AU 508.08g)]
j.
k.
An opinion as to whether the financial statements present fairly, 
in all material respects, the financial position of the reporting 
entity as of the balance sheet date and the results of its operations 
and its cash flows for the period then ended in conformity with 
generally accepted accounting principles?
[SAS 58, par.8h (AU 508.08h)]
The manual or printed signature of the auditor's firm? 
[SAS 58, par.8i (AU 508.08i)]
3. If the auditor is not independent, is the appropriate disclaimer ex­
pressed, regardless of the extent of services provided?
[SAS 26, par. 10 (AU 504.10); SSARS 1, pars. 22 and 38 (AR 100.22 and 
.38)]
4. Does the reporting language conform with the auditor's standard 
report on:
a. Financial statements of a single year or period?
b. Comparative financial statements? 
[SAS 58, par. 8 (AU 508.08)]
5. Does the report include appropriate language for the following 
situations:
a. Only one basic financial statement is presented and there are no 
scope limitations?
[SAS 58, pars. 33 and 34, as amended by SAS 79 (AU 508.33 and 
.34)]
b. Audited and unaudited financial statements are presented in com­
parative form?
[SAS 26, pars. 14-17 (AU 504.14-.17)]
6. Is an explanatory paragraph (or other explanatory language) added 
to the standard report if:
a. There is substantial doubt about the entity's ability to continue as 
a going concern for a reasonable period of time and that conclusion 
is expressed through the use of the phrase "substantial doubt 
about its (the entity's) ability to continue as a going concern"? 
[SAS 64, par. 1 (AU 341.12 and .13)]
b. There is a material change between periods in accounting princi­
ples or in the method of their application?
[SAS 58, pars. 16-18, as amended by SAS 79 (AU 508.16-.18)]
c. In an updated report on comparative financial statements, the 
current opinion on the prior period is different from the one 
previously expressed?
[SAS 58, pars. 68, 69, 72, and 73, as amended by SAS 79 (AU 508.68, 
.69, .72, and .73)]
d. The prior period financial statements are audited by a predecessor 
auditor whose report is not presented?
[SAS 64, par. 2 (AU 508.74)]
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Yes No N/A
e. The auditor's opinion is based in part on the report of another 
auditor?
[SAS 1, sec. 543 (AU 543); SAS 58, pars. 12 and 13 (AU 508.12 and .13)]
f. The financial statements contain a departure from a promulgated 
accounting principle when conformity with GAAP would result 
in a misleading presentation?
[SAS 58, pars. 14 and 15 (AU 508.14 and .15)]
g. Other information in a document containing audited financial 
statements is materially inconsistent with information appearing 
in the financial statements?
[SAS 8, par. 4 (AU 550.04)]
h. The auditor decides to emphasize a matter in the report?
[SAS 58, par. 19, as amended by SAS 79 (AU 508.19); Interpretation 3 
of SAS 1, sec. 410 (AU 9410.18); Interpretation 1 of SAS 57 (AU 9342.03)]
Note: In a going concern paragraph, the auditor should not use condi­
tional language in expressing a conclusion concerning the existence of 
substantial doubt about the entity's ability to continue as a going concern. 
See SAS 77 for an example.
7. Is a qualified opinion or disclaimer of opinion expressed if scope 
limitations preclude application of one or more auditing procedures 
considered necessary in the circumstances?1
1 This includes when the auditor is unable to obtain sufficient, evidential matter to support management's assertions about the 
nature of a matter involving an uncertainty and its presentation or disclosure in the financial statements. [SAS 58, par. 31, as amended 
by SAS 79]
2 The auditor should express a qualified or an adverse opinion if the auditor concludes that (a) a matter involving a risk or an 
uncertainty is not adequately disclosed, (b) the accounting principles used cause the financial statements to be materially misstated 
when the inability to make a reasonable estimate raises questions about the appropriateness of the accounting principles used, and (c) 
management's estimate is unreasonable and its effect is to cause the financial statements to be materially misstated. [SAS 58, pars. 
46-49, as amended by SAS 79]
[SAS 58, pars. 22-27 (AU 508.22-.27); SAS 31, par. 22 (AU 326.23); SAS 
84, par. 18 (AU 315.18); SAS 85, par. 13.14 (AU 333.14)]
Note: Consult the Topical Index to the AICPA Professional Standards under 
"Scope of Audit—Limitations" for additional references to specific types of 
scope limitations that could result in either a qualified or disclaimer of opinion.
8. Is a qualified opinion or adverse opinion expressed if a lack of conformity 
with GAAP (including inadequate disclosure) is present?1 2 
[SAS 58, pars. 35-57, as amended by SAS 79 (AU 508.35-.59); SAS 32, 
par. 3 (AU 431.03)]
Note: Consult the Topical Index to the AICPA Professional Standards under 
"Departures from Established Principles," "Adverse Opinions," and "Quali­
fied Opinions" for additional references to specific types of GAAP departures 
that could result in either a qualified or adverse opinion.
9. If a qualified opinion, adverse opinion, or disclaimer of opinion is 
expressed, are all the substantive reasons for the opinion or disclaimer 
disclosed and is the reporting language appropriately modified? 
[SAS 58, pars. 21, 59, 60, and 62, as amended by SAS 79 (AU 508.21, 
.59, .60, and .62)]
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Yes No N/A
10. If information accompanies the basic financial statements and audi­
tor's report in an auditor-submitted document, does the report on the 
accompanying information:
a. State that the audit is performed for the purpose of forming an 
opinion on the basic financial statements taken as a whole?
b. Specifically identify the accompanying information?
c. State that the accompanying information is presented for purposes 
of additional analysis and is not a required part of the basic 
financial statements?
d. State whether the accompanying information is subject to the audit­
ing procedures applied in the audit of the basic financial statements 
and the appropriate expression of opinion or disclaimer?
[SAS 29, pars. 6-11 (AU 551.06-.11)]
11. Is the reporting form and content of SAS 60, paragraphs 9-19, fol­
lowed when communicating internal control related matters noted in 
an audit?3
3 Reportable conditions in internal control structure that have not been corrected must be communicated, preferably in writing, to 
senior management and the board of trustees or its audit committee. [SAS 60]
[SAS 60, pars. 9-19, as amended by SAS 87 (AU 325.09-.19)]
Note: SAS 87, Restricting the Use of an Auditor's Report, provides guidance 
to auditors in determining whether an engagement requires a restricted- 
use report and, if so, what elements to include in that report. SAS 87 is 
effective for reports issued after December 31, 1998.
12. Is the reporting form and content of SAS 72, as amended by SAS 76 
and SAS 86, followed for comfort letters submitted to underwriters 
and other requesting parties on tax-exempt bond offerings?
[SAS 72, as amended by SAS 76 and SAS 86 (AU 634)]
13. If, during a GAAS audit of the financial statements, the auditor 
becomes aware that the entity is subject to an audit requirement of 
legal, regulatory, or contracted nature not encompassed in the en­
gagement, did the auditor consider the client's actions in response to 
such requirement including the potential effect on the financial state­
ments and the auditor's report?
[SAS 74, par. 23 (AU 801.22 and .23)]
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FSP Section 11,400
Auditors’ Reports on Audits Performed 
Under Government Auditing Standards 
and Under OMB Circular A-133 Checklist
.01 This checklist, developed by the staff of the Accounting and Auditing Publications Team of the 
AICPA as a nonauthoritative practice aid, addresses the auditor's reporting requirements addressed by 
AICPA Statement of Position (SOP) 98-3, Audits of States, Local Governments, and Not-for-Profit Organizations 
Receiving Federal Awards. SOP 98-3 was issued in March of 1998. It provides guidance on the auditor's 
responsibilities when conducting a single audit or program-specific audit in accordance with the Single Audit 
Act Amendments of 1996 and OMB Circular A-133.
.02 Explanation of References:
AICPA Statement of PositionSOP =
AU =
GAAP = 
GAAS =
OMB =
Reference to section number in AICPA Professional Standards (vol. 1) 
Generally accepted accounting principles
Generally accepted auditing standards
Office of Management and Budget
.03 Checklist questionnaire:
Yes No N/A
General
Circular A-133 Requirements
1. Does the auditor's report include:
a. An opinion (or disclaimer of opinion) on whether the financial 
statements are presented fairly in all material respects in conform­
ity with GAAP and an opinion (or a disclaimer of opinion) on 
whether the schedule of expenditures of federal awards is pre­
sented fairly in all material respects in relation to the financial 
statements taken as a whole?
b. A report on the internal control related to the financial statements 
and on the internal control related to major programs?
c. A report on compliance with laws, regulations, and the provisions 
of contracts or grant agreements, noncompliance with which 
could have a material effect on the financial statements, including 
an opinion (or a disclaimer of opinion) on whether the auditee 
complied with laws, regulations, and the provisions of contracts 
or grant agreements that could have a direct and material effect 
on each major program, and, where applicable, refers to the sepa­
rate schedule of findings and questioned costs?
d. A schedule of findings and questioned costs? 
[SOP 98-3, par. 10.3]
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Yes No N/A
Reporting on the Financial Statements and Supplementary 
Schedule of Expenditures of Federal Awards in Accordance 
With Government Auditing Standards
Government Auditing Standards Requirements
2. Does the auditor's report on the audit of the financial statements:
a. Include a statement that the audit was made in accordance with 
generally accepted government auditing standards?
[SOP 98-3, par. 10.16b]
b. Describe the scope of the auditor's testing of compliance with laws 
and regulations and internal control and present the results of 
those tests?
or
refer to separate reports containing that information?
[SOP 98-3, par. 10.16c]
c. State the nature of information omitted and the requirement that 
makes the omission necessary when certain information is prohib­
ited from general disclosure?
[SOP 98-3, par. 10.16d]
3. Did the auditor communicate certain information related to the con­
duct and reporting of the audit to the audit committee or to the 
individuals with whom he or she has contracted for the audit, includ­
ing the auditor's responsibility in a financial statement audit and the 
nature of any additional testing of internal control and compliance 
required by laws or regulations?
[SOP 98-3, par. 10.16a]
4. Were written audit reports:
a. Submitted to the appropriate officials of the auditee and to the 
appropriate officials of the organizations requiring or arranging 
for the audit (including external funding organizations), unless 
legal restrictions prevent it?
b. Sent to other officials who have legal oversight authority or who 
may be responsible for acting on audit findings and recommenda­
tions and others authorized to receive such reports?
c. Made available for public inspection unless restricted by law or 
regulation?
[SOP 98-3, par. 10.16e]
Fraud, Illegal Acts, and Other Noncompliance
5. If a report presenting fraud, illegal acts, or other noncompliance that are 
required to be reported is prepared, have the report contents standards 
in chapter 7 of Government Auditing Standards been followed?
[SOP 98-3, par. 10.21]
6. If the auditor detected fraud, illegal acts, or other noncompliance that 
do not meet the criteria for reporting in paragraph 5.18 of Government 
Auditing Standards:
a. Did he or she communicate those findings to the auditee, prefer­
ably in writing?
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No N/A
b. If those findings were communicated in a management letter, was 
the management letter referred to in the report on compliance? 
[SOP 98-3, par. 10.22]
7. If applicable, did the auditor comply with the guidance in paragraphs 
5.21 through 5.25 of Government Auditing Standards on direct reporting 
of fraud and illegal acts?
[SOP 98-3, par. 10.23]
Internal Control Over Financial Reporting
8. Does the auditor's report on internal control matters:
a. Describe the extent of the work performed, as required by SAS No. 
55?
b. Include the report requirements of SAS No. 60 and separately 
identify material weaknesses?
c. Follow the report contents standards in chapter 7 of Government 
Auditing Standards when reporting reportable conditions and ma­
terial weaknesses?
d. Report to the auditee detected deficiencies in the internal control 
that are not reportable conditions, preferably in writing?
e. If a management letter was used to report the nonreportable 
conditions, was that letter referred to in the report on internal 
control?
[SOP 98-3, pars. 10.27-10.29]
Implementing Regulations of Certain Federal Awarding Agencies May 
Define Entity to Be Audited Differently Than GAAP
9. Where parent-only financial statements have been audited because 
the regulations of the federal agency that provides federal awards to 
a parent company define the entity for single audit purposes to consist 
of only the parent, and consolidated financial statements are not also 
prepared as required by GAAP, has the auditor's report been modi­
fied due to a material departure from GAAP, if necessary?
[SOP 98-3, par. 10.34]
Opinion on the Financial Statements and on the Supplementary 
Schedule of Expenditures of Federal Awards
10. Does the auditor's standard report on the financial statements and on 
the supplementary schedule of expenditures of federal awards in­
clude the following:
a. Identification of the financial statements audited in an opening 
(introductory) paragraph?
b. A description of the nature of an audit in a scope paragraph?
c. An expression of the auditor's opinion on the financial statements 
and supplementary schedule of expenditures of federal awards in 
separate opinion paragraphs?
[SOP 98-3, par. 10.35]
d. A title that includes the word independent? 
[SOP 98-3, par. 10.35a]
e. A statement that the financial statements identified in the report 
were audited?
[SOP 98-3, par. 10.35b]
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Yes No
f. A statement that the financial statements are the responsibility of 
the auditee's management and that the auditor's responsibility is 
to express an opinion on the financial statements based on his or 
her audit?
[SOP 98-3, par. 10.35c]
g. A statement that the audit was conducted in accordance with 
GAAS and the standards applicable to financial audits contained 
in Government Auditing Standards issued by the Comptroller Gen­
eral of the United States?1
[SOP 98-3, par. 10.35d]
h. A statement that those standards require that the auditor plan and 
perform the audit to obtain reasonable assurance about whether 
the financial statements are free of material misstatement?
[SOP 98-3, par. 10.35e]
i. A statement that an audit includes—
(1) Examining, on a test basis, evidence supporting the amounts 
and disclosures in the financial statements?
(2) Assessing the accounting principles used and significant es­
timates made by management?
(3) Evaluating the overall financial statement presentation? 
[SOP 98-3, par. 10.35f]
j. A statement that the auditor believes that the audit provides a 
reasonable basis for his or her opinion?
[SOP 98-3, par. 10.35g]
k. An opinion on whether the financial statements for a not-for-profit 
organization present fairly, in all material respects, the financial 
position of the auditee as of the date of the statement of financial 
position, and the changes in its net assets and its cash flows for the 
period then ended in conformity with GAAP; or, for a govern­
ment, the financial position of the auditee as of the balance sheet 
date, and the results of its operations and cash flows for the period 
then ended in conformity with GAAP?
[SOP 98-3, par. 10.35h]
Note: If an auditee prepares financial statements in conformity with a 
comprehensive basis of accounting other than GAAP, the auditor is still 
required to express or disclaim an opinion and should follow the reporting 
in SAS 62, Special Reports.
l. A reference to the separate report on compliance with certain 
provisions of laws, regulations, contracts, and grant agreements 
and on the internal control over financial reporting prepared in 
accordance with Government Auditing Standards, if this reporting 
is not included in the report on the financial statement? (SOP 98-3 
recommends separate reporting.)
[SOP 98-3, par. 10.35i]
m. A description of the accompanying supplementary information 
(for example, the schedule of expenditures of federal awards) by 
descriptive title or by page number of the document?
[SOP 98-3, par. 10.35j]
1 The standards applicable to financial audits include the general, fieldwork, and reporting standards described in chapters 3, 4, and 
5 of Government Auditing Standards.
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N/A
Yes No N/A
n. A statement that the accompanying supplementary information, 
including the schedule of expenditures of federal awards required 
by Circular A-133, is presented for purposes of additional analysis 
and is not a required part of the financial statements?
[SOP 98-3, par. 10.35k]
o. An opinion on whether the accompanying supplementary infor­
mation is fairly stated, in all material respects, in relation to the 
financial statements taken as a whole?
[SOP 98-3, par. 10.351]
p. The manual or printed signature of the auditor's firm? 
[SOP 98-3, par. 10.35m]
q. The date of the audit report?
[SOP 98-3, par. 10.35n]
11. If a separate single audit package is issued for the schedule of expen­
diture of federal awards, is the required reporting on the schedule 
incorporated in the report issued to meet the requirements of Circular 
A-133?
[SOP 98-3, par. 10.36]
Report on Compliance and on Internal Control Over Financial Reporting 
Based on an Audit of Financial Statements Performed in Accordance 
With Government Auditing Standards
12. Is the reporting on the scope of the auditor's testing of compliance and 
on the internal control over financial reporting based on an audit of 
the financial statements as required by Government Auditing Standards 
combined in one report? (This is encouraged but not required by SOP 
98-3.)
[SOP 98-3, par. 10.38]
13. Does the auditor's standard report on compliance and on the internal 
control over financial reporting based on an audit of the financial 
statements in accordance with Government Auditing Standards include:
a. A statement that the auditor has audited the financial statements 
of the auditee and a reference to the auditor's report on the 
financial statements, including a description of any departure 
from the standard report?
b. A statement that the audit was conducted in accordance with 
GAAS and with the standards applicable to financial audits con­
tained in Government Auditing Standards issued by the Comptroller 
General of the United States?
c. A statement that as part of obtaining reasonable assurance about 
whether the auditee's financial statements are free of material 
misstatement, the auditor performed tests of the auditee's compli­
ance with certain provisions of laws, regulations, contracts, and 
grants, noncompliance with which could have a direct and mate­
rial effect on the determination of financial statement amounts?
d. A statement that providing an opinion on compliance with those 
provisions was not an objective of the audit and that, accordingly, 
the auditor does not express such an opinion?
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e. A statement that notes whether the results of tests disclosed in­
stances of noncompliance that are required to be reported under 
Government Auditing Standards and, if they are, describes the in­
stances of noncompliance or refers to the schedule of findings and 
questioned costs in which they are described?
f. If applicable, a statement that certain immaterial instances of 
noncompliance were communicated to management in a separate 
letter?
g. A statement that in planning and performing the audit, the auditor 
considered the auditee's internal control over financial reporting 
in order to determine the auditing procedures for the purpose of 
expressing an opinion on the financial statements and not to 
provide assurance on the internal control over financial reporting?
h. If applicable, a statement that reportable conditions were noted 
and the definition of a reportable condition?
i. If no reportable conditions are noted, a statement that the auditor's 
consideration of the internal control over financial reporting 
would not necessarily disclose all matters in the internal control 
that might be material weaknesses; if reportable conditions are 
noted, a statement that the auditor's consideration of the internal 
control over financial reporting would not necessarily disclose all 
matters in the internal control that might be reportable conditions 
and, accordingly, would not necessarily disclose all reportable 
conditions that are also considered to be material weaknesses?
j. If applicable, a description of the reportable condition noted or a 
reference to the schedule of findings and questioned costs in which 
the reportable conditions are described?
k. The definition of a material weakness?
l. If applicable, a statement about whether the auditor believes any 
of the reportable conditions noted are material weaknesses and, if 
they are, describes the material weaknesses noted or refers to the 
schedule of findings and questioned costs in which they are de­
scribed?
m. If reportable conditions are not noted, a statement that no material 
weaknesses were noted?
n. If applicable, a statement that other matters involving the internal 
control over financial reporting were communicated to manage­
ment in a separate letter?
o. A statement that the report is intended for the information of the 
audit committee, management, specified legislative or regulatory 
bodies, federal awarding agencies, and (if applicable) pass- 
through entities?
Note: SAS 87, Restricting the Use of an Auditor's Report, provides guidance 
to auditors in determining whether an engagement requires a restricted- 
use report and, if so, what elements to include in that report. SAS 87 is 
effective for reports issued after December 31, 1998.
p. If the report is a matter of public record, a statement that the report 
is a matter of public record and its distribution is not limited?
q. The manual or printed signature of the auditor's firm?
r. The date of the auditor's report?
[SOP 98-3, par. 10.39]
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Reporting on a Compliance Audit of Major Federal Programs in 
Accordance With Circular A-133
Material Instances of Noncompliance
14. If an audit of compliance with requirements applicable to a major 
program detects material instances of noncompliance with those 
requirements:
a. Is a qualified or adverse opinion expressed?
b. Does the report state the basis for such an opinion? 
[SOP 98-3, par. 10.42]
15. If the scope of an audit of compliance with laws, regulations, and the 
provisions of contracts or grant agreements is restricted so as to impair 
the auditor's ability to form an opinion on compliance with require­
ments governing each major program:
a. Is a qualified opinion or disclaimer of opinion expressed?
b. Are the reasons for such a qualification or disclaimer of opinion 
described in the auditor's report?
[SOP 98-3, pars. 10.43 and 10.44]
16. When disclaiming an opinion because of a scope limitation, does the 
auditor's report:
a. Include a separate paragraph that indicates all of the substantive 
reasons for the disclaimer?
b. State that the scope of the audit was not sufficient to warrant the 
expression of an opinion?
c. Exclude the scope paragraph (identification of the procedures that 
were performed or a description of the characteristics of an audit) 
so as not to overshadow the disclaimer?
d. Disclose any reservations the auditor has regarding compliance 
with applicable laws and regulations?
[SOP 98-3, par. 10.45]
Report on Compliance With Requirements Applicable to Each Major 
Program and on Internal Control Over Compliance in Accordance With 
Circular A-133
17. Does the auditor's standard report on compliance with requirements 
applicable to each major program and on the internal control over 
compliance in accordance with Circular A-133 include:
a. A statement that the auditor has audited the compliance of the 
auditee with the types of compliance requirements described in 
the OMB Circular A-133 Compliance Supplement that are applicable 
to each of its major programs?
b. A statement that the auditee's major programs are identified in the 
summary of the auditor's results section of the accompanying 
schedule of findings and questioned costs?
c. A statement that compliance with the requirements of laws, regu­
lations, contracts, and grants applicable to each of the auditee's 
major federal programs is the responsibility of the auditee's man­
agement, and that the auditor's responsibility is to express an 
opinion on the auditee's compliance based on the audit?
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d. A statement that the audit of compliance was conducted in accord­
ance with GAAS, the standards applicable to financial audits 
contained in Government Auditing Standards issued by the Comp­
troller General of the United States, and Circular A-133?
e. A statement that those standards and Circular A-133 require that 
the auditor plan and perform the audit to obtain reasonable assur­
ance about whether noncompliance with the types of compliance 
requirements that could have a direct and material effect on a 
major federal program occurred?
f. A statement that an audit includes the examining, on a test basis, 
evidence about the auditee's compliance with those requirements 
and performing of such other procedures as the auditor consid­
ered necessary in the circumstances?
g. A statement that the auditor believes that the audit provides a 
reasonable basis for the auditor's opinion?
h. A statement that the audit does not provide a legal determination 
of the auditee's compliance with those requirements?
i. If instances of noncompliance are noted that result in an opinion 
modification, a reference to a description in the accompanying 
schedule of findings and questioned costs, including:
(1) The reference number(s) of the finding(s)?
(2) An identification of the type(s) of compliance requirements 
and related major program(s)?
(3) A statement that compliance with such requirements is nec­
essary, in the auditor's opinion, for the auditee to comply 
with the requirements applicable to the program(s)?
j. An opinion on whether the auditee complied, in all material 
respects, with the types of compliance requirements that are ap­
plicable to each of its major federal programs?
k. If applicable, a statement that the results of the auditing proce­
dures disclosed instances of noncompliance that are required to 
be reported in accordance with Circular A-133 and a reference to 
the schedule of findings and questioned costs in which they are 
described?
l. A statement that the auditee's management is responsible for 
establishing and maintaining effective internal control over com­
pliance with the requirements of laws, regulations, contracts, and 
grants applicable to federal programs?
m. A statement that in planning and performing the audit, the auditor 
considered the auditee's internal control over compliance with 
requirements that could have a direct and material effect on a 
major federal program, to determine the auditing procedures for 
the purpose of expressing an opinion on compliance and to test 
and report on the internal control over compliance in accordance 
with Circular A-133?
n. If applicable, a statement that reportable conditions were noted 
and the definition of a reportable condition?
o. If applicable, a reference to a description of reportable conditions 
noted in the accompanying schedule of findings and questioned 
costs, including the reference number of the finding(s)?
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p. If no reportable conditions are noted, a statement that the auditor's 
consideration of the internal control over compliance would not 
necessarily disclose all matters in internal control that might be 
material weaknesses; if reportable conditions are noted, a state­
ment that the auditor's consideration of the internal control over 
compliance would not necessarily disclose all matters in the inter­
nal control that might be reportable conditions and, accordingly, 
would not necessarily disclose all reportable conditions that are 
also considered to be material weaknesses?
q. The definition of a material weakness?
r. If applicable, a statement about whether the auditor believes any 
of the reportable conditions noted are material weaknesses and, if 
they are, a reference to a description of the material weaknesses in 
the schedule of findings and questioned costs, including the refer­
ence number of the finding(s)?
s. If there are no reportable conditions, a statement that no material 
weaknesses were noted?
t. A statement that the report is intended for the information of the 
audit committee, management, specified legislative or regulatory 
bodies, federal awarding agencies, and (if applicable) pass- 
through entities?
u. If the report is a matter of public record, a statement that the report 
is a matter of public record and its distribution is not limited?
v. The manual or printed signature of the auditor's firm?
w. The date of the auditor's report?
[SOP 98-3, par. 10.46]
18. Are all audit findings required to be reported under Circular A-133 
included in the schedule of findings and questioned costs?
[SOP 98-3, par. 10.48]
Other Reporting Considerations:
Dating of Reports
19. Do the report on the supplementary schedule of expenditures of 
federal awards and the report on compliance and internal control over 
financial reporting, as required by Government Auditing Standards, 
carry the same date as that on the report on the basic financial 
statements?
[SOP 98-3, par. 10.50]
20. Does the auditor's report on compliance and on the internal control 
over compliance related to major programs, as required by Circular 
A-133:
a. Carry the same date as that of other reports?
b. Because some of the audit work to satisfy Circular A-133 require­
ments was done subsequent to the work on the financial state­
ments, carry the date when the fieldwork required to support the 
report on the audit of compliance is completed?
[SOP 98-3, par. 10.51]
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21. If the schedule of expenditures of federal awards is reported on in the 
report on compliance and the internal control over compliance issued 
to meet Circular A-133 requirements, but using the same dates for 
reporting on the schedule and the report on the financial statements 
is not possible, has the auditor:
a. Dual dated the report issued to meet Circular A-133 requirements? ____
b. Issued a separate report on the schedule of expenditures of federal 
awards, dated the same date as that of the financial statement
report? ____
[SOP 98-3, par. 10.52]
Other Auditors
22. If the auditor is engaged to issue a stand-alone opinion on the sched­
ule of expenditures of federal awards either as part of the report issued 
to meet the requirements of Circular A-133 or separately (dated the 
same as the Circular A-133 report), has the guidance in SAS No. 58
been followed? ____
[SOP 98-3, par. 10.52]
When the Audit of Federal Awards Does Not Encompass the Entirety of 
the Auditee's Operations
23. If the audit of federal awards did not encompass the entirety of the 
auditee's operations expending federal awards, were the operations 
that were not included identified in a separate paragraph following
the first paragraph of the report on major programs? ____
[SOP 98-3, par. 10.54]
Schedule of Findings and Questioned Costs
24. Does the schedule of findings and questioned costs include the fol­
lowing sections:
a. A summary of the auditor's results, including:
(1) The type of report the auditor issued on the financial state­
ments of the auditee (that is, unqualified opinion, qualified 
opinion, adverse opinion, or disclaimer of opinion)? ____
(2) Where applicable, a statement that reportable conditions in
internal control were disclosed by the audit of the financial 
statements and whether any such conditions were material 
weaknesses? ____
(3) A statement on whether the audit disclosed any noncompli­
ance that is material to the financial statement of the auditee? ____
(4) Where applicable, a statement that reportable conditions in
the internal control over major programs were disclosed by 
the audit and whether any such conditions were material 
weaknesses? ____
(5) The type of report the auditor issued on compliance for major
programs (that is, unqualified opinion, qualified opinion, 
adverse opinion, or disclaimer of opinion)? ____
(6) A statement on whether the audit disclosed any audit find­
ings that the auditor is required to report under section 510(a)
of Circular A-133? ____
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(7) An identification of major programs?
(8) The dollar threshold used to distinguish between type A and 
type B programs as described in section 520(b) of Circular 
A-133?
(9) A statement on whether the auditee qualified as a low-risk 
auditee under section 530 of Circular A-133?
[SOP 98-3, par. 10.56]
b. Findings relating to the financial statements which are required to 
be reported in accordance with Government Auditing Standards 
including:
(1) All reportable conditions in the internal control over financial 
reporting and other findings relative to the audit of the finan­
cial statements that are required to be reported by GAAS and 
Government Auditing Standards, including those that do not 
affect federal awards?
(2) All but clearly inconsequential fraud and illegal acts that the 
auditor concludes, based on the evidence obtained, either 
occurred or are likely to have occurred?
(3) Other noncompliance (for example, violations of the provi­
sions of contract or grant agreements) that is material to the 
financial statements?
[SOP 98-3, par. 10.57]
c. Findings and questioned costs for federal awards as defined in 
section 510(a) of Circular A-133, that:
(1) Present audit findings (for example, internal control findings, 
compliance findings, questioned costs, or fraud) that relate to 
the same issue as a single audit finding?
(2) Where practical, are audit findings organized by federal 
agency or pass-through entity?
(3) Report audit findings that relate to both the financial state­
ments and the federal awards in both sections of the sched­
ule? (The reporting in one section of the schedule may be in 
summary form, with a reference to a detailed reporting in the 
other section of the schedule.)
[SOP 98-3, par. 10.56]
25. Are reportable conditions that are—individually or in the aggregate— 
material weaknesses so identified?
[SOP 98-3, par. 10.58]
26. Do the findings identify at least the criteria (what should be), condi­
tion (what is), and possible asserted effect (the difference between 
what is and what should be) and, if known, the cause (why it 
happened)?
[SOP 98-3, pars. 10.59-10.65]
27. In presenting reportable conditions, fraud, illegal acts, and other 
noncompliance, were the report content standards in chapter 7 of 
Government Auditing Standards that pertain to objectives, scope, and 
methodology; audit results; the views of responsible officials; and the 
reports presentation standards (as appropriate) followed?
[SOP 98-3, par. 10.61]
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28. With respect to uncorrected material findings and recommendations 
from prior audits that affect the financial statement audit:
a. Have such uncorrected items been reported?
b. Have those material findings and recommendations from pre­
vious audits that are repeated identified as repeat findings?
c. Has the status of uncorrected findings from previous audits that 
are not repeated as current-year findings been reported?
[SOP 98-3, par. 10.62]
Audit Findings Reported—Federal Awards
29. As required by section 510(a) of Circular A-133, have the following 
items been reported as audit findings in the schedule of findings and 
questioned costs:
a. Reportable conditions in the internal control over major programs?
b. Reportable conditions that are individually or cumulatively ma­
terial weaknesses?
c. Material noncompliance with the provisions of laws, regulations, 
contracts, or grant agreements that are related to a major program?
d. Known questioned costs that are greater than $10,000 for a type of 
compliance requirement for a major program?
e. Known questioned costs when likely questioned costs are greater 
than $10,000 for a type compliance requirement for a major pro­
gram, including information to provide proper perspective for 
judging the prevalence and consequences of the questioned costs?
f. Known questioned costs that are greater than $10,000 for pro­
grams that are not audited as major, if the auditor becomes aware 
of such questioned costs?
g. The circumstances concerning why the auditor's report on com­
pliance for major programs is other than an unqualified opinion, 
unless such circumstances are otherwise reported as audit find­
ings in the schedule of findings and questioned costs for federal 
awards (for example, a scope limitation that is not otherwise 
reported as a finding)?
h. Known fraud affecting a federal award, unless such fraud is other­
wise reported as an audit finding in the schedule of findings and 
questioned costs for federal awards? (The auditor is not required to 
make an additional reporting when the auditor confirms that the 
fraud was reported outside of the auditor's reports under the direct 
reporting requirements of Government Auditing Standards.)
i. Instances where the results of audit follow-up procedures dis­
closed that the summary schedule of prior audit findings prepared 
by the auditee in accordance with section 315(b) of Circular A-133 
materially misrepresents the status of any prior audit finding? 
[SOP 98-3, par. 10.63]
Detail of Audit Findings—Federal Awards
30. In accordance with section 510(b) of Circular A-133, do audit findings 
present:
a. Identification of the federal program and specific federal award 
including the CFDA title and number, the federal award number 
and year, the name of federal agency, and the name of the appli­
cable pass-through entity or, if certain information is not available, 
the best information available to describe the federal award?
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b. The criteria or specific requirement upon which the audit finding 
is based, including the statutory, regulatory, or other citation?
c. The condition found, including facts that support the deficiency 
identified in the audit finding?
d. Identification of questioned costs and how they were computed?
e. Information to provide a proper perspective for judging the preva­
lence and consequences of the audit findings (for example, 
whether the audit findings represent an isolated instance or a 
systemic problem) and, where appropriate, the instances identi­
fied are related to the universe and the number of cases examined 
and quantified in terms of the dollar value?
f. The possible asserted effect to provide sufficient information to 
the auditee and federal agency (or pass-through entity, in the case 
of a subrecipient) to permit them to determine the cause and effect, 
to facilitate prompt and proper corrective action?
g. Recommendations to prevent future occurrences of the deficiency 
identified in the audit finding?
h. To the extent practical, the views of responsible officials of the 
auditee when there is disagreement with the audit findings?
i. If the auditor does not agree with the auditee's position in the 
corrective action plan, a statement of the auditor's reasons for 
rejecting it?
[SOP 98-3, par. 10.64]
Other Preparation Guidance
31. Does each audit finding in the schedule of findings and questioned 
costs include a reference number to allow for easy referencing of the 
audit findings during follow-up?
[SOP 98-3, par. 10.65]
32. In a situation where there are no findings or questioned costs, has the 
summary of auditor's results section of the schedule of findings and 
questioned costs been prepared and indication been made in the other 
required sections that no matters were reportable?
[SOP 98-3, par. 10.66]
Summary Schedule of Prior Audit Findings and Corrective 
Action Plan
33. Has the auditor reported, as a current year audit finding, any in­
stances where the auditor concludes that the summary schedule of 
prior audit findings materially misrepresents the status of any prior 
audit finding in accordance with the requirements of section 500(e) of 
Circular A-133?
[SOP 98-3, par. 10.69]
Data Collection Form
34. With respect to the data collection form required by Circular A-133, 
has the auditor:
a. Completed required sections of the form, including information 
on the auditor and information on the results of the financial 
statement audit and the audit of federal programs?
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b. Signed a statement in the form that indicates, at a minimum, the 
source of the information included in the form, the auditor's 
responsibility for the information, that the form is not a substitute 
for the reporting package, and that the content of the form is 
limited to the data elements prescribed by the OMB?
c. Dated the form as of the date on which he or she completes and 
sign the form?
[SOP 98-3, par. 10.72]
Program-Specific Audits
Circular A-133 Requirements
35. Is the auditor's report in the form of either combined or separate
reports? ____
[SOP 98-3, par. 11.8]
36. Does the auditor's report state that the audit was conducted in accord­
ance with GAAS, Government Auditing Standards, and Circular A-133? ____
[SOP 98-3, par. 11.8]
37. Does the auditor's report include the following:
a. An opinion (or disclaimer of opinion) on whether the financial 
statement(s) of the federal program are presented fairly in all 
material respects in conformity with the stated accounting poli­
cies?
b.
c.
d.
A report on the internal control related to the federal program, 
which describes the scope of the testing of the internal control and 
the results of the tests?
A report on compliance, which includes an opinion (or a dis­
claimer of opinion) on whether the auditee complied with laws, 
regulations, and the provisions of contracts or grant agreements 
that could have a direct and material effect on the federal pro­
gram?
A schedule of findings and questioned costs for the federal pro­
gram, which includes a summary of the auditor's results relative 
to the audit of the federal program in a format consistent with the 
requirements for the summary of auditor's results in section 
505(d)(1) of the circular, as well as findings and questioned costs 
for federal awards consistent with the requirements of section 
505(d)(3) of the circular?
[SOP 98-3, par. 11.8]
Note: The following auditor's reports are suggested for program specific 
audits.
38. Are the following reports issued:
a. An opinion on the financial statement(s) of the federal program? ____
b. A report on compliance with requirements applicable to the fed­
eral program and on the internal control over compliance in 
accordance with the program-specific audit option under OMB 
Circular A-133? ____
84
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c. If the financial statements of the program only present the activity 
of the federal program, a separate Government Auditing Standards 
report? ____  ___
[SOP 98-3, pars. 11.8-11.10]
39. If the financial statements of the program present more than the 
program's activity, is a separate Government Auditing Standards report, 
modified so that it refers only to the financial statement(s) of the 
federal program, issued? ____  ___
[SOP 98-3, par. 11.10]
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FSP Section 11,500
Illustrative Financial Statements
.01 The following illustrative financial statements demonstrate the practical applications of the reporting 
practices discussed in the June 1996 AICPA Audit and Accounting Guide Health Care Organizations (the 
Guide). The checklists and illustrative financial statements do not include all disclosures and presentation 
items promulgated. Pronouncements deemed remote for audits of health care providers are not included in 
this document. Specific types of health care organizations have been selected to illustrate a wide diversity of 
reporting practices; it is not intended that these illustrations represent either the only types of disclosure or 
the only statement formats that would be appropriate. Health care providers are urged to develop financial 
statement formats that are appropriate for their individual circumstances while being consistent with the 
accounting and reporting practices discussed in the Guide.
The illustrative financial statements are reproduced from the May 1998 AICPA Audit and Accounting Guide 
Health Care Organizations, and are in conformity with accounting standards issued up to and including FASB 
Statement SFAS No. 132, Employers' Disclosures about Pensions and Other Postretirement Benefits. Preparers and 
auditors of financial statements should refer to subsequent FASB Statements and other GAAP for additional 
requirements.
This section contains illustrative financial statements for the following types of health care organizations:
• Not-for-Profit Hospital
• For-Profit Nursing Home
• Not-for-Profit Continuing Care Retirement Community
• Not-for-Profit Home Health Agency
• Not-for-Profit Health Maintenance Organization
• Not-for-Profit Ambulatory Care Organization
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The checklists and illustrative financial statements do not include all disclosures 
and presentation items promulgated.
ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NOT-FOR-PROFIT HOSPITAL
.02
Sample Not-for-Profit Hospital
Balance Sheets
December 31, 19X7 and 19X6
(in thousands)
19X7 19X6
Assets
Current assets:
Cash and cash equivalents $ 4,758 $ 5,877
Short-term investments 15,836 10,740
Assets limited as to use 970 1,300
Patient accounts receivable, net of allowance 
for doubtful accounts of $2,500 in 19X7
and $2,400 in 19X6 15,100 14,194
Other current assets 2,670 2,856
Total current assets 39,334 34,967
Assets limited as to use:
Internally designated for capital acquisition 12,000 12,500
Held by trustee 6,949 7,341
18,949 19,841
Less amount required to meet current obligations (970) (1,300)
17,979 18,541
Long-term investments 4,680 4,680
Long-term investments restricted for capital acquisition 320 520
Property and equipment, net 51,038 50,492
Other assets 1,695 1,370
Total assets $115,046 $110,570
Liabilities and Net Assets
Current liabilities:
Current portion of long-term debt $ 1,470 $ 1,750
Accounts payable and accrued expenses 5,818 5,382
Estimated third-party payor settlements 2,143 1,942
Other current liabilities 1,969 2,114
Total current liabilities 11,400 11,188
Long-term debt, net of current portion 23,144 24,014
Other liabilities 3,953 3,166
Total liabilities 38,497 38,368
Net assets:
Unrestricted 70,846 66,199
Temporarily restricted 2,115 2,470
Permanently restricted 3,588 3,533
Total net assets 76,549 72,202
Total liabilities and net assets $115,046 $110,570
See accompanying notes to financial statements.
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.03
FORMAT A
Sample Not-for-Profit Hospital 
Statements of Operations 
Years Ended December 31, 19X7 and 19X6 
(in thousands)
See accompanying notes to financial statements.
19X7 19X6
Unrestricted revenues, gains and other support:
Net patient service revenue $85,156 $78,942
Premium revenue 11,150 10,950
Other revenue 2,601 5,212
Net assets released from restrictions used for operations 300
Total revenues, gains and other support 99,207 95,104
Expenses:
Operating expenses 88,521 80,585
Depreciation and amortization 4,782 4,280
Interest 1,752 1,825
Provision for bad debts 1,000 1,300
Other 2,000 1,300
Total expenses 98,055 89,290
Operating income 1,152 5,814
Other income:
Investment income 3,900 3,025
Excess of revenues over expenses 5,052 8,839
Change in net unrealized gains and losses on other than
trading securities 300 375
Net assets released from restrictions used for purchase of
property and equipment 200
Contributions from Sample Hospital
Foundation for property acquisitions 235 485
Transfers to parent (640) (3,000)
Increase in unrestricted net assets, before extraordinary item 5,147 6,699
Extraordinary loss from extinguishment of debt (500)
Increase in unrestricted net assets $ 4,647 $ 6,699
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Sample Not-for-Profit Hospital 
Statements of Operations 
Years Ended December 31, 19X7 and 19X6 
(in thousands)
FORMAT B
See accompanying notes to financial statements.
19X7 19X6
Unrestricted revenues, gains and other support:
Net patient service revenue $85,156 $78,942
Premium revenue 11,150 10,950
Other, primarily investment income 6,501 8,237
Net assets released from restrictions used for operations 300
Total revenues, gains and other support 103,107 98,129
Expenses:
Salaries and benefits 53,900 49,938
Medical supplies and drugs 26,532 22,121
Insurance 8,089 8,526
Depreciation and amortization 4,782 4,280
Interest 1,752 1,825
Provision for bad debts 1,000 1,300
Other 2,000 1,300
Total expenses 98,055 89,290
Excess of revenues, gains, and other support over expenses 5,052 8,839
Change in net unrealized gains and losses on other than
trading securities 300 375
Net assets released from restrictions used for purchase of
property and equipment 200
Contributions from Sample Hospital
Foundation for property acquisitions 235 485
Transfers to parent (640) (3,000)
Increase in unrestricted net assets, before extraordinary item 5,147 6,699
Extraordinary loss from extinguishment of debt (500)
Increase in unrestricted net assets $ 4,647 $ 6,699
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Sample Not-for-Profit Hospital 
Statements of Changes in Net Assets 
Years Ended December 31, 19X7 and 19X6 
(in thousands)
See accompanying notes to financial statements.
19X7 19X6
Unrestricted net assets:
Excess of revenues over expenses $ 5,052 $ 8,839
Net unrealized gains on investments, other than trading 
securities 300 375
Contributions from Sample Hospital Foundation for 
property acquisitions 235 485
Transfers to parent (640) (3,000)
Net assets released from restrictions used for purchase 
of property and equipment 200
Increase in unrestricted net assets before 
extraordinary item 5,147 6,699
Extraordinary loss from extinguishment of debt (500)
Increase in unrestricted net assets 4,647 6,699
Temporarily restricted net assets: 
Contributions for charity care 140 996
Net realized and unrealized gains on investments 5 8
Net assets released from restrictions (500)
Increase (decrease) in temporarily restricted net assets (355) 1,004
Permanently restricted net assets: 
Contributions for endowment funds 50 411
Net realized and unrealized gains on investments 5 2
Increase in permanently restricted net assets 55 413
Increase in net assets 4,347 8,116
Net assets, beginning of year 72,202 64,086
Net assets, end of year $76,549 $72,202
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Sample Not-for-Profit Hospital 
Statements of Cash Flows (Indirect Method) 
Years Ended December 31, 19X7 and 19X6
(in thousands)
19X7 19X6
Cash flows from operating activities:
Change in net assets
Adjustments to reconcile change in net assets to net 
cash provided by operating activities: 
Extraordinary loss from extinguishment of debt 
Depreciation and amortization
Net realized and unrealized gains on investments, 
other than trading
Transfers to parent 
Provision for bad debts 
Restricted contributions and investment income 
received
(Increase) decrease in:
Patient accounts receivable
Trading securities
Other current assets
Other assets
Increase (decrease) in:
Accounts payable and accrued expenses
Estimated third-party payor settlements
Other current liabilities
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Purchase of investments
Capital expenditures
Net cash used in investing activities
Cash flows from financing activities:
Transfers to parent
Proceeds from restricted contributions and restricted 
investment income
Payments on long-term debt
Payments on capital lease obligations
Proceeds from issuance of long-term debt
Net cash used in financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
$ 4,347
500
$ 8,116
4,782 4,280
(450) (575)
640 3,000
1,000 1,300
(290) (413)
(1,906) (2,036)
215
186 (2,481)
(325) (241)
436 679
201 305
(145) (257)
787 (128)
9,978 11,549
(3,769) (2,150)
(4,728) (5,860)
(8,497) (8,010)
(640) (3,000)
290 413
(24,700) (804)
(150) (100)
22,600 500
(2,600) (2,991)
(1,119) 548
5,877 5,329
$ 4,758 $ 5,877
Supplemental Disclosures of Cash Flow Information:
The Hospital entered into capital lease obligations in the amount of $600,000 for new 
equipment in 19X7.
Cash paid for interest (net of amount capitalized) in 19X7 and 19X6 was $1,780,000 
and $1,856,000, respectively.
See accompanying notes to financial statements.
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Sample Not-for-Profit Hospital
Notes to Financial Statements
December 31, 19X7 and 19X6
1. Description of Organization and Summary of Significant Accounting Policies
Organization. The Sample Not-for-Profit Hospital (the Hospital), located in Tulsa, Oklahoma, 
is a not-for-profit acute care hospital. The Hospital provides inpatient, outpatient and emergency 
care services for residents of northeastern Oklahoma. Admitting physicians are primarily practi­
tioners in the local area. The Hospital was incorporated in Oklahoma in 19X1 and is affiliated with 
the Sample Health System.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include certain investments in highly 
liquid debt instruments with original maturities of three months or less.
The Hospital routinely invests its surplus operating funds in money market mutual funds. These 
funds generally invest in highly liquid U.S. government and agency obligations.
Investments. Investments in equity securities with readily determinable fair values and all 
investments in debt securities are measured at fair value in the balance sheet. Investment income 
or loss (including realized gains and losses on investments, interest and dividends) is included in 
the excess of revenues over expenses unless the income or loss is restricted by donor or law. 
Unrealized gains and losses on investments are excluded from the excess of revenues over 
expenses unless the investments are trading securities.
Assets limited as to use. Assets limited as to use primarily include assets held by trustees under 
indenture agreements and designated assets set aside by the Board of Trustees for future capital 
improvements, over which the Board retains control and may at its discretion subsequently use 
for other purposes. Amounts required to meet current liabilities of the hospital have been 
reclassified in the balance sheet at December 31, 19X7 and 19X6.
Property and equipment. Property and equipment acquisitions are recorded at cost. Depreciation 
is provided over the estimated useful life of each class of depreciable asset and is computed using 
the straight-line method. Equipment under capital lease obligations is amortized on the straight- 
line method over the shorter period of the lease term or the estimated useful life of the equipment. 
Such amortization is included in depreciation and amortization in the financial statements. 
Interest cost incurred on borrowed funds during the period of construction of capital assets is 
capitalized as a component of the cost of acquiring those assets.
Gifts of long-lived assets such as land, buildings, or equipment are reported as unrestricted 
support, and are excluded from the excess of revenues over expenses, unless explicit donor 
stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit 
restrictions that specify how the assets are to be used and gifts of cash or other assets that 
must be used to acquire long-lived assets are reported as restricted support. Absent explicit 
donor stipulations about how long those long-lived assets must be maintained, expirations of 
donor restrictions are reported when the donated or acquired long-lived assets are placed in 
service.
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Temporarily and permanently restricted net assets. Temporarily restricted net assets are those 
whose use by the Hospital has been limited by donors to a specific time period or purpose. 
Permanently restricted net assets have been restricted by donors to be maintained by the Hospital 
in perpetuity.
Excess of revenues over expenses. The statement of operations includes excess of revenues over 
expenses. Changes in unrestricted net assets which are excluded from excess of revenues over 
expenses, consistent with industry practice, include unrealized gains and losses on investments 
other than trading securities, permanent transfers of assets to and from affiliates for other than goods 
and services, and contributions of long-lived assets (including assets acquired using contributions 
which by donor restriction were to be used for the purposes of acquiring such assets).
Net patient service revenue. The Hospital has agreements with third-party payors that provide 
for payments to the Hospital at amounts different from its established rates. Payment arrange­
ments include prospectively determined rates per discharge, reimbursed costs, discounted 
charges, and per diem payments. Net patient service revenue is reported at the estimated net 
realizable amounts from patients, third-party payors, and others for services rendered, including 
estimated retroactive adjustments under reimbursement agreements with third-party payors. 
Retroactive adjustments are accrued on an estimated basis in the period the related services are 
rendered and adjusted in future periods as final settlements are determined.
Premium revenue. The Hospital has agreements with various Health Maintenance Organiza­
tions (HMOs) to provide medical services to subscribing participants. Under these agreements, 
the Hospital receives monthly capitation payments based on the number of each HMO's participants, 
regardless of services actually performed by the Hospital. In addition, the HMOs make fee-for-service 
payments to the Hospital for certain covered services based upon discounted fee schedules.
Charity care. The Hospital provides care to patients who meet certain criteria under its charity care 
policy without charge or at amounts less than its established rates. Because the Hospital does not 
pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.
Donor-restricted gifts. Unconditional promises to give cash and other assets to the Hospital are 
reported at fair value at the date the promise is received. Conditional promises to give and 
indications of intentions to give are reported at fair value at the date the gift is received. The gifts 
are reported as either temporarily or permanently restricted support if they are received with 
donor stipulations that limit the use of the donated assets. When a donor restriction expires, that 
is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily 
restricted net assets are reclassified as unrestricted net assets and reported in the statement of 
operations as net assets released from restrictions. Donor-restricted contributions whose restric­
tions are met within the same year as received are reported as unrestricted contributions in the 
accompanying financial statements.
Estimated malpractice costs. The provision for estimated medical malpractice claims includes 
estimates of the ultimate costs for both reported claims and claims incurred but not reported.
Income taxes. The Hospital is a not-for-profit corporation and has been recognized as tax-ex­
empt pursuant to Sec. 501(c)(3) of the Internal Revenue Code.
2. Net Patient Service Revenue
The Hospital has agreements with third-party payors that provide for payments to the Hospital 
at amounts different from its established rates. A summary of the payment arrangements with 
major third-party payors follows:
• Medicare. Inpatient acute care services rendered to Medicare program beneficiaries are 
paid at prospectively determined rates per discharge. These rates vary according to a pa­
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tient classification system that is based on clinical, diagnostic, and other factors. Inpatient 
nonacute services, certain outpatient services, and defined capital and medical education 
costs related to Medicare beneficiaries are paid based on a cost reimbursement methodol­
ogy. The Hospital is reimbursed for cost reimbursable items at a tentative rate with final 
settlement determined after submission of annual cost reports by the Hospital and audits 
thereof by the Medicare fiscal intermediary. Beginning in 19X3, the Hospital claimed 
Medicare payments based on an interpretation of certain "disproportionate share" rules. 
The intermediary disagreed and declined to pay the excess reimbursement claimed under 
that interpretation. Through 1996, the Hospital has not included the claimed excess in net 
patient revenues pending resolution of the matter. In 19X7, the intermediary accepted the 
claims and paid the outstanding claims, including $950,000 applicable to 19X6 and $300,000 
applicable to 19X5 and prior, which has been included in 19X7 net revenues.
• Medicaid. Inpatient and outpatient services rendered to Medicaid program beneficiaries 
are reimbursed under a cost reimbursement methodology. The Hospital is reimbursed at 
a tentative rate with final settlement determined after submission of annual cost reports 
by the Hospital and audits thereof by the Medicaid fiscal intermediary.
The Hospital also has entered into payment agreements with certain commercial insurance 
carriers, health maintenance organizations, and preferred provider organizations. The basis for 
payment to the Hospital under these agreements includes prospectively determined rates per 
discharge, discounts from established charges, and prospectively determined daily rates.
3. Investments
Assets Limited as to Use
The composition of assets limited as to use at December 31, 19X7 and 19X6, is set forth in the 
following table. Investments are stated at fair value.
Other investments, stated at fair value, at December 31, 19X7 and 19X6, include:
19X7 19X6
Internally designated for capital acquisition: 
Cash $ 545,000 $ 350,000
U.S. Treasury obligations 11,435,000 12,115,000
Interest receivable 20,000 35,000
12,000,000 12,500,000
Held by trustee under indenture agreement: 
Cash and short-term investments 352,000 260,000
U.S. Treasury obligation 6,505,000 7,007,000
Interest receivable 92,000 74,000
6,949,000 7,341,000
$18,949,000 $19,841,000
Other Investments
19X7 19X6
Trading:
U.S. Corporate Bonds $ 1,260,000 $ 1,475,000
Other:
U.S. Treasury obligations $19,266,000 $14,233,000
Interest receivable 310,000 232,000
20,836,000 15,940,000
Less:
Long-term investments 4,680,000 4,680,000
Long-term investments restricted for capital
acquisitions 320,000 520,000
Short-term investments $15,836,000 $10,740,000
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Investment income and gains for assets limited as to use, cash equivalents, and other invest­
ments are comprised of the following for the years ending December 31, 19X7 and 19X6:
19X7 19X6
Income:
Interest income $3,585,000 $2,725,000
Realized gains on sales of securities 150,000 200,000
Unrealized gains on trading securities 165,000 100,000
$3,900,000 $3,025,000
Other Changes in Unrestricted Net Assets:
Unrealized gains on other than trading securities $ 300,000 $ 375,000
4. Property and Equipment
A summary of property and equipment at December 31, 19X7 and 19X6, follows:
19X7 19X6
Land $ 3,000,000 $ 3,000,000
Land improvements 472,000 472,000
Buildings and improvements 46,852,000 46,636,000
Equipment 29,190,000 26,260,000
Equipment under capital lease obligations 2,851,000
82,365,000
2,752,000
79,120,000
Less accumulated depreciation and amortization 34,928,000
47,437,000
30,661,000
48,459,000
Construction in progress 3,601,000 2,033,000
Property and equipment, net $51,038,000 $50,492,000
Depreciation expense for the years ended December 31, 19X7 and 19X6 amounted to approxi­
mately $4,782,000 and $4,280,000. Accumulated amortization for equipment under capital lease 
obligations was $689,000 and $453,000 at December 31, 19X7 and 19X6, respectively. Construction 
contracts of approximately $7,885,000 exist for the remodeling of Hospital facilities. At December 
31, 19X7, the remaining commitment on these contracts approximated $4,625,000.
5. Long-Term Debt
A summary of long-term debt and capital lease obligations at December 31, 19X7 and 19X6,
follows:
19X7 19X6
7.25 percent 19X7 Tax-Exempt Revenue Bonds, principal mat­
uring in varying annual amounts, due November 1, 20XX, 
collateralized by a pledge of the Hospital's gross receipts $21,479,000
8.50 percent 19X2 Tax-Exempt Revenue Bonds, principal 
maturing in varying annual amounts, due June 1, 19XX $22,016,000
7.75 percent mortgage loan, principal maturing in varying 
annual amounts, due January 20XX, collateralized by a 
mortgage on certain property and equipment 2,010,000 2,127,000
7.75 percent note payable, payable in monthly installments 
of $12,000, including interest, due March 19XX, unsecured 125,000 671,000
Capital lease obligations, at varying rates of imputed interest from
6.8 percent to 9.3 percent collateralized by leased equipment 1,000,000 950,000
24,614,000 25,764,000
Less current portion 1,470,000 1,750,000
$23,144,000 $24,014,000
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Under the terms of the 19X7 and 19X2 revenue bond indentures, the Hospital is required to 
maintain certain deposits with a trustee. Such deposits are included with assets limited as to use. 
The revenue note indenture also places limits on the incurrence of additional borrowings and 
requires that the Hospital satisfy certain measures of financial performance as long as the notes 
are outstanding.
Scheduled principal repayments on long-term debt and payments on capital lease obligations 
are as follows:
$1,000,000
Year Ending
December 31,
Long-Term 
Debt
Capital Leases 
Obligations
19X8 $ 970,000 $ 550,000
19X9 912,000 260,000
20Y0 983,000 260,000
20Y1 1,060,000 45,000
20Y2 1,143,000 —
Thereafter 18,546,000 —
$23,614,000 1,115,000
Less amount representing interest under 
capital leases obligations 115,000
A summary of interest cost and investment income on borrowed funds held by the trustee under 
the 19X7 and 19X2 revenue bond indentures during the years ended December 31, 19X7 and 19X6, 
follows:
19X7 19X6
Interest cost:
Capitalized $ 740,000 $ 700,000
Charged to operations 1,752,000 1,825,000
Total $2,492,000 $2,525,000
Investment income:
Capitalized $ 505,000 $ 663,000
Credited to other revenue 330,000 386,000
Total $ 835,000 $1,049,000
6. Temporarily and Permanently Restricted Net Assets
Temporarily restricted net assets are available for the following purposes or periods at Decem­
ber 31, 19X7 and 19X6:
19X7 19X6
Health care services
Purchase of equipment
Indigent care
Health education
For periods after December 31, 19X9
$ 320,000
840,000
350,000
605,000
$ 520,000
950,000
400,000
600,000
$2,115,000 $2,470,000
97
Permanently restricted net assets at December 31, 19X7 and 19X6, are restricted to:
19X7 19X6
Investments to be held in perpetuity, the income 
from which is expendable to support health care 
services (reported as operating income) $2,973,000 $2,923,000
Endowment requiring income to be added to 
original gift until fund value is $1,500,000 615,000 610,000
$3,588,000 $3,533,000
During 19X7, net assets were released from donor restrictions by incurring expenses satisfying 
the restricted purposes of indigent care and health care education in the amounts of $250,000 and 
$50,000, respectively.
7. Medical Malpractice Claims
The Hospital purchases professional and general liability insurance to cover medical mal­
practice claims. There are known claims and incidents that may result in the assertion of 
additional claims, as well as claims from unknown incidents that may be asserted arising from 
services provided to patients. The Hospital has employed independent actuaries to estimate 
the ultimate costs, if any, of the settlement of such claims. Accrued malpractice losses have 
been discounted at 7 percent and in management's opinion provide an adequate reserve for 
loss contingencies.
On March 15, 19X7, a patient filed a suit against the Hospital for malpractice during care received 
as an inpatient. The Hospital believes it has meritorious defenses against the suit; however, the 
ultimate resolution of the matter could result in a loss. The patient has claimed $16 million in 
actual damages. Under state law, punitive damages are determined at trial. The Hospital main­
tains insurance coverage for malpractice claims. The coverage does not include punitive damages 
awards. Trial is scheduled to occur within the next year.
8. Pension and Other Postretirement Benefit Plans
The Hospital has a defined benefit pension plan covering substantially all of its employees. The 
plan benefits are based on years of service and the employees' compensation during the last five 
years of covered employment. Contributions are intended to provide not only for benefits 
attributed to service to date but also for those expected to be earned in the future.
Note: The following paragraph is encouraged but not required.
The Hospital also sponsors two defined benefit postretirement plans that cover both salaried 
and nonsalaried employees. One plan provides medical and dental benefits, and the other 
provides for the payment of life insurance premiums. The postretirement health care plan is 
contributory, with retiree contributions adjusted annually; the life insurance plan is noncontribu­
tory. The accounting for the health care plan anticipates future cost-sharing changes to the written 
plan that are consistent with the Hospital's expressed intent to increase retiree contributions each 
year to 50 percent of the excess of the expected general inflation rate over 6 percent. Beginning in 
19X7, the Hospital adopted a funding policy for its postretirement health care plan similar to its 
funding policy for its life insurance plan—an amount equal to a level percentage of the employees' 
salaries is contributed to the plan annually. For 19X7, that percentage was 4.25, and the aggregate 
contribution for both plans was $34,000.
The following table sets forth the changes in benefit obligations, changes in plan assets and 
components of net periodic benefit cost for both the pension plan and the other postretirement 
benefit plans:
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Change in benefit obligation:
Benefit obligation at beginning of year
Service cost
Interest cost
Plan participants' contributions
Actuarial gain
Benefits paid
Benefit obligation at end of year
Change in plan assets:
Fair value of plan assets at beginning of year 
Actual return on plan assets
Employer contribution
Plan participants' contributions
Benefits paid
Fair value of plan assets at end of year
Funded status
Unrecognized net actuarial gain
Unrecognized prior service cost
Unrecognized transition obligation
Unrecognized transition asset
Prepaid (accrued) benefit cost
Weighted-average assumptions as of December 31: 
Discount rate
Expected return on plan assets
Rate of compensation increase
Pension Benefits Other Benefits
19X7 19X6 19X7 19X6
$ 9,710 $9,700 $585 $500
905 770 14 15
700 650 50 44
34 34
(20) (7)
(375) (1,410) (66) (8)
10,920 9,710 610 585
9,800 9,610 89 40
950 800 4 4
750 620 40 19
34 34
(450) (1,230) (67) (8)
11,050 9,800 100 89
130 90 (510) (496)
(30) (40) (30) (40)
50 55 16 19
445 470
(15) (20)
$ 135 $ 85 $ (79) $ (47)
7.00% 7.00% 7.00% 7.00%
8.00% 8.00% 6.60% 6.60%
6.00% 6.00%
For measurement purposes, a 7 percent annual rate of increase in the per capita cost of covered 
health care benefits was assumed for 19X8. The rate was assumed to decrease gradually to 5 
percent over the next five years.
Pension Benefits Other Benefits 
19X7 19X6 19X7 19X6
Components of net periodic benefit cost:
Service cost $906 $771 $14 $15
Interest cost 700 650 50 44
Expected return on plan assets (885) (725) (3) (4)
Amortization of prior service cost 7 7 2 2
Recognized net actuarial gain (2) (2) (2) (1)
Amortization of transition obligation 25 25
Amortization of transition asset (1) (1)
Net periodic benefit cost $725 $700 $86 $81
Assumed health care cost trend rates have a significant effect on the amounts reported for the 
health care plans. A one-percentage-point change in assumed health care cost trend rates would 
have the following effects:
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1-Percentage- 
Point Increase
1-Percentage- 
Point Decrease
Effect on total of service and interest
$(11)cost components $13
Effect on postretirement benefit obligation 73 (67)
9. Concentrations of Credit Risk
The Hospital grants credit without collateral to its patients, most of whom are local residents 
and are insured under third-party payor agreements. The mix of receivables from patients and 
third-party payors at December 31, 19X7 and 19X6, was as follows:
19X7 19X6
Medicare 51% 53%
Medicaid 17 14
Blue Cross 18 17
Other third-party payors 7 9
Patients 7 7
100% 100%
10. Commitments and Contingencies
Operating leases. The Hospital leases various equipment and facilities under operating leases 
expiring at various dates through April 20X2. Total rental expense in 19X7 and 19X6 for all 
operating leases was approximately $859,000 and $770,000, respectively.
The following is a schedule by year of future minimum lease payments under operating leases 
as of December 31, 19X7, that have initial or remaining lease terms in excess of one year.
Year Ending
December 31,
19X8
19X9
20Y0
20Y1
20Y2
Amount
$517,000
506,000
459,000
375,000
343,000
Litigation. The Hospital is involved in litigation and regulatory investigations arising in the 
course of business. After consultation with legal counsel, management estimates that these 
matters will be resolved without material adverse effect on the Hospital's future financial position 
or results from operations.
Allowance for doubtful accounts. Beginning in 19X5, the Hospital has provided care under an 
agreement with Associated HMO. The HMO currently owes the Hospital $950,000, substantially 
all of which is overdue. The Hospital has notified the HMO that further services under the contract 
cannot be provided without payment on the outstanding balance. The HMO has assured the 
Hospital that additional funds are being obtained in order to pay the overdue balance and 
continue service under the agreement, however, if the HMO is unable to make payments, 
additional allowances for bad debts would need to be accrued.
11. Extraordinary Loss
In 19X7, the Hospital advance refunded its 19X2 Revenue Bonds in the amount of $22 million 
by issuing 19X7 Revenue Bonds. As a result of this in-substance defeasance transaction, an 
extraordinary loss totaling $500,000 was recorded. As of December 31, 19X7, $21 million of 
advance refunded bonds, which are considered extinguished, remain outstanding.
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12. Related Party Transactions
During the years ended December 31, 19X7 and 19X6, the Hospital contributed capital to Sample 
Health System, an affiliate with some board members in common with the Hospital, in the 
amounts of $640,000 and $3 million, respectively.
The Sample Hospital Foundation (the Foundation), which is controlled by Sample Health 
System, was established to solicit contributions from the general public and to support the 
Hospital. Funds are distributed to the Hospital as determined by the Foundation's Board of 
Directors. A summary of the foundation's assets, liabilities, net assets, results of operations, and 
changes in net assets follows.
December 31,
19X6 19X7
Assets, principally cash and cash equivalents $521,000 $472,000
Liabilities 11,000 10,000
Net assets 510,000 462,000
Total liabilities and net assets $521,000 $472,000
Support and revenue $269,000 $535,000
Expenses
Distributions to Sample Hospital for property acquisitions 235,000 485,000
Other 13,000 16,000
Total expenses 248,000 501,000
Excess of support and revenue over expenses 21,000 34,000
Other changes in net assets 27,000 17,000
Net assets, beginning of year 462,000 411,000
Net assets, end of year $510,000 $462,000
Liabilities include $10,000 payable at the end of each year to Sample Hospital. These amounts 
were paid after the end of each year.
13. Functional Expenses
The Hospital provides general health care services to residents within its geographic location. 
Expenses related to providing these services are as follows (in thousands):
December 31,
19X7 19X6
Health care services $86,000 $78,647
General and administrative 12,055
$98,055
10,643 
$89,290
14. Fair Value of Financial Instruments
The following methods and assumptions were used by the Hospital in estimating the fair value 
of its financial instruments:
Cash and cash equivalents: The carrying amount reported in the balance sheet for cash and cash 
equivalents approximates its fair value.
Investments: Fair values, which are the amounts reported in the balance sheet, are based on quoted 
market prices, if available, or estimated using quoted market prices for similar securities.
Assets limited as to use: These assets consist primarily of cash and short-term investments and 
interest receivable. The carrying amount reported in the balance sheet is fair value.
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Accounts payable and accrued expenses: The carrying amount reported in the balance sheet for 
accounts payable and accrued expenses approximates its fair value.
Estimated third-party payor settlements: The carrying amount reported in the balance sheet for 
estimated third-party payor settlements approximates its fair value.
Long-term debt: Fair values of the Hospital's revenue notes are based on current traded value. 
The fair value of the Hospital's remaining long-term debt is estimated using discounted cash 
flow analyses, based on the Hospital's current incremental borrowing rates for similar types 
of borrowing arrangements.
The carrying amounts and fair values of the Hospital's financial instruments at December 31, 19X7 
and 19X6, are as follows (In thousands):
19X7 19X6
Carrying 
Amount Fair Value
Carrying 
Amount Fair Value
Cash and cash equivalents $ 4,758 $ 4,758 $ 5,877 $ 5,877
Short-term investments 15,836 15,836 10,740 10,740
Assets limited as to use 18,949 18,949 19,841 19,841
Long-term investments 4,680 4,680 4,680 4,680
Long-term investments restricted 
for capital acquisition 320 320 520 520
Accounts payable and 
accrued expenses 5,818 5,818 5,382 5,382
Estimated third-party 
payor settlements 2,143 2,143 1,942 1,942
Long-term debt 24,614 23,980 25,764 24,918
15. Promises to Contribute
At December 31, 19X7, the Hospital had received $1,500,000 of conditional promises to contrib­
ute to the building of a new facility for outpatient services. These contributions will be recorded 
as temporarily restricted support when received. The Hospital had no material outstanding 
unconditional promises of support at December 31, 19X7.
16. Charity Care
The amount of charges foregone for services and supplies furnished under the Hospital's charity 
care policy aggregated approximately $4,500,000 and $4,100,000 in 19X7 and 19X6, respectively.
17. Subsequent Event
On February 9, 19X8, the Hospital signed a contract in the amount of $1,050,000 for the purchase 
of certain real estate.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A NURSING HOME
.08
Sample For-Profit Nursing Home, Inc.
Balance Sheets
December 31, 19X5 and 19X4
19X5 19X4
Assets
Current assets:
Cash and cash equivalents $ 95,000 $ 129,000
Investments 150,000
Assets limited as to use 50,000 50,000
Patient accounts receivable, net of allowance 
for doubtful accounts of $6,700 in 19X5 and 
$5,300 in 19X4 162,000 152,000
Estimated third-party payor settlements 71,000 62,000
Interest receivable 7,000
Supplies 47,000 43,000
Prepaid expenses 3,000 2,000
Deferred tax asset 12,000 14,000
Total current assets 597,000 452,000
Assets limited as to use, net of amount required 
for current liabilities 173,000 150,000
Property and equipment: 
Land 205,000 205,000
Land improvements 37,000 32,000
Buildings 1,399,000 1,399,000
Furniture, fixtures, and equipment 228,000 189,000
1,869,000 1,825,000
Less accumulated depreciation 210,000 141,000
Property and equipment, net 1,659,000 1,684,000
Other assets 150,000 127,000
Total assets $2,579,000 $2,413,000
Liabilities and Shareholders' Equity
Current liabilities:
Current maturities of long-term debt $ 50,000 $ 50,000
Accounts payable 78,000 52,000
Accrued expenses 175,000 188,000
Deposits from patients 50,000 45,000
Other current liabilities 74,000 15,000
Total current liabilities 427,000 350,000
Deferred tax liability 6,000 14,000
Long-term debt, net of current maturities 1,700,000 1,750,000
Shareholders' equity:
Common stock, $20 par value; authorized 
5,000 shares; issued and outstanding 
3,500 shares 70,000 70,000
Retained earnings 376,000 229,000
Total shareholders' equity 446,000 299,000
Total liabilities and shareholders' equity $2,579,000 $2,413,000
See accompanying notes to financial statements.
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Sample For-Profit Nursing Home, Inc. 
Statements of Income and Retained Earnings 
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Revenue:
Net patient service revenue $2,163,000 $1,949,000
Other revenue 67,000 22,000
Interest on investments held by trustee 13,000 7,000
Total revenue 2,243,000 1,978,000
Expenses:
Salaries and benefits 969,000 919,000
Medical supplies and drugs 511,000 499,000
Insurance and other 216,000 176,000
Provision for bad debts 92,000 83,000
Depreciation 69,000 57,000
Interest 164,000 172,000
Total expenses 2,021,000 1,906,000
Operating income 222,000 72,000
Nonoperating income:
Other interest income 5,000
Income before provision for income taxes 227,000 72,000
Provision for income taxes 80,000 29,000
Net income 147,000 43,000
Retained earnings, beginning of year 229,000 186,000
Retained earnings, end of year $ 376,000 $ 229,000
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Sample For-Profit Nursing Home, Inc. 
Statements of Cash Flows 
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Cash flows from operating activities:
Cash received from residents and third-party payors $2,019,000 $1,796,000
Cash received from others 67,000 22,000
Cash paid to employees and suppliers (1,679,000) (1,495,000)
Interest and dividends received 10,000 10,000
Interest paid (160,000) (170,000)
Taxes paid (29,000) (30,000)
Deposits received from patients 35,000 15,000
Deposits refunded to patients (30,000) (20,000)
Net cash provided by operating activities 233,000 128,000
Cash flows from investing activities: 
Purchase of investments (150,000)
Proceeds from sale of property 2,000
Capital expenditures (44,000) (79,000)
Purchase of assets limited as to use (23,000)
Net cash used in investing activities (217,000) (77,000)
Cash flows from financing activities: 
Repayment of long-term debt (50,000) (50,000)
Net cash used in financing activities (50,000) (50,000)
Net increase (decrease) in cash and cash equivalents (34,000) 1,000
Cash and cash equivalents, beginning of year 129,000 128,000
Cash and cash equivalents, end of year $ 95,000 $ 129,000
Reconciliation of net income to net cash 
provided by operating activities:
Net income $ 147,000 $ 43,000
Adjustments to reconcile net income to net cash 
provided by operating activities: 
Depreciation 69,000 57,000
Provision for bad debts 92,000 83,000
Loss on sale of property — 11,000
Change in deferred income taxes (6,000) (14,000)
(Increase) decrease in: 
Patient accounts receivable (102,000) (41,000)
Other current assets (21,000) (15,000)
Estimated third-party payor settlements (9,000) (10,000)
Interest receivable (7,000) (3,000)
Other assets (7,000) (10,000)
Increase (decrease) in:
Accounts payable and accrued expenses 13,000 43,000
Deposits from patients 5,000 (5,000)
Other current liabilities 59,000 (11,000)
Net cash provided by operating activities $ 233,000 $ 128,000
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Sample For-Profit Nursing Home, Inc.
Notes to Financial Statements
December 31, 19X5 and 19X4
1. Description of Organization and Summary of Significant Accounting Policies
Organization. The Sample Nursing Home, Inc. (the Company) was incorporated in New State 
in 19X1 and operates a 128-bed nursing home in Abacus, New State. A summary of the Company's 
significant accounting policies follows:
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less, excluding amounts whose use is 
limited by note indenture.
Investments. Investments in debt instruments, including assets limited as to use, are classified 
as held-to-maturity because the Company has the positive intent and ability to hold the securities 
until maturity. Held-to-maturity securities are carried at cost adjusted for amortization of premi­
ums and accretion of discounts.
Assets limited as to use. Assets deposited with a trustee under terms of the note indenture and assets 
set aside by the Board of Directors for capital improvements are classified as assets limited as to use. 
Amounts required to meet current liabilities have been reclassified in the balance sheet.
Property and equipment. Property and equipment are recorded at cost. Depreciation is calculated 
on the straight-line method over the estimated useful lives of depreciable assets.
Bond issuance costs. Costs incurred in issuing the Series 19X1 bonds are being amortized based 
on the effective interest method.
Net patient service revenue. Net patient service revenue is reported at the estimated net realizable 
amounts from residents, third-party payors, and others for service rendered.
Revenue under third-party payor agreements is subject to audit and retroactive adjustment. 
Provisions for estimated third-party payor settlements are provided in the period the related 
services are rendered. Differences between the estimated amounts accrued and interim and final 
settlements are reported in operations in the year of settlement.
Income taxes. The provisions for income taxes are based on amounts estimated to be currently 
payable and those deferred because of temporary differences between the financial statement and tax 
bases of assets and liabilities. These differences consist principally of bad debts and depreciation.
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2. Assets Limited as to Use
Assets limited as to use include:
Assets held by trustee under the Series 19X1 note indenture agreement 
at December 31, 19X5 and 19X4.
19X5 19X4
U.S. Government obligations $150,000 $130,000
Cash 24,000 21,000
Accrued interest income 2,000 2,000
Internally designated by the Board of 
Directors for capital improvements
176,000 153,000
Certificate of deposit $ 45,000 $ 45,000
Accrued interest 2,000 2,000
47,000 47,000
$223,000 $200,000
3. Investments
The amortized cost and approximate fair value of held-to-maturity securities at December 31, 
19X5 and 19X4, are as follows:
December 31, 19X5
Amortized 
Cost
Gross 
Unrealized
Gains
Gross 
Unrealized 
(Losses)
Approximate 
Fair Value
U.S. Treasury obligations $150,000 $11,000 $(16,000) $145,000
U.S. Government agency
obligations 83,000 (7,000) 76,000
Other debt securities 67,000 (18,000) 49,000
$300,000 $11,000 $(41,000) $270,000
December 31,19X4
Amortized 
Cost
Gross 
Unrealized
Gains
Gross 
Unrealized 
(Losses)
Approximate 
Fair Value
U.S. Treasury obligations $103,000 $ $(10,000) $ 93,000
U.S. Government agency
obligations 27,000 2,000 29,000
$130,000 $2,000 $(10,000) $122,000
Maturities of held-to-maturity securities at December 31, 19X5, are as follows:
One year or less
After one through five years
After five through ten years
After ten years
Amortized 
Cost
$131,000 
31,000 
68,000 
70,000
$300,000
Approximate 
Fair Value
$126,000 
29,000 
62,000 
53,000
$270,000
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4. Long-Term Debt
Long-term debt at December 31, 19X5 and 19X4, was as follows:
9.5 percent bonds payable to the City 
of Abacus, maturing $50,000 annually 
through November 1, 19YY, with a 
final maturity of $1 million on 
November 1, 19YY
Less current maturities
$1,750,000 
50,000
$1,800,000 
50,000
$1,700,000 $1,750,000
The notes are collateralized by a first-mortgage lien on all property and equipment of the 
Company and a security interest in all of its receipts. The note indenture requires the maintenance 
of certain deposits with a trustee, which are included in assets limited as to use.
Future maturities of long-term debt as of December 31, 19X5, follow:
Year ending December 31, Amount
19X6 $ 50,000
19X7 50,000
19X8 50,000
19X9 50,000
19Y0 50,000
Thereafter 1,500,000
Total $1,750,000
5. Income Taxes
The provisions for income taxes are as follows:
19X5 19X4
Current:
Federal $72,000 $15,000
State 2,000
Total current 74,000 15,000
Deferred:
Federal 6,000 13,000
State 1,000
Total deferred 6,000 14,000
Total provision for income taxes $80,000 $29,000
Deferred income taxes are provided for the temporary differences between the financial report­
ing basis and the tax basis of the Company's assets and liabilities.
For the years ended December 31, 19X5 and 19X4, the effective tax rate approximated the 
statutory rate of 34 percent and 40 percent, respectively.
The net current and noncurrent components of deferred income taxes recognized in the balance
sheet at December 31, 19X5 and 19X4, follows:
19X5 19X4
Net current assets $12,000 $14,000
Net noncurrent liabilities 6,000 14,000
$ 6,000 $____ 0
Management has determined that no valuation allowance related to deferred tax assets is 
necessary at December 31, 19X5 and 19X4, respectively.
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6. Concentration in State Medicaid Program
The Company has 100 of its 128 beds designated for care of patients under the state's Medicaid 
program. The current funding of that program is 90 days behind filed claims. The current state 
budget has no provision for reducing that lag and, while the proposed budget for 19X6 includes 
additional funding, there is no assurance that the final budget will include the needed additional 
funds.
7. Risks and Uncertainties Disclosures*
8. Pension and Other Postretirement Benefit Plans*
9. Fair Values of Financial Instruments*
10. Concentrations of Credit Risk*
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
not-for-profit hospital and, therefore, are not repeated here.
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FOR A CONTINUING CARE RETIREMENT COMMUNITY
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Sample Not-for-Profit Continuing Care Retirement Community 
Balance Sheets
December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Assets
Current assets:
Cash $ 375,000 $ 330,000
Assets limited as to use 265,000 170,000
Accounts receivable, net of allowance for 
doubtful accounts of $4,000 in 19X5 and
$5,000 in 19X4 187,000 197,000
Supplies 40,000 21,000
Prepaid expenses 115,000 73,000
Total current assets 982,000 791,000
Assets limited as to use, net of amount required
for current liabilities 1,865,000 1,583,000
Property and equipment, net 14,893,000 15,280,000
Deferred financing costs, net of accumulated 
amortization of $28,000 in 19X5 and
$21,000 in 19X4 83,000 90,000
Total assets $17,823,000 $17,744,000
Liabilities and Net Assets
Liabilities:
Current maturities of long-term debt $ 90,000 $ 77,000
Accounts payable 180,000 174,000
Accrued expenses 161,000 178,000
Deposits on unoccupied units 22,000 40,000
Total current liabilities 453,000 469,000
Long-term debt, less current maturities 8,871,000 8,935,000
Refundable fees 59,000 144,000
Estimated obligation to provide future 
services, in excess of amounts received
or to be received 88,000 100,000
Deferred revenue from advance fees 6,304,000 6,585,000
Total liabilities 15,775,000 16,233,000
Net assets:
Unrestricted 1,286,000 833,000
Temporarily restricted 311,000 294,000
Permanently restricted 451,000 384,000
Total net assets 2,048,000 1,511,000
Total liabilities and net assets $17,823,000 $17,744,000
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Sample Not-for-Profit Continuing Care Retirement Community
Statements of Operations
Years Ended December 31, 19X5 and 19X4
Revenue, gains, and other support:
Resident services, including amortization 
of advance fees of $935,000 in 19X5 
and $915,000 in 19X4
Patient revenue from nonresidents
Change in obligation to provide future services 
Contributions
Net assets released from restrictions used for 
operations
Investment income
Other
Total revenue, gains, and other support
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Depreciation
Interest
Total expenses
Operating income (loss)
Net assets released from restriction—
purchase of equipment
Increase (decrease) in unrestricted net assets
19X419X5
$3,946,000 $3,152,000
249,000 275,000
12,000 (82,000)
54,000 39,000
24,000 50,000
29,000 30,000
75,000 68,000
4,389,000 3,532,000
1,708,000 1,250,000
543,000 742,000
291,000 311,000
452,000 447,000
967,000 955,000
3,961,000 3,705,000
428,000 (173,000)
25,000 45,000
$ 453,000 $ (128,000)
See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community
Statements of Changes in Net Assets
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Unrestricted net assets:
Operating income (loss) $ 428,000 $ (173,000)
Net assets released from restriction— 
purchase of equipment 25,000 45,000
Increase (decrease) in unrestricted net assets 453,000 (128,000)
Temporarily restricted net assets: 
Contributions 40,000 15,000
Net assets released from restrictions used 
for operations (24,000) (50,000)
Net assets released from restriction— 
purchase of equipment (25,000) (45,000)
Investment income 26,000 15,000
Increase (decrease) in temporarily restricted 
net assets 17,000 (65,000)
Permanently restricted net assets: 
Contributions 67,000 52,000
Increase in permanently restricted net assets 67,000 52,000
Increase (decrease) in net assets 537,000 (141,000)
Net assets, beginning of year 1,511,000 1,652,000
Net assets, end of year $2,048,000 $1,511,000
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Sample Not-for-Profit Continuing Care Retirement Community
Statements of Cash Flows
Years Ended December 31, 19X5 and 19X4
19X5 19X4
Cash flows from operating activities: 
Cash received from residents and
third-party payors $3,252,000 $2,341,000
Advance fees received 654,000 857,000
Other receipts from operations 75,000 68,000
Investment income received 68,000 53,000
Contributions received 51,000 44,000
Cash paid to employees and suppliers (2,576,000) (2,040,000)
Interest paid (950,000) (945,000)
Net cash provided by operating activities 574,000 378,000
Cash flows from investing activities: 
Purchase of property and equipment (65,000) (250,000)
Purchase of assets limited as to use (377,000) 229,000
Net cash used in investing activities (442,000) (21,000)
Cash flows from financing activities: 
Permanently restricted funds received 67,000 52,000
Refunds of deposits and refundable fees (103,000) (52,000)
Proceeds from issuance of long-term debt 26,000
Principal payments of long-term debt (77,000) (307,000)
Net cash used in financing activities (87,000) (307,000)
Net increase in cash 45,000 50,000
Cash, beginning of year 330,000 280,000
Cash, end of year $ 375,000 $ 330,000
Reconciliation of change in net assets to 
net cash provided by operating activities:
Change in net assets $ 537,000 $ (141,000)
Adjustments to reconcile change in net assets 
to net cash provided by operating activities: 
Advance fees received 654,000 857,000
Restricted net assets received (67,000) (52,000)
Amortization of advance fees (935,000) (915,000)
Loss (gain) on obligation to provide 
future services (12,000) 82,000
Depreciation 452,000 447,000
Amortization of deferred financing costs 7,000 34,000
Provision for bad debts 3,000 3,000
(Increase) decrease in: 
Accounts receivable 7,000 (33,000)
Other assets (61,000) (4,000)
Increase (decrease) in:
Accounts payable and accrued expenses (11,000) 100,000
Net cash provided by operating 
activities $ 574,000 $ 378,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Continuing Care Retirement Community
Notes to Financial Statements
December 31, 19X5 and 19X4
1. Description of Organization and Summary of Significant Accounting Policies1
1 Does not include all disclosures common to all health care entities.
Organization. The Sample Continuing Care Retirement Community (the CCRC) is a nonprofit 
organization that principally provides housing, health care, and other related services to residents 
through the operation of a retirement facility containing 249 apartments and a 78-bed health care 
facility located in Evergreen Park, Illinois. The CCRC was incorporated in Illinois in 19X1. A 
summary of significant accounting policies follows.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value 
in the balance sheet. Investment income (including realized gains and losses on investments, 
interest, and dividends) is included in operating income (loss) unless restricted by donor or law. 
Unrealized gains and losses on investments, if any, are excluded from operating income (loss).
Deferred financing costs. Deferred financing costs are amortized using the effective interest 
method over the term of the related financing agreement.
Advance fees. Fees paid by a resident upon entering into a continuing care contract, net of the 
portion thereof that is refundable to the resident, are recorded as deferred revenue and are 
amortized to income using the straight-line method over the estimated remaining life expectancy 
of the resident.
Obligation to provide future services. The CCRC annually calculates the present value of the net 
cost of future services and the use of facilities to be provided to current residents and compares 
that amount with the balance of deferred revenue from advance fees. If the present value of the 
net cost of future services and the use of facilities exceeds the deferred revenue from advance fees, 
a liability is recorded (obligation to provide future services and use of facilities) with the 
corresponding charge to income. The obligation is discounted at 9 percent, based on the expected 
long-term rate of return on government obligations.
Donor restrictions. The CCRC reports gifts of cash and other assets as restricted support if they 
are received with donor stipulations that limit the use of the donated assets. When a donor 
restriction expires (that is, when a stipulated time restriction ends or a purpose restriction is 
accomplished), temporarily restricted net assets are reclassified as unrestricted net assets and 
reported in the statement of operations as net assets released from restrictions. Donor-restricted 
contributions whose restrictions are met within the same year as received are reflected as 
unrestricted contributions in the accompanying financial statements.
The CCRC reports gifts of property and equipment (or other long-lived assets) as unrestricted 
support unless explicit donor stipulations specify how the donated assets must be used. Gifts of 
long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of 
cash or other assets that must be used to acquire long-lived assets are reported as restricted 
support. Absent explicit donor stipulations about how long those long-lived assets must be 
maintained, the CCRC reports expirations of donor restrictions when the donated or acquired 
long-lived assets are placed in service.
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Income taxes. The CCRC has been recognized by the Internal Revenue Service as a not-for-profit 
corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from 
federal income taxes pursuant to Sec. 501(a) of the IRC.
Property and equipment. Property and equipment are stated at cost. Donated property is re­
corded at its estimated fair value at the date of receipt. Depreciation is computed on the 
straight-line method based on the following estimated useful lives:
Land improvements
Buildings and improvements
Furniture and equipment
20 years
40 years
5-15 years
Operating income (loss). The statement of operations includes operating income (loss). Changes in 
unrestricted net assets which are excluded from operating income (loss), consistent with industry 
practice, include unrealized gains and losses on investments other than trading securities, 
permanent transfers of assets to and from affiliates for other than goods and services, and 
contributions of long-lived assets (including assets acquired using contributions which by donor 
restriction were to be used for the purposes of acquiring such assets).
2. Property and Equipment
A summary of property and equipment at December 31, 19X5 and 19X4, follows:
3.
19X5 19X4
Land $ 557,000 $ 557,000
Land improvements 205,000 203,000
Buildings and improvements 14,573,000 14,564,000
Furniture and equipment 752,000 698,000
16,087,000 16,022,000
Less: accumulated depreciation (1,194,000) (742,000)
$14,893,000 $15,280,000
Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
19X5 19X4
Purchase of equipment $169,000 $152,000
Charity care 142,000 142,000
$311,000 $294,000
Net assets were released from donor restrictions by incurring expenses satisfying the restricted 
purposes or by occurrence of other events specified by donors:
19X5
$24,000
$25,000
Charity care
Purchase of equipment
19X4 
$50,000 
$45,000
4. Permanently Restricted Net Assets
Permanently restricted net assets are restricted to investment in perpetuity, the income from 
which is expendable to support:
Charity care
Community activities
19X5 
$168,000
283,000 
$451,000
19X4 
$168,000
216,000 
$384,000
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5. Long-Term Debt
Long-term debt at December 31, 19X5 and 19X4, is as follows:
19X5 19X4
10.75 percent mortgage note payable $8,901,000 $8,965,000
Notes payable to bank—unsecured 34,000 14,000
Other 26,000
8,961,000
33,000
9,012,000
Less current maturities 90,000
$8,871,000
77,000
$8,935,000
The mortgage note is payable in consecutive monthly installments of principal and interest of 
$85,425 to May 20XX. The note is collateralized by a first mortgage on property and equipment with 
a depreciated cost at December 31, 19X5, of $14,893,000 and by a pledge of all operating revenue.
As required by the mortgage note agreement, the CCRC established an initial debt service 
reserve fund of $1,000,000 at April 15, 19X3. All resident fees received thereafter, net of resident 
fee refunds and debt service payments not to exceed $300,000 annually in the first four years and 
$200,000 annually thereafter, are to be added to the debt service reserve fund until the total sum 
of $2,050,000 is accumulated. Since June 1, 19X4, the CCRC has been required to deliver to the 
trustee $5,500 per month to establish maintenance reserves until the aggregate of such payments 
equals a residential unit reserve and a health care center reserve of $240,000 and $90,000, 
respectively. At December 31, 19X5 and 19X4, the trustee held investments aggregating $2,130,000 
and $1,753,000, respectively. Such amount has been classified as assets limited as to use.
Scheduled annual principal maturities of long-term debt for the next five years are as follows:
Year ending December 31,
19X6
19X7
19X8
19X9
20Y0
Amount 
$ 90,000
90,000
95,000 
105,000 
105,000
6. Classification of Expenses
Program activities
General and administrative
19X5
3,368,000
593,000 
$3,961,000
19X4
3,135,000 
570,000 
$3,705,000
7. Assets Limited as to Use*
8. Risks and Uncertainties Disclosures*
9. Pension and Other Postretirement Benefit Plans*
10. Fair Values of Financial Instruments"
11. Concentrations of Credit Risk*
12. Investments*
* The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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Sample Not-for-Profit Home Health Agency 
Balance Sheets
December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Assets
Current assets:
Cash and cash equivalents $ 74,000 $ 41,000
Investments 147,000 137,000
Accounts receivable, net of allowance for doubtful
accounts of $61,000 in 19X5 and $30,000 in 19X4 752,000 476,000
Other receivables 27,000 22,000
Total current assets 1,000,000 676,000
Investments 100,000 100,000
Equipment:
Medical and office equipment 56,000 39,000
Vehicles 50,000 37,000
Less accumulated depreciation
106,000
(45,000)
76,000
(24,000)
Equipment, net 61,000 52,000
Deferred finance charges, net of accumulated amort­
ization of $15,000 in 19X5 and $10,000 in 19X4 20,000 25,000
Total assets $1,181,000 $853,000
Liabilities and Net Assets
Current liabilities:
Current maturities of long-term debt $ 13,000 $ 13,000
Accounts payable 40,000 21,000
Accrued payroll and vacation costs 496,000 352,000
Estimated third-party payor settlements 28,000 31,000
Advances from third-party payors 70,000 66,000
Total current liabilities 647,000 483,000
Long-term debt, less current maturities 105,000 118,000
Total liabilities 752,000 601,000
Net assets:
Unrestricted 330,000 167,000
Temporarily restricted 9,000 5,000
Permanently restricted 90,000 80,000
Total net assets 429,000 252,000
Total liabilities and net assets $1,181,000 $853,000
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Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31, 19X5 and 19X4
FORMAT A
See accompanying notes to financial statements.
19X5 19X4
Revenue, gains, and other support: 
Net patient service revenue $4,042,000 $2,687,000
Contributions 5,000 22,000
Net assets released from restrictions 5,000 —
Investment income 13,000 6,000
Other revenue 27,000 32,000
Total revenue, gains, and other support 4,092,000 2,747,000
Expenses:
Salaries and benefits 2,714,000 1,835,000
Medical supplies and drugs 1,042,000 675,000
Insurance and other 90,000 83,000
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Interest 16,000 19,000
Total expenses 3,929,000 2,648,000
Excess of revenue over expenses and 
change in unrestricted net assets $ 163,000 $ 99,000
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Sample Not-for-Profit Home Health Agency
Statements of Operations
Years Ended December 31, 19X5 and 19X4
FORMAT B
See accompanying notes to financial statements.
19X5 19X4
Revenue, gains, and other support:
Net patient service revenue $4,042,000 $2,687,000
Contributions 5,000 22,000
Net assets released from restrictions 5,000 —
Other revenue 27,000 32,000
Total revenue, gains, and other support 4,079,000 2,741,000
Expenses:
Salaries and benefits 2,714,000 1,835,000
Medical supplies and drugs 1,042,000 675,000
Insurance and other 90,000 83,000
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Interest 16,000 19,000
Total expenses 3,929,000 2,648,000
Operating income 150,000 93,000
Other income:
Investment income 13,000 6,000
Excess of revenue over expenses and
change in unrestricted net assets $ 163,000 $ 99,000
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Sample Not-for-Profit Home Health Agency
Statements of Changes in Net Assets
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Unrestricted net assets:
Excess of revenue over expenses $163,000 $ 99,000
Increase in unrestricted net assets 163,000 99,000
Temporarily restricted net assets:
Contributions 9,000 5,000
Net assets released from restrictions (5,000) —
Increase in temporarily restricted net assets 4,000 5,000
Permanently restricted net assets:
Contributions 10,000 6,000
Increase in permanently restricted net assets 10,000 6,000
Increase in net assets 177,000 110,000
Net assets, beginning of year 252,000 142,000
Net assets, end of year $429,000 $252,000
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Sample Not-for-Profit Home Health Agency
Statements of Cash Flows
Years Ended December 31, 19X5 and 19X4
Net cash provided by operating activities $ 76,000 $ 41,000
19X5 19X4
Cash flows from operating activities: 
Cash received from patients and 
third-party payors $3,721,000 $2,542,000
Other receipts from operations 22,000 32,000
Cash paid to employees and suppliers (3,679,000) (2,541,000)
Interest paid (11,000) (14,000)
Nonoperating revenue 23,000 22,000
Net cash provided by operating activities 76,000 41,000
Cash flows from investing activities: 
Purchase of equipment (30,000) (19,000)
Purchase of investments (10,000) (15,000)
Net cash used in investing activities (40,000) (34,000)
Cash flows from financing activities: 
Proceeds from contributions restricted for: 
Endowment 10,000 6,000
Other financing activities: 
Payment of long-term debt (13,000) —
Net cash provided by (used in) financing activities (3,000) 6,000
Net increase in cash and cash equivalents 33,000 13,000
Cash and cash equivalents, beginning of year 41,000 28,000
Cash and cash equivalents, end of year $ 74,000 $ 41,000
Reconciliation of change in net assets to net 
cash provided by operating activities:
Change in net assets $ 177,000 $ 110,000
Adjustments to reconcile change in net assets 
to net cash provided by operating activities: 
Increase in permanently restricted net assets (10,000) (6,000)
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Amortization of deferred financing charges 5,000 5,000
(Increase) decrease in: 
Accounts receivable (322,000) (150,000)
Other receivables (5,000) 4,000
Increase (decrease) in:
Accounts payable, accrued payroll, and 
vacation costs 163,000 38,000
Estimated third-party payor settlements 1,000 4,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Home Health Agency
Notes to Financial Statements
Years Ended December 31, 19X5 and 19X4
1. Description of Organization and Summary of Significant Accounting Policies
Organization. The Sample Home Health Agency (the Agency) was incorporated in 19X0 in New 
State as a not-for-profit corporation. The Agency provides health and supportive services to 
individuals at their homes, primarily in the New State area.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value 
in the balance sheet. Investment income (including realized gains and losses on investments, 
interest and dividends) is included in excess of revenues over expenses unless restricted by donor 
or law. Unrealized gains and losses on investments, if any, are excluded from excess of revenues 
over expenses.
Equipment. Equipment is recorded at cost. Depreciation is computed using the straight-line 
method over the estimated useful lives of the assets.
Deferred financing costs. Deferred financing costs are being amortized using the effective interest 
method over the term of the related financing agreement.
Donor restrictions. The Agency reports gifts of cash and other assets as restricted support if they 
are received with donor stipulations that limit the use of the donated assets. When a donor 
restriction expires, that is, when a stipulated time restriction ends or purpose restriction is 
accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and 
reported in the statement of operations as net assets released from restrictions. When long-lived 
assets are placed in service, thus satisfying purpose restrictions, the amount is included as a 
change in net assets, restricted and unrestricted. Donor-restricted contributions whose restrictions 
are met within the same year as received are reflected as unrestricted contributions in the 
accompanying financial statements.
The Agency reports gifts of equipment (or other long-lived assets) as unrestricted support unless 
explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets 
with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets 
that must be used to acquire long-lived assets are reported as restricted support. Absent explicit 
donor stipulations about how long those long-lived assets must be maintained, the Agency 
reports expirations of donor restrictions when the donated or acquired long-lived assets are 
placed in service.
Net patient service revenue. Net patient service revenue represents the estimated net realizable 
amounts from patients, third-party payors, and others for services rendered.
Charity care. The Agency has a policy of providing charity care to patients who are unable to 
pay. Such patients are identified based on financial information obtained from the patient and 
subsequent analysis. Since the Agency does not expect payment, estimated charges for charity 
care are not included in revenue.
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Income taxes. The Agency has been recognized by the Internal Revenue Service as a not-for- 
profit corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and is exempt 
from federal income taxes on related income pursuant to Sec. 501(a) of the IRC.
Excess of revenue over expenses. The statement of operations includes excess of revenue over 
expenses. Changes in unrestricted net assets which are excluded from excess of revenue over 
expenses, consistent with industry practice, include unrealized gains and losses on investments 
other than trading securities, permanent transfers of assets to and from affiliates for other than goods 
and services, and contributions of long-lived assets (including assets acquired using contributions 
which by donor restriction were to be used for the purposes of acquiring such assets).
2. Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
19X5 19X4
Charity care $ - $5,000
Purchase of equipment 9,000 —
$9,000 $5,000
Net assets were released from donor restrictions by incurring expenses satisfying the restricted 
purposes or by occurrence of other events specified by donors:
19X5 19X4
Charity care expenditures $5,000 $ —
3. Permanently Restricted Net Assets
Permanently restricted net assets are restricted in perpetuity, the income from which is expend-
able to support:
19X5 19X4
Program A activities $10,000 $ —
Any activities of the Agency 80,000 80,000
$90,000 $80,000
4. Third-Party Rate Adjustments and Revenue
Approximately 38 percent in 19X5 and 37 percent in 19X4 of net patient service revenue was 
derived under federal and state third-party reimbursement programs. These revenues are based, 
in part, on cost reimbursement principles and are subject to audit and retroactive adjustment by 
the respective third-party fiscal intermediaries. In the opinion of management, retroactive adjust­
ments, if any, would not be material to the financial position or results of operations of the Agency.
5. Internally-Designated Assets
The Board of Directors has designated investments aggregating $135,000 to be used for future 
major capital improvements. Those assets are classified in the balance sheet as investments.
6. Long-Term Debt
Long-term debt at December 31, 19X5 and 19X4, is as follows:
19X5 19X4
Note payable to bank, interest at 15 percent, 
payable in monthly installments of $2,200 per 
month, including interest, collateralized by 
equipment with a depreciated cost of $42,000 $118,000 $131,000
Less current maturities 13,000 13,000
$105,000 $118,000
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Scheduled maturities of long-term debt at December 31, 19X5, are as follows:
Year ending December 31, Amount
19X6 $ 13,000
19X7 13,000
19X8 13,000
19X9 13,000
20Y0 13,000
Thereafter 53,000
Total $118,000
7. Classification of Expenses
General and 
Administrative
$289,000
32,000
16,000
3,000 
$340,000
$241,000
19,000
9,000
2,000
$271,000
Program
Total A B C
Expenses incurred for the
year ended December 31,
19X5, were for:
Salaries and benefits $2,714,000 $1,363,000 $699,000 $363,000
Medical supplies and drugs 1,042,000 511,000 246,000 285,000
Insurance and other 90,000 58,000
Provision for bad debts 46,000 16,000 30,000
Depreciation 21,000 5,000
Interest 16,000 10,000 3,000
Total expenses $3,929,000 $1,963,000 $978,000 $648,000
Expenses incurred for the
year ended December 31,
19X4, were for:
Salaries and benefits $1,835,000 $ 915,000 $463,000 $216,000
Medical supplies and drugs 675,000 335,000 211,000 129,000
Insurance and other 83,000 64,000
Provision for bad debts 21,000 21,000
Depreciation 15,000 6,000
Interest 19,000 12,000 5,000
Total expenses $2,648,000 $1,353,000 $679,000 $345,000
(The preparer of the financial statements may wish to include a brief description of the types of programs.)
8. Charity Care
Charity care represented approximately 3 percent and 4 percent of visits in 19X5 and 19X4, 
respectively.
9. Risks and Uncertainties Disclosures*
* The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
10. Pension and Other Postretirement Benefit Plans’
11. Fair Value of Financial Statements*
12. Concentrations of Credit Risk*
13. Investments*
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Sample Not-for-Profit Health Maintenance Organization 
Balance Sheets
June 30, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Assets
Current assets:
Cash and cash equivalents $2,937,000 $1,021,000
Premiums receivable, net of allowance for 
doubtful accounts of $36,000 in 19X5 
and $42,000 in 19X4 358,000 407,000
Other receivables 263,000 261,000
Supplies 190,000 184,000
Prepaid expenses 197,000 99,000
Total current assets 3,945,000 1,972,000
Property and equipment, net 5,756,000 5,626,000
State guaranty fund deposit 150,000 150,000
Debt issuance costs, net of accumulated 
amortization of $42,000 in 19X5 and 
$39,000 in 19X4 18,000 21,000
Total assets $9,869,000 $7,769,000
Liabilities and Net Assets
Current liabilities:
Unsecured 12 percent note payable to a bank $ - $ 44,000
Current maturities of long-term debt 241,000 109,000
Accounts payable—medical services 2,245,000 1,471,000
Other accounts payable and accrued expenses 829,000 661,000
Unearned premium revenue 141,000 202,000
Total current liabilities 3,456,000 2,487,000
Long-term debt, less current maturities 4,295,000 2,382,000
Total liabilities 7,751,000 4,869,000
Net assets—unrestricted 2,118,000 2,900,000
Total liabilities and net assets $9,869,000 $7,769,000
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Sample Not-for-Profit Health Maintenance Organization 
Statements of Operations and Changes in Net Assets 
Years Ended June 30, 19X5 and 19X4
19X5 19X4
Revenue:
Premiums earned
Coinsurance
Interest and other income
Total revenue
Expenses:
Salaries and benefits
Medical supplies and drugs
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses
Operating income (loss)
Net assets, beginning of year
Net assets, end of year
See accompanying notes to financial statements.
$27,682,000
689,000
242,000
28,613,000
16,154,000
8,507,000
3,963,000
19,000
367,000
385,000
29,395,000 
(782,000)
2,900,000 
$ 2,118,000
$22,500,000
500,000 
100,000
23,100,000
13,328,000
5,988,000
2,463,000 
20,000 
336,000 
375,000
22,510,000 
590,000
2,310,000 
$ 2,900,000
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Sample Not-for-Profit Health Maintenance Organization 
Statements of Cash Flows
Years Ended June 30, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Cash flows from operating activities:
Cash received from premiums,
stop-loss insurance recoveries,
and coinsurance $28,969,000 $24,410,000
Cash paid to employees and to
providers of health care services (28,405,000) (22,818,000)
Interest and other income received 230,000 90,000
Interest paid (382,000) (372,000)
Net cash provided by operating activities 412,000 1,310,000
Cash flows from investing activities:
Capital expenditures (497,000) (121,000)
Net cash used in investing activities (497,000) (121,000)
Cash flows from financing activities:
Proceeds from long-term debt 2,300,000 —
Principal payments on long-term debt (255,000) (1,000,000)
Principal payments on note payable (44,000) —
Net cash provided by (used in)
financing activities 2,001,000 (1,000,000)
Net increase in cash and cash equivalents 1,916,000 189,000
Cash and cash equivalents, beginning of year 1,021,000 832,000
Cash and cash equivalents, end of year $ 2,937,000 $ 1,021,000
Reconciliation of change in net assets to net cash
provided by operating activities:
Change in net assets $ (782,000) $ 590,000
Adjustments to reconcile change in net assets to
net cash provided by operating activities:
Depreciation and amortization 370,000 339,000
Provision for bad debts 19,000 20,000
(Increase) decrease in:
Premiums receivables 30,000 64,000
Other current assets 230,000 (93,000)
Increase (decrease) in:
Accounts payable—medical services 774,000 335,000
Other accounts payable and accrued expenses (168,000) (60,000)
Unearned premium revenue (61,000) 115,000
Net cash provided by operating activities $412,000 $ 1,310,000
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Sample Not-for-Profit Health Maintenance Organization 
Notes to Financial Statements
June 30, 19X5 and 19X4
1. Organization
The Sample Health Maintenance Organization (the HMO) was incorporated in 19X0 in New 
State as a not-for-profit corporation for the purpose of providing comprehensive health care 
services on a prepaid basis and for the purpose of establishing and operating organized health 
maintenance and health care delivery systems.
The HMO has been determined to be a qualified health maintenance organization under Title 
XIII of the Public Health Service Act.
2. Summary of Significant Accounting Policies
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less.
Supplies. Inventories of drugs and other supplies are stated at the lower of cost (first-in, 
first-out) or market.
Property and equipment. Property and equipment are recorded at cost. Maintenance and repairs 
are charged to expense, and betterments are capitalized. Property and equipment costing approxi­
mately $700,000 was financed by health maintenance organization initial development grants 
received in 19X1 and 19X2 from the U.S. Department of Health and Human Services (HHS). This 
property will be owned by the HMO as long as the equipment and facilities are used for projects 
related to the objectives of the Public Health Service Act.
Depreciation is computed using the straight-line method over the estimated useful lives of the 
related assets as follows:
Building
Improvements
Data processing and laboratory 
equipment and automobiles
Medical equipment
Office equipment
40 years
20-25 years
3-7 years
10 years
5-10 years
Amortization of debt issuance costs. Debt issuance costs are deferred and amortized using the 
effective interest method over the term of the related debt.
Health care service cost recognition. The HMO contracts with various health care providers for 
the provision of certain medical care services to its members. The HMO compensates these 
providers on a capitation basis. As part of a cost control incentive program, the HMO retains up 
to 20 percent of the capitation as a risk-sharing fund. In the event of hospital utilization in excess 
of budget, those providers bear the risk to the extent of 15 percent of the capitation fee. Operating 
expenses include all amounts incurred by the HMO under the aforementioned contracts.
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The cost of other health care services provided or contracted for is accrued in the period in which 
it is provided to a member based in part on estimates, including an accrual for medical services 
provided but not reported to the HMO.
Premiums revenue. Membership contracts are on a yearly basis subject to cancellation by the 
employer group or the HMO upon 30 days written notice. Premiums are due monthly and are 
recognized as revenue during the period in which the HMO is obligated to provide services to 
members.
Reinsurance (stop-loss insurance). Reinsurance premiums are reported as health care costs, and 
reinsurance recoveries are reported as a reduction of related health care costs.
Federal income tax. The HMO is exempt from federal income taxes under Sec. 501(c)(4) of the 
Internal Revenue Code; accordingly, no provision for federal income taxes has been made in the 
accompanying financial statements.
3. Property and Equipment
Property and equipment at June 30, 19X5 and 19X4, consists of the following:
19X5 19X4
Land $ 300,000 $ 300,000
Buildings and improvements 5,473,000 5,459,000
Furniture and equipment 1,786,000
7,559,000
1,303,000
7,062,000
Less accumulated depreciation (1,803,000)
$5,756,000
(1,436,000)
$5,626,000
4. Long-Term Debt
Long-term debt is collateralized by assets with a depreciated cost of $4,943,000. A summary of 
long-term debt at June 30, 19X5 and 19X4, follows.
HHS loan, interest at 7.5 percent, 
payable in monthly installments 
of $50,000, including interest
HHS loan, interest at 9.25 percent, 
payable in monthly installments 
of $10,000, including interest
Secured equipment loans, payable 
in monthly installments of $15,000, 
including interest
Less current maturities
19X5 19X4
$2,020,000 $ 111,000
1,658,000 1,694,000
858,000 686,000
4,536,000 2,491,000
241,000 109,000
$4,295,000 $2,382,000
Scheduled principal payments on long-term debt are as follows:
Year ending December 31,
19X6
19X7
19X8
19X9
20Y0
Amount
$ 241,000 
259,000 
280,000 
800,000 
2,956,000
$4,536,000
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5. State Guarantee Fund Deposit
In August 19X4 the state in which the HMO is domiciled enacted legislation specifically 
governing HMOs. Under this legislation, the corporation is required to maintain a deposit of 
$150,000 with the director of the division of insurance of the state.
6. Employee Retirement Plan
The HMO has a contributory defined contribution retirement plan covering substantially all 
employees. Expense determined in accordance with the plan formula (4 percent to 10 percent of 
eligible covered compensation) was $354,000 and $275,000 for the years ended June 30, 19X5 and 
19X4, respectively.
7. Stop-Loss Insurance
The HMO entered into a stop-loss insurance agreement with an insurance company to limit its 
losses on individual claims. Under the terms of this agreement, the insurance company will 
reimburse the HMO approximately 25 percent of the cost of each member's annual hospital 
services, in excess of a $1,000 deductible, up to a lifetime limitation of $500,000 per member. In 
the event the HMO ceases operations, (a) plan benefits will continue for members who are 
confined in an acute care hospital on the date of insolvency until their discharge, and (b) plan 
benefits will continue for any other member until the end of the contract period for which 
premiums have been paid.
Stop-loss insurance premiums of approximately $700,000 and $500,000 are included in insurance 
expense (Note 9) in 19X5 and 19X4, respectively. Approximately $600,000 and $400,000 in stop-loss 
insurance recoveries are deducted from insurance expense in 19X5 and 19X4, respectively.
Included in other receivables is approximately $50,000 recoverable from insurers.
8. Malpractice Claims
Malpractice claims have been asserted against the HMO by various claimants. The claims are in 
various stages of processing, and some may ultimately be brought to trial. In the opinion of counsel, 
the outcome of these actions will not have a significant effect on the financial position or the operating 
income of the HMO. Incidents occurring through June 30, 19X5, may result in the assertion of 
additional claims. Other claims may be asserted arising from past services provided. Management 
believes that these claims, if asserted, would be settled within the limits of insurance coverage.
9. Classification of Expenses
19X5 19X4
Program activities 26,921,000 20,909,000
General and administrative 2,474,000
$29,395,000
1,601,000
$22,510,000
10. Risks and Uncertainties Disclosures*
11. Pension and Other Postretirement Benefit Plans*
12. Fair Value of Financial Instruments*
13. Concentrations of Credit Risk*
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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Sample Not-for-Profit Ambulatory Care, Inc. 
Balance Sheets
December 31,19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Assets
Current assets:
Cash $ 65,000 $ 76,000
Patient accounts receivable, net of allowance for
doubtful accounts of $15,000 in 19X5 and
$5,000 in 19X4 290,000 278,000
Estimated retroactive adjustments—third-party payors 19,000 32,000
Accounts receivable—other 13,000 8,000
Supplies 21,000 18,000
Prepaid expenses and deposits 5,000 9,000
Total current assets 413,000 421,000
Property and equipment, at cost:
Land 100,000 100,000
Land improvements 322,000 322,000
Buildings 682,000 682,000
Equipment 1,390,000 1,389,000
2,494,000 2,493,000
Less accumulated depreciation 217,000 100,000
Property and equipment, net 2,277,000 2,393,000
Other assets:
Advances receivable 14,000 5,000
Total assets $2,704,000 $2,819,000
Liabilities and Net Assets
Current liabilities:
Notes payable $ 138,000 $ 144,000
Accounts payable 52,000 87,000
Accrued payroll, benefits, and taxes 33,000 22,000
Estimated retroactive adjustments—third-party payors 30,000 24,000
Financing advance from third-party payors — 1,000
Total current liabilities 253,000 278,000
Net assets—unrestricted 2,451,000 2,541,000
Total liabilities and net assets $2,704,000 $2,819,000
131
.28
Sample Not-for-Profit Ambulatory Care, Inc. 
Statements of Operations and Changes in Net Assets 
Years Ended December 31, 19X5 and 19X4
See accompanying notes to financial statements.
19X5 19X4
Revenue and gains:
Net patient service revenue $ 860,000 $ 357,000
Other 29,000 15,000
Total revenue and gains 889,000 372,000
Expenses:
Salaries and benefits 485,000 243,000
Medical supplies and drugs 189,000 66,000
Insurance 154,000 98,000
Provision for bad debts 14,000 4,000
Depreciation 117,000 100,000
Interest 20,000 18,000
Total expenses 979,000 529,000
Operating loss (90,000) (157,000)
Net assets, beginning of year 2,541,000 2,698,000
Net assets, end of year $2,451,000 $2,541,000
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Sample Not-for-Profit Ambulatory Care, Inc. 
Statements of Cash Flows
Years Ended December 31, 19X5 and 19X4
Cash flows from operating activities:
Cash received from patients and third-party payors 
Cash received from others
Interest received
Interest paid
Cash paid to employees and suppliers
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Purchase of equipment 
Advances made to XYZ Affiliate
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from notes payable 
Payments on notes payable
Net cash provided by (used in) financing activities
Net increase (decrease) in cash
Cash, beginning of year
Cash, end of year
Reconciliation of change in net assets 
to net cash provided by (used in) 
operating activities:
Change in net assets
Adjustments to reconcile change in net 
assets to net cash provided by (used in) 
operating activities:
Depreciation
Provision for bad debts
(Increase) decrease in:
Patient accounts receivable
Other current assets
Increase (decrease) in:
Accounts payable and accrued payroll, 
benefits, and taxes
Other current liabilities
Net cash provided by (used in) 
operating activities
See accompanying notes to financial statements.
19X5 19X4
$866,000 $ 368,000
21,000 6,000
3,000 11,000
(15,000) (16,000)
(870,000) (432,000)
5,000 (63,000)
(1,000) (4,000)
(9,000) (5,000)
(10,000) (9,000)
__ 144,000
(6,000) —
(6,000) 144,000
(11,000) 72,000
76,000 4,000
$ 65,000 $ 76,000
$(90,000) $(157,000)
117,000 100,000
14,000 4,000
(12,000) (19,000)
1,000 (2,000)
(24,000) 10,000
(1,000) 1,000
$ 5,000 $ (63,000)
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Sample Not-for-Profit Ambulatory Care, Inc.
Notes to Financial Statements
December 31, 19X5 and 19X4
1. Description of Organization and Summary of Significant Accounting Policies
Organization. Ambulatory Care, Inc. was incorporated on September 7, 19X3, in New State, to 
operate an ambulatory care health facility to treat or prevent injury and disease, to provide funds 
or to expend funds to further the treatment or prevention of injury or disease, and to develop and 
participate in activities designed to promote the general health of the community.
Three area hospitals—ABC Hospital and Health Center, DEF Hospital, and GHI Hospital—en­
tered into a members' agreement to develop this ambulatory care center. In accordance with this 
agreement, each hospital contributed capital of $947,000 to Ambulatory Care, Inc. Ambulatory 
Care, Inc. began operations in October 19X3.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles requires management to make estimates and assumptions that affect the 
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the 
date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Supplies. Supplies are stated at the lower of cost (first-in, first-out) or net realizable value.
Depreciation. Depreciation of property and equipment is computed on the straight-line method 
over the estimated lives of depreciable assets.
Third-party contractual adjustments. Retroactively calculated third-party contractual adjust­
ments are accrued on an estimated basis in the period the related services are rendered. Net patient 
service revenue is adjusted as required in subsequent periods based on final settlements.
Net patient service revenue. Patient service revenue is reported at the estimated net realizable 
amounts from patients, third-party payors, and others for services rendered.
Charity care. Ambulatory Care, Inc. has a policy of providing charity care to patients who are 
unable to pay. Such patients are identified and related charges are estimated, based on financial 
information obtained from the patient and subsequent analysis. Since management does not 
expect payment for charity care, the estimated charges are excluded from revenue.
Income taxes. Ambulatory Care, Inc. has been recognized by the Internal Revenue Service as a 
not-for-profit corporation as described in Sec. 501(c)(3) of the Internal Revenue Code (IRC) and 
is exempt from federal income taxes on related income pursuant to Sec. 501(a) of the IRC.
2. Advances Receivable
In May 19X4, Ambulatory Care, Inc. entered into a five-year agreement with XYZ Affiliates 
(XYZ). Under this agreement, XYZ is to provide emergency medical services as well as charge 
and bill each patient treated at Ambulatory Care, Inc. Ambulatory Care, Inc. has guaranteed that XYZ 
will collect at least $18,000 per month during the term of this agreement. In any month in which XYZ 
does not collect the minimum guarantee, Ambulatory Care, Inc. advances funds to XYZ to cover the 
deficiency. Such advances are to be repaid to the extent XYZ's net cash collections exceed the minimum 
guarantee amount. Management estimates that the advances will be fully recovered in 19X8.
3. Related-Party Transactions
During 19X3, Ambulatory Care, Inc. entered into a contract with one of the member hospitals 
(the managing hospital) for the management of the business and affairs of Ambulatory Care, Inc. 
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Under this agreement, Ambulatory Care, Inc. pays $4,000 per month to the managing hospital. 
The agreement with the managing hospital was to remain in effect through December 31, 19X5, 
but has been extended on a month-to-month basis.
In addition, during 19X4 each hospital loaned $48,000 to Ambulatory Care, Inc. in the form of 
promissory notes at an interest rate of prime rate plus 1 percent (effective rates of 10 percent and 
9 percent in 19X5 and 19X4, respectively). Of the total $144,000 liability, $48,000 is payable on 
demand after November 28, 19X5, to one member hospital, with the remaining portion ($96,000) 
payable on demand after December 8, 19X5, to the other two member hospitals. During 19X5, 
Ambulatory Care, Inc. paid $2,000 to each member hospital, thereby reducing the obligation to 
$138,000.
4. Revenue From Contracting Agencies
Ambulatory Care, Inc. participates as a provider of health care services to Blue Cross, Medicare, 
and County Indigent Plan patients. Reimbursement for covered services is based on tentative 
payment rates. Final reimbursement is determined after submission of annual cost reports and 
audits thereof by the fiscal intermediaries. Provisions for estimated reimbursement adjustments 
are reported in the financial statements in the period that the services are rendered.
5. Charity Care
Ambulatory Care, Inc. has a policy of providing charity care to indigent patients in emergency 
situations. These services, which are excluded from revenues, amounted to $27,000 and $13,000 
in 19X5 and 19X4, respectively, when measured at Ambulatory Care, Inc.'s established rates.
6. Classification of Expenses
Total
Expenses incurred for the
year ended December 31,
19X5, were for:
Salaries and benefits $485,000
Medical supplies and drugs 189,000
Insurance 154,000
Provision for bad debts 14,000
Depreciation 117,000
Interest 20,000
Total expenses $979,000
Expenses incurred for the
year ended December 31,
19X4, were for:
Salaries and benefits $243,000
Medical supplies and drugs 66,000
Insurance 98,000
Provision for bad debts 4,000
Depreciation 100,000
Interest 18,000
Total expenses $529,000
Program
General and 
AdministrativeA B C
$216,000 $102,000 $121,000 $46,000
98,000 43,000 48,000 —
79,000 45,000 14,000 16,000
9,000 — 5,000 —
100,000 — 17,000 —
9,000 — — 11,000
$511,000 $190,000 $205,000 $73,000
$111,000 $ 46,000 $ 57,000 $29,000
31,000 15,000 20,000 —
45,000 19,000 26,000 8,000
— 4,000 — —
56,000 — 44,000 —
7,000 — — 11,000
$250,000 $ 84,000 $147,000 $48,000
(The preparer of the financial statements may wish to include a brief description of the types of 
programs.)
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7. Risks and Uncertainties Disclosures*
8. Pension and Other Postretirement Benefit Plans’
9. Fair Value of Financial Instruments’
10. Concentrations of Credit Risk’
The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for 
the not-for-profit hospital and, therefore, are not repeated here.
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Comment Letter
We welcome any comments and suggestions you have regarding this Checklist. Please send this 
completed form to: AICPA Accounting and Auditing Publications Team, Harborside Financial Center, 
201 Plaza Three, Jersey City, NJ, 07311-3881. Thank you.
Checklist Title:_______________________________________________________________________________
Comments and Suggestions:
TECHNICAL HOTLINE
The AICPA Technical Hotline answers 
inquiries about specific audit or accounting problems.
Call Toll Free 
(888)777-7077
This service is free to AICPA members.
www.aicpa.org r 008739
